US20130310389A1 - Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands - Google Patents
Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands Download PDFInfo
- Publication number
- US20130310389A1 US20130310389A1 US13/949,323 US201313949323A US2013310389A1 US 20130310389 A1 US20130310389 A1 US 20130310389A1 US 201313949323 A US201313949323 A US 201313949323A US 2013310389 A1 US2013310389 A1 US 2013310389A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- disorders
- optionally substituted
- piperidine
- spiro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000003053 piperidines Chemical class 0.000 title abstract description 4
- 239000003446 ligand Substances 0.000 title description 5
- 238000000034 method Methods 0.000 claims abstract description 58
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 32
- 208000035475 disorder Diseases 0.000 claims abstract description 28
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 201000003631 narcolepsy Diseases 0.000 claims abstract description 11
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims abstract description 10
- 208000008589 Obesity Diseases 0.000 claims abstract description 9
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 9
- 235000020824 obesity Nutrition 0.000 claims abstract description 9
- 208000020016 psychiatric disease Diseases 0.000 claims abstract description 9
- 208000030814 Eating disease Diseases 0.000 claims abstract description 6
- 208000019454 Feeding and Eating disease Diseases 0.000 claims abstract description 6
- 208000018522 Gastrointestinal disease Diseases 0.000 claims abstract description 6
- 206010061218 Inflammation Diseases 0.000 claims abstract description 6
- 208000019695 Migraine disease Diseases 0.000 claims abstract description 6
- 208000019022 Mood disease Diseases 0.000 claims abstract description 6
- 208000002193 Pain Diseases 0.000 claims abstract description 6
- 230000004075 alteration Effects 0.000 claims abstract description 6
- 230000037007 arousal Effects 0.000 claims abstract description 6
- 235000014632 disordered eating Nutrition 0.000 claims abstract description 6
- 206010015037 epilepsy Diseases 0.000 claims abstract description 6
- 230000004634 feeding behavior Effects 0.000 claims abstract description 6
- 230000004054 inflammatory process Effects 0.000 claims abstract description 6
- 206010027599 migraine Diseases 0.000 claims abstract description 6
- 230000036651 mood Effects 0.000 claims abstract description 6
- 201000003152 motion sickness Diseases 0.000 claims abstract description 6
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 6
- 208000023504 respiratory system disease Diseases 0.000 claims abstract description 6
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 6
- 208000026139 Memory disease Diseases 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 94
- 239000000203 mixture Substances 0.000 claims description 72
- 229910052731 fluorine Inorganic materials 0.000 claims description 62
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 46
- 229910052801 chlorine Inorganic materials 0.000 claims description 46
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 44
- 125000004432 carbon atom Chemical group C* 0.000 claims description 38
- 229910052794 bromium Inorganic materials 0.000 claims description 36
- 229910052739 hydrogen Inorganic materials 0.000 claims description 34
- 125000005842 heteroatom Chemical group 0.000 claims description 27
- 229910052760 oxygen Inorganic materials 0.000 claims description 26
- 229910052717 sulfur Inorganic materials 0.000 claims description 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 21
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 229910052740 iodine Inorganic materials 0.000 claims description 16
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 15
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 15
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 15
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 14
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 13
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 11
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 9
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000002971 oxazolyl group Chemical group 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 6
- 125000001544 thienyl group Chemical group 0.000 claims description 6
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract description 20
- 229960001340 histamine Drugs 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 4
- 230000001404 mediated effect Effects 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 273
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 108
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 91
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 61
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 59
- 239000000047 product Substances 0.000 description 53
- -1 imidazole alkylamine Chemical class 0.000 description 47
- 239000000243 solution Substances 0.000 description 42
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 239000012267 brine Substances 0.000 description 30
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 29
- 102000005962 receptors Human genes 0.000 description 26
- 108020003175 receptors Proteins 0.000 description 26
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 24
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 24
- 239000012043 crude product Substances 0.000 description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 24
- 238000003786 synthesis reaction Methods 0.000 description 24
- 0 CC.CC.[1*]N1CCC2(CC1)OC1=CC=CC=C1[W]2 Chemical compound CC.CC.[1*]N1CCC2(CC1)OC1=CC=CC=C1[W]2 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 21
- 238000005160 1H NMR spectroscopy Methods 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 20
- 239000010410 layer Substances 0.000 description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 19
- 239000012528 membrane Substances 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 125000000217 alkyl group Chemical group 0.000 description 15
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- 238000004587 chromatography analysis Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- 239000011324 bead Substances 0.000 description 12
- 125000003118 aryl group Chemical group 0.000 description 11
- 235000019439 ethyl acetate Nutrition 0.000 description 11
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 239000008188 pellet Substances 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- SHQSVMDWKBRBGB-UHFFFAOYSA-N cyclobutanone Chemical compound O=C1CCC1 SHQSVMDWKBRBGB-UHFFFAOYSA-N 0.000 description 8
- 229910001629 magnesium chloride Inorganic materials 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- XNQIOISZPFVUFG-RXMQYKEDSA-N (R)-alpha-methylhistamine Chemical compound C[C@@H](N)CC1=CN=CN1 XNQIOISZPFVUFG-RXMQYKEDSA-N 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- UDHWASUWLXEIRP-UHFFFAOYSA-N [H]N1N=C(C2=CC=C3OC4(CCC3=C2)CCN(C2CCC2)CC4)C2CCC2C1=O Chemical compound [H]N1N=C(C2=CC=C3OC4(CCC3=C2)CCN(C2CCC2)CC4)C2CCC2C1=O UDHWASUWLXEIRP-UHFFFAOYSA-N 0.000 description 7
- 229910052786 argon Inorganic materials 0.000 description 7
- 125000001072 heteroaryl group Chemical group 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000000908 ammonium hydroxide Substances 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 239000013058 crude material Substances 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 201000002859 sleep apnea Diseases 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical group OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 5
- CULWTATXISFIGP-UHFFFAOYSA-N 2,2,2-trifluoro-1-spiro[3,4-dihydrochromene-2,4'-piperidine]-1'-ylethanone Chemical compound C1CN(C(=O)C(F)(F)F)CCC21OC1=CC=CC=C1CC2 CULWTATXISFIGP-UHFFFAOYSA-N 0.000 description 5
- ASXUZZQVSIVLPM-UHFFFAOYSA-N 3-(1'-cyclobutylspiro[3,4-dihydrochromene-2,4'-piperidine]-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound N1C(=O)CCC(C=2C=C3CCC4(CCN(CC4)C4CCC4)OC3=CC=2)=N1 ASXUZZQVSIVLPM-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 150000001371 alpha-amino acids Chemical class 0.000 description 5
- 235000008206 alpha-amino acids Nutrition 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 229940125425 inverse agonist Drugs 0.000 description 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 125000003003 spiro group Chemical group 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- JTEOIKVFAWVRIE-UHFFFAOYSA-N 1-[1'-(2,2,2-trifluoroacetyl)spiro[3,4-dihydrochromene-2,4'-piperidine]-6-yl]propan-1-one Chemical compound C1CC2=CC(C(=O)CC)=CC=C2OC21CCN(C(=O)C(F)(F)F)CC2 JTEOIKVFAWVRIE-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- JEHHXHAAORKMBB-UHFFFAOYSA-N 3-(1'-cyclobutylspiro[3,4-dihydrochromene-2,4'-piperidine]-6-yl)-4-methyl-1h-pyridazin-6-one Chemical compound CC1=CC(=O)NN=C1C1=CC=C(OC2(CCN(CC2)C2CCC2)CC2)C2=C1 JEHHXHAAORKMBB-UHFFFAOYSA-N 0.000 description 4
- CDLDEWPXTKWSRT-UHFFFAOYSA-N 6-bromo-1'-cyclobutylspiro[4h-1,3-benzodioxine-2,4'-piperidine] Chemical compound O1CC2=CC(Br)=CC=C2OC1(CC1)CCN1C1CCC1 CDLDEWPXTKWSRT-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 4
- 239000003395 histamine H3 receptor antagonist Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000009871 nonspecific binding Effects 0.000 description 4
- 208000001797 obstructive sleep apnea Diseases 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- 239000002287 radioligand Substances 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 description 4
- IMUBZWKHOKPLRE-UHFFFAOYSA-N 2-spiro[3,4-dihydrochromene-2,4'-piperidine]-6-yl-3,4-diazabicyclo[4.1.0]hept-2-en-5-one Chemical compound C12CC2C(=O)NN=C1C(C=C1CC2)=CC=C1OC12CCNCC1 IMUBZWKHOKPLRE-UHFFFAOYSA-N 0.000 description 3
- ACJPFLIEHGFXGP-UHFFFAOYSA-N 3,3-dimethyloxolane-2,5-dione Chemical compound CC1(C)CC(=O)OC1=O ACJPFLIEHGFXGP-UHFFFAOYSA-N 0.000 description 3
- IOCCCPYPEALJRV-UHFFFAOYSA-N 3-spiro[3,4-dihydrochromene-2,4'-piperidine]-6-yl-4,5-dihydro-1h-pyridazin-6-one Chemical compound N1C(=O)CCC(C=2C=C3CCC4(CCNCC4)OC3=CC=2)=N1 IOCCCPYPEALJRV-UHFFFAOYSA-N 0.000 description 3
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 3
- 102000000543 Histamine Receptors Human genes 0.000 description 3
- 108010002059 Histamine Receptors Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 238000006069 Suzuki reaction reaction Methods 0.000 description 3
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 3
- ALHRIFVEFDOHQU-UHFFFAOYSA-N [H]N1N=C(C2=CC=C3OC4(CCC3=C2)CCN(C2CCC2)CC4)C(C)CC1=O Chemical compound [H]N1N=C(C2=CC=C3OC4(CCC3=C2)CCN(C2CCC2)CC4)C(C)CC1=O ALHRIFVEFDOHQU-UHFFFAOYSA-N 0.000 description 3
- NQISYSBTCXECTJ-UHFFFAOYSA-N [H]N1N=C(C2=CC=C3OC4(CCC3=C2)CCN(C2CCC2)CC4)C=CC1=O Chemical compound [H]N1N=C(C2=CC=C3OC4(CCC3=C2)CCN(C2CCC2)CC4)C=CC1=O NQISYSBTCXECTJ-UHFFFAOYSA-N 0.000 description 3
- AAIVKCANBVJDMH-UHFFFAOYSA-N [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)CC3=C2)C(C)CC1=O Chemical compound [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)CC3=C2)C(C)CC1=O AAIVKCANBVJDMH-UHFFFAOYSA-N 0.000 description 3
- WSRSFUIZCIOVHK-UHFFFAOYSA-N [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)CC3=C2)CCC1=O Chemical compound [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)CC3=C2)CCC1=O WSRSFUIZCIOVHK-UHFFFAOYSA-N 0.000 description 3
- HEIHAWZBEKWMAS-UHFFFAOYSA-N [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)C(C2=CC=CC=C2)=CC1=O Chemical compound [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)C(C2=CC=CC=C2)=CC1=O HEIHAWZBEKWMAS-UHFFFAOYSA-N 0.000 description 3
- UHSUILZGSPCIBJ-UHFFFAOYSA-N [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)C=CC1=O Chemical compound [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)C=CC1=O UHSUILZGSPCIBJ-UHFFFAOYSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000037765 diseases and disorders Diseases 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- VBNMQAAVTMCEGO-UHFFFAOYSA-N spiro[3,4-dihydrochromene-2,4'-piperidine]-6-ol Chemical compound C1CC2=CC(O)=CC=C2OC21CCNCC2 VBNMQAAVTMCEGO-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- HBXRPXYBMZDIQL-UHFFFAOYSA-N 1$l^{2}-borolane Chemical compound [B]1CCCC1 HBXRPXYBMZDIQL-UHFFFAOYSA-N 0.000 description 2
- XNSIOOWXLKAYPW-UHFFFAOYSA-N 1'-cyclobutylspiro[3,4-dihydrochromene-2,4'-piperidine]-4-ol Chemical compound O1C2=CC=CC=C2C(O)CC1(CC1)CCN1C1CCC1 XNSIOOWXLKAYPW-UHFFFAOYSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- GUSWJGOYDXFJSI-UHFFFAOYSA-N 3,6-dichloropyridazine Chemical compound ClC1=CC=C(Cl)N=N1 GUSWJGOYDXFJSI-UHFFFAOYSA-N 0.000 description 2
- 125000005917 3-methylpentyl group Chemical group 0.000 description 2
- ORSUMIZRRGPJBR-UHFFFAOYSA-N 4,5-dihydro-1h-pyridazin-6-one Chemical compound O=C1CCC=NN1 ORSUMIZRRGPJBR-UHFFFAOYSA-N 0.000 description 2
- GLIQFCUWRSPISG-UHFFFAOYSA-N 4-methyl-3-spiro[3,4-dihydrochromene-2,4'-piperidine]-6-yl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(OC2(CCNCC2)CC2)C2=C1 GLIQFCUWRSPISG-UHFFFAOYSA-N 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- LUCJAWANBKICPE-UHFFFAOYSA-N CC(C)(CC(c1ccc2OC(CC3)(CCN3C3CCC3)OCc2c1)=NN1)C1=O Chemical compound CC(C)(CC(c1ccc2OC(CC3)(CCN3C3CCC3)OCc2c1)=NN1)C1=O LUCJAWANBKICPE-UHFFFAOYSA-N 0.000 description 2
- ZZXBETJMUPSWHG-UHFFFAOYSA-N CC1=C(C2=NN(C)C(=O)C=C2)C=C2COC3(CCN(C4CCC4)CC3)OC2=C1 Chemical compound CC1=C(C2=NN(C)C(=O)C=C2)C=C2COC3(CCN(C4CCC4)CC3)OC2=C1 ZZXBETJMUPSWHG-UHFFFAOYSA-N 0.000 description 2
- CAIWOIKBNJOIAG-UHFFFAOYSA-N CN1N=C(C2=CC=C3OC4(CCC3=C2)CCN(C2CCC2)CC4)C=CC1=O Chemical compound CN1N=C(C2=CC=C3OC4(CCC3=C2)CCN(C2CCC2)CC4)C=CC1=O CAIWOIKBNJOIAG-UHFFFAOYSA-N 0.000 description 2
- VSJAJSNHJXLLNN-UHFFFAOYSA-N CN1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)C=CC1=O Chemical compound CN1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)C=CC1=O VSJAJSNHJXLLNN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- HJFNUEJDXXSNIK-UHFFFAOYSA-N ClC1=NN=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)CC3=C2)C=C1 Chemical compound ClC1=NN=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)CC3=C2)C=C1 HJFNUEJDXXSNIK-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010007979 Glycocholic Acid Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 2
- USMTXTIKYQPOGN-UHFFFAOYSA-N O=C1C=CC(OC2=CC=C3OC4(CCC3=C2)CCN(C2CCC2)CC4)=NN1 Chemical compound O=C1C=CC(OC2=CC=C3OC4(CCC3=C2)CCN(C2CCC2)CC4)=NN1 USMTXTIKYQPOGN-UHFFFAOYSA-N 0.000 description 2
- ZKBGMDRKZXHBPU-UHFFFAOYSA-N O=C1C=CC=NN1CC(O)COC1=CC=C2OC3(CCC2=C1)CCN(C1CCC1)CC3 Chemical compound O=C1C=CC=NN1CC(O)COC1=CC=C2OC3(CCC2=C1)CCN(C1CCC1)CC3 ZKBGMDRKZXHBPU-UHFFFAOYSA-N 0.000 description 2
- KSVUNMYHMPXFBW-UHFFFAOYSA-N O=C1C=CC=NN1CCCOC1=CC=C2OC3(CCC2=C1)CCN(C1CCC1)CC3 Chemical compound O=C1C=CC=NN1CCCOC1=CC=C2OC3(CCC2=C1)CCN(C1CCC1)CC3 KSVUNMYHMPXFBW-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- VKCHQHVDBJLCJP-UHFFFAOYSA-N [H]N1N=C(C2=C(C)C=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)C=CC1=O Chemical compound [H]N1N=C(C2=C(C)C=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)C=CC1=O VKCHQHVDBJLCJP-UHFFFAOYSA-N 0.000 description 2
- QEIPNNMTCZXFNW-UHFFFAOYSA-N [H]N1N=C(C2=CC=C3OC4(CCC3=C2)CCN(C(C)C)CC4)C2CC2C1=O Chemical compound [H]N1N=C(C2=CC=C3OC4(CCC3=C2)CCN(C(C)C)CC4)C2CC2C1=O QEIPNNMTCZXFNW-UHFFFAOYSA-N 0.000 description 2
- YRKNSRYAIMSJOQ-UHFFFAOYSA-N [H]N1N=C(C2=CC=C3OC4(CCC3=C2)CCN(C(C)C)CC4)CC(C)(C)C1=O Chemical compound [H]N1N=C(C2=CC=C3OC4(CCC3=C2)CCN(C(C)C)CC4)CC(C)(C)C1=O YRKNSRYAIMSJOQ-UHFFFAOYSA-N 0.000 description 2
- RWPQZULPMDMNEZ-UHFFFAOYSA-N [H]N1N=C(C2=CC=C3OC4(CCC3=C2)CCN(C2CCC2)CC4)C2CC2C1=O Chemical compound [H]N1N=C(C2=CC=C3OC4(CCC3=C2)CCN(C2CCC2)CC4)C2CC2C1=O RWPQZULPMDMNEZ-UHFFFAOYSA-N 0.000 description 2
- TZRQNOGIHRJTMO-UHFFFAOYSA-N [H]N1N=C(C2=CC=C3OC4(CCC3=C2)CCN(C2CCC2)CC4)CC(C)(C)C1=O Chemical compound [H]N1N=C(C2=CC=C3OC4(CCC3=C2)CCN(C2CCC2)CC4)CC(C)(C)C1=O TZRQNOGIHRJTMO-UHFFFAOYSA-N 0.000 description 2
- FROZTXVDOQFBBV-UHFFFAOYSA-N [H]N1N=C(C2=CC=C3OC4(CCC3=C2)CCN(C2CCCC2)CC4)C2CC2C1=O Chemical compound [H]N1N=C(C2=CC=C3OC4(CCC3=C2)CCN(C2CCCC2)CC4)C2CC2C1=O FROZTXVDOQFBBV-UHFFFAOYSA-N 0.000 description 2
- QAFZRDZLQKYVOJ-UHFFFAOYSA-N [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)CC3=C2)C(C)=CC1=O Chemical compound [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)CC3=C2)C(C)=CC1=O QAFZRDZLQKYVOJ-UHFFFAOYSA-N 0.000 description 2
- HNFTXBZORVKNKK-UHFFFAOYSA-N [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)CC3=C2)C2CC2C1=O Chemical compound [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)CC3=C2)C2CC2C1=O HNFTXBZORVKNKK-UHFFFAOYSA-N 0.000 description 2
- MHARAQVUBPKDRO-UHFFFAOYSA-N [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)CC3=C2)C=CC1=O Chemical compound [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)CC3=C2)C=CC1=O MHARAQVUBPKDRO-UHFFFAOYSA-N 0.000 description 2
- PBZPXHQWZRUNFN-UHFFFAOYSA-N [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)C(C)=C(C)C1=O Chemical compound [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)C(C)=C(C)C1=O PBZPXHQWZRUNFN-UHFFFAOYSA-N 0.000 description 2
- OAHZDJDDWNYGFL-UHFFFAOYSA-N [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)C(C)=CC1=O Chemical compound [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)C(C)=CC1=O OAHZDJDDWNYGFL-UHFFFAOYSA-N 0.000 description 2
- PJVCCMLFQNMNEY-UHFFFAOYSA-N [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)C(C)CC1=O Chemical compound [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)C(C)CC1=O PJVCCMLFQNMNEY-UHFFFAOYSA-N 0.000 description 2
- JFLIZSNLWLEWRC-UHFFFAOYSA-N [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)C2=C(C=CC=C2)C1=O Chemical compound [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)C2=C(C=CC=C2)C1=O JFLIZSNLWLEWRC-UHFFFAOYSA-N 0.000 description 2
- YDCFREOGOGBQGC-UHFFFAOYSA-N [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)C2CC2C1=O Chemical compound [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)C2CC2C1=O YDCFREOGOGBQGC-UHFFFAOYSA-N 0.000 description 2
- JFWWFCJNDORGKZ-UHFFFAOYSA-N [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)C2CCC2C1=O Chemical compound [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)C2CCC2C1=O JFWWFCJNDORGKZ-UHFFFAOYSA-N 0.000 description 2
- DMODGSYGYAELBJ-UHFFFAOYSA-N [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)CCC1=O Chemical compound [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)CCC1=O DMODGSYGYAELBJ-UHFFFAOYSA-N 0.000 description 2
- HIWQBRBTTYFQQE-UHFFFAOYSA-N [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2C)C=CC1=O Chemical compound [H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2C)C=CC1=O HIWQBRBTTYFQQE-UHFFFAOYSA-N 0.000 description 2
- BDJFGEUFDBFQPE-UHFFFAOYSA-N [H]N1N=CC(C2=CC=C3OC4(CCC3=C2)CCN(C2CCC2)CC4)=CC1=O Chemical compound [H]N1N=CC(C2=CC=C3OC4(CCC3=C2)CCN(C2CCC2)CC4)=CC1=O BDJFGEUFDBFQPE-UHFFFAOYSA-N 0.000 description 2
- IFAAZBKTSPCZBN-UHFFFAOYSA-N [H]N1N=CC(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)=CC1=O Chemical compound [H]N1N=CC(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)=CC1=O IFAAZBKTSPCZBN-UHFFFAOYSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- UCAIEVHKDLMIFL-UHFFFAOYSA-N clobenpropit Chemical compound C1=CC(Cl)=CC=C1CNC(=N)SCCCC1=CNC=N1 UCAIEVHKDLMIFL-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000004590 drinking behavior Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000003821 enantio-separation Methods 0.000 description 2
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000000742 histaminergic effect Effects 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 229940068917 polyethylene glycols Drugs 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000002469 receptor inverse agonist Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- UWLKTOAQGBSYCT-UHFFFAOYSA-N tert-butyl 4,6-dihydroxyspiro[3,4-dihydrochromene-2,4'-piperidine]-1'-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21OC1=CC=C(O)C=C1C(O)C2 UWLKTOAQGBSYCT-UHFFFAOYSA-N 0.000 description 2
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 2
- UMDXOBNTRMPHQY-UHFFFAOYSA-N tert-butyl 6-hydroxy-4-oxospiro[3h-chromene-2,4'-piperidine]-1'-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21OC1=CC=C(O)C=C1C(=O)C2 UMDXOBNTRMPHQY-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 210000001103 thalamus Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- QXQAPNSHUJORMC-UHFFFAOYSA-N 1-chloro-4-propylbenzene Chemical compound CCCC1=CC=C(Cl)C=C1 QXQAPNSHUJORMC-UHFFFAOYSA-N 0.000 description 1
- MFJCPDOGFAYSTF-UHFFFAOYSA-N 1H-isochromene Chemical compound C1=CC=C2COC=CC2=C1 MFJCPDOGFAYSTF-UHFFFAOYSA-N 0.000 description 1
- WLDWSGZHNBANIO-UHFFFAOYSA-N 2',5'-Dihydroxyacetophenone Chemical compound CC(=O)C1=CC(O)=CC=C1O WLDWSGZHNBANIO-UHFFFAOYSA-N 0.000 description 1
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- IAOGFPQYESWTHK-UHFFFAOYSA-N 2-(hydroxymethyl)-5-iodopyridazin-3-one Chemical compound OCN1N=CC(I)=CC1=O IAOGFPQYESWTHK-UHFFFAOYSA-N 0.000 description 1
- WIQUGPUJTQIEAX-UHFFFAOYSA-N 2-(oxiran-2-ylmethyl)pyridazin-3-one Chemical compound O=C1C=CC=NN1CC1OC1 WIQUGPUJTQIEAX-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
- XXZCIYUJYUESMD-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(morpholin-4-ylmethyl)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CN1CCOCC1 XXZCIYUJYUESMD-UHFFFAOYSA-N 0.000 description 1
- WWSJZGAPAVMETJ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethoxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OCC WWSJZGAPAVMETJ-UHFFFAOYSA-N 0.000 description 1
- FYELSNVLZVIGTI-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-5-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1CC)CC(=O)N1CC2=C(CC1)NN=N2 FYELSNVLZVIGTI-UHFFFAOYSA-N 0.000 description 1
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
- OZDAOHVKBFBBMZ-UHFFFAOYSA-N 2-aminopentanedioic acid;hydrate Chemical compound O.OC(=O)C(N)CCC(O)=O OZDAOHVKBFBBMZ-UHFFFAOYSA-N 0.000 description 1
- XFKCVVFQGHCLIP-UHFFFAOYSA-N 2-ethylbutanedioyl dichloride Chemical compound CCC(C(Cl)=O)CC(Cl)=O XFKCVVFQGHCLIP-UHFFFAOYSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- XBJLKXOOHLLTPG-UHFFFAOYSA-N 3-chloro-6-methoxypyridazine Chemical compound COC1=CC=C(Cl)N=N1 XBJLKXOOHLLTPG-UHFFFAOYSA-N 0.000 description 1
- CXXDPKJHJJBQLE-UHFFFAOYSA-N 3-spiro[3,4-dihydrochromene-2,4'-piperidine]-6-yloxy-1h-pyridazin-6-one Chemical compound N1C(=O)C=CC(OC=2C=C3CCC4(CCNCC4)OC3=CC=2)=N1 CXXDPKJHJJBQLE-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- GKOFFGQUWTYEDQ-UHFFFAOYSA-N 5-oxaspiro[2.3]hexane-4,6-dione Chemical compound O=C1OC(=O)C11CC1 GKOFFGQUWTYEDQ-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- IMBNTYIRTCQBRJ-UHFFFAOYSA-N 6-chloro-2-methylpyridazin-3-one Chemical compound CN1N=C(Cl)C=CC1=O IMBNTYIRTCQBRJ-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102000007527 Autoreceptors Human genes 0.000 description 1
- 108010071131 Autoreceptors Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- BOPLJTUELDQFFV-UHFFFAOYSA-N BrC1=CC=C2OC3(CCN(C4CCC4)CC3)CC2=C1 Chemical compound BrC1=CC=C2OC3(CCN(C4CCC4)CC3)CC2=C1 BOPLJTUELDQFFV-UHFFFAOYSA-N 0.000 description 1
- AHDOPEWAVSQURU-UHFFFAOYSA-N BrC1=CC=C2OC3(CCN(C4CCC4)CC3)OCC2=C1.CC(C)(CC(=O)C1=CC=C2OC3(CCN(C4CCC4)CC3)OCC2=C1)C(=O)O.CC1(C)CC(=O)OC1=O.CC1(C)CC(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)=NNC1=O.[H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)CC(C)(C)C1=O Chemical compound BrC1=CC=C2OC3(CCN(C4CCC4)CC3)OCC2=C1.CC(C)(CC(=O)C1=CC=C2OC3(CCN(C4CCC4)CC3)OCC2=C1)C(=O)O.CC1(C)CC(=O)OC1=O.CC1(C)CC(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)=NNC1=O.[H]N1N=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)CC(C)(C)C1=O AHDOPEWAVSQURU-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- NXQVPOPZPVASBX-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC2(CC1)OCC1=CC(Br)=CC=C1O2.CC(C)(C)OC(=O)N1CCC2(CC1)OCC1=CC(C(=O)CC(C)(C)C(=O)O)=CC=C1O2.CC1(C)CC(=O)OC1=O.CC1(C)CC(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)=NNC1=O.O=C1CCC1 Chemical compound CC(C)(C)OC(=O)N1CCC2(CC1)OCC1=CC(Br)=CC=C1O2.CC(C)(C)OC(=O)N1CCC2(CC1)OCC1=CC(C(=O)CC(C)(C)C(=O)O)=CC=C1O2.CC1(C)CC(=O)OC1=O.CC1(C)CC(C2=CC=C3OC4(CCN(C5CCC5)CC4)OCC3=C2)=NNC1=O.O=C1CCC1 NXQVPOPZPVASBX-UHFFFAOYSA-N 0.000 description 1
- YKOKNSPJTCUZOQ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1(OCc1c2)Oc1ccc2Br)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1(OCc1c2)Oc1ccc2Br)=O YKOKNSPJTCUZOQ-UHFFFAOYSA-N 0.000 description 1
- URRDJJVGBUBXSM-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1(OCc1c2)Oc1ccc2C(CC(C)(C)C(O)=O)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1(OCc1c2)Oc1ccc2C(CC(C)(C)C(O)=O)=O)=O URRDJJVGBUBXSM-UHFFFAOYSA-N 0.000 description 1
- LOCFUWCMCYVVRK-UHFFFAOYSA-N CC(C)N1CCC2(CCC3=C(C=CC(C4=NNC(=O)C(C)(C)C4)=C3)O2)CC1.CC(C)N1CCC2(CCC3=C(C=CC(C4=NNC(=O)C5CC45)=C3)O2)CC1.CC1(C)CC(C2=CC3=C(C=C2)OC2(CC3)CCN(C3CCC3)CC2)=NNC1=O.CC1=CC(=O)NN=C1C1=CC2=C(C=C1)OC1(CC2)CCN(C2CCC2)CC1.CC1CC(=O)NN=C1C1=CC2=C(C=C1)OC1(CC2)CCN(C2CCC2)CC1.O=C1NN=C(C2=CC3=C(C=C2)OC2(CC3)CCN(C3CCC3)CC2)C2CCC12.O=C1NN=C(C2=CC3=C(C=C2)OC2(CC3)CCN(C3CCCC3)CC2)C2CC12 Chemical compound CC(C)N1CCC2(CCC3=C(C=CC(C4=NNC(=O)C(C)(C)C4)=C3)O2)CC1.CC(C)N1CCC2(CCC3=C(C=CC(C4=NNC(=O)C5CC45)=C3)O2)CC1.CC1(C)CC(C2=CC3=C(C=C2)OC2(CC3)CCN(C3CCC3)CC2)=NNC1=O.CC1=CC(=O)NN=C1C1=CC2=C(C=C1)OC1(CC2)CCN(C2CCC2)CC1.CC1CC(=O)NN=C1C1=CC2=C(C=C1)OC1(CC2)CCN(C2CCC2)CC1.O=C1NN=C(C2=CC3=C(C=C2)OC2(CC3)CCN(C3CCC3)CC2)C2CCC12.O=C1NN=C(C2=CC3=C(C=C2)OC2(CC3)CCN(C3CCCC3)CC2)C2CC12 LOCFUWCMCYVVRK-UHFFFAOYSA-N 0.000 description 1
- ILLZKVVSZTVGAD-UHFFFAOYSA-N CC1=CC(=O)NN=C1C1=CC2=C(C=C1)OC1(CCN(C3CCC3)CC1)C2.CC1CC(=O)NN=C1C1=CC2=C(C=C1)OC1(CCN(C3CCC3)CC1)C2.O=C1CCC(C2=CC3=C(C=C2)OC2(CC3)CCN(C3CCC3)CC2)=NN1.O=C1CCC(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)C3)=NN1.O=C1NN=C(C2=CC3=C(C=C2)OC2(CC3)CCN(C3CCC3)CC2)C2CC12.O=C1NN=C(C2=CC3=C(C=C2)OC2(CCCCC2)CC3)C2CC12.O=C1NN=C(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)C3)C2CC12 Chemical compound CC1=CC(=O)NN=C1C1=CC2=C(C=C1)OC1(CCN(C3CCC3)CC1)C2.CC1CC(=O)NN=C1C1=CC2=C(C=C1)OC1(CCN(C3CCC3)CC1)C2.O=C1CCC(C2=CC3=C(C=C2)OC2(CC3)CCN(C3CCC3)CC2)=NN1.O=C1CCC(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)C3)=NN1.O=C1NN=C(C2=CC3=C(C=C2)OC2(CC3)CCN(C3CCC3)CC2)C2CC12.O=C1NN=C(C2=CC3=C(C=C2)OC2(CCCCC2)CC3)C2CC12.O=C1NN=C(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)C3)C2CC12 ILLZKVVSZTVGAD-UHFFFAOYSA-N 0.000 description 1
- KJFYXHNCUHIASK-UHFFFAOYSA-N CC1=CC2=C(C=C1C1=NN(C)C(=O)C=C1)COC1(CCN(C3CCC3)CC1)O2.[H]N1N=C(C2=C(C)C3=C(C=C2)OC2(CCN(C4CCC4)CC2)OC3)C=CC1=O.[H]N1N=C(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)OC3)C2=C(C=CC=C2)C1=O.[H]N1N=C(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)OC3)C=CC1=O.[H]N1N=C(C2=CC3=C(C=C2C)OC2(CCN(C4CCC4)CC2)OC3)C=CC1=O Chemical compound CC1=CC2=C(C=C1C1=NN(C)C(=O)C=C1)COC1(CCN(C3CCC3)CC1)O2.[H]N1N=C(C2=C(C)C3=C(C=C2)OC2(CCN(C4CCC4)CC2)OC3)C=CC1=O.[H]N1N=C(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)OC3)C2=C(C=CC=C2)C1=O.[H]N1N=C(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)OC3)C=CC1=O.[H]N1N=C(C2=CC3=C(C=C2C)OC2(CCN(C4CCC4)CC2)OC3)C=CC1=O KJFYXHNCUHIASK-UHFFFAOYSA-N 0.000 description 1
- ZYHROHGYBKRIEV-UHFFFAOYSA-N CCC(=O)C1=CC=C2OC3(CCN(C(=O)C(F)(F)F)CC3)CC2=C1 Chemical compound CCC(=O)C1=CC=C2OC3(CCN(C(=O)C(F)(F)F)CC3)CC2=C1 ZYHROHGYBKRIEV-UHFFFAOYSA-N 0.000 description 1
- RJTJVVYSTUQWNI-UHFFFAOYSA-N CCC1=CC2=CC=CC=C2C=C1 Chemical compound CCC1=CC2=CC=CC=C2C=C1 RJTJVVYSTUQWNI-UHFFFAOYSA-N 0.000 description 1
- HFLGBNBLMBSXEM-UHFFFAOYSA-N CCC1=CC=C(O)C(O)=C1 Chemical compound CCC1=CC=C(O)C(O)=C1 HFLGBNBLMBSXEM-UHFFFAOYSA-N 0.000 description 1
- ZMXIYERNXPIYFR-UHFFFAOYSA-N CCC1=CC=CC2=CC=CC=C21 Chemical compound CCC1=CC=CC2=CC=CC=C21 ZMXIYERNXPIYFR-UHFFFAOYSA-N 0.000 description 1
- GOVXKUCVZUROAN-UHFFFAOYSA-N CCC1=CNC2=CC=CC=C12 Chemical compound CCC1=CNC2=CC=CC=C12 GOVXKUCVZUROAN-UHFFFAOYSA-N 0.000 description 1
- NJQHZENQKNIRSY-UHFFFAOYSA-N CCC1=CNC=N1 Chemical compound CCC1=CNC=N1 NJQHZENQKNIRSY-UHFFFAOYSA-N 0.000 description 1
- XCVCSKZRRZKVTM-UHFFFAOYSA-N CCOC(=O)CC(C)C(=O)C1=CC=C2OC3(CCC2=C1)CCN(C(=O)C(F)(F)F)CC3 Chemical compound CCOC(=O)CC(C)C(=O)C1=CC=C2OC3(CCC2=C1)CCN(C(=O)C(F)(F)F)CC3 XCVCSKZRRZKVTM-UHFFFAOYSA-N 0.000 description 1
- HEHMZUHBSOQULQ-UHFFFAOYSA-N CCOC(=O)CC(C)C(=O)C1=CC=C2OC3(CCN(C(=O)C(F)(F)F)CC3)CC2=C1 Chemical compound CCOC(=O)CC(C)C(=O)C1=CC=C2OC3(CCN(C(=O)C(F)(F)F)CC3)CC2=C1 HEHMZUHBSOQULQ-UHFFFAOYSA-N 0.000 description 1
- QFZLZVFLYZKVSG-UHFFFAOYSA-N CCOC(=O)CCC(=O)C1=CC=C2OC3(CCN(C(=O)C(F)(F)F)CC3)CC2=C1 Chemical compound CCOC(=O)CCC(=O)C1=CC=C2OC3(CCN(C(=O)C(F)(F)F)CC3)CC2=C1 QFZLZVFLYZKVSG-UHFFFAOYSA-N 0.000 description 1
- AIBGSDIXVKPEIZ-UHFFFAOYSA-N CN1N=C(C2=CC3=C(C=C2)OC2(CC3)CCN(C3CCC3)CC2)C=CC1=O.ClC1=NN=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)CC3=C2)C=C1.O=C1C=C(C2=CC3=C(C=C2)OC2(CC3)CCN(C3CCC3)CC2)C=NN1.O=C1C=CC(C2=CC=C3OC4(CCN(C5CCC5)CC4)CC3=C2)=NN1.[H]N1N=C(C2=CC3=C(C=C2)OC2(CC3)CCN(C3CCC3)CC2)C=CC1=O.[H]N1N=C(OC2=CC3=C(C=C2)OC2(CC3)CCN(C3CCC3)CC2)C=CC1=O Chemical compound CN1N=C(C2=CC3=C(C=C2)OC2(CC3)CCN(C3CCC3)CC2)C=CC1=O.ClC1=NN=C(C2=CC=C3OC4(CCN(C5CCC5)CC4)CC3=C2)C=C1.O=C1C=C(C2=CC3=C(C=C2)OC2(CC3)CCN(C3CCC3)CC2)C=NN1.O=C1C=CC(C2=CC=C3OC4(CCN(C5CCC5)CC4)CC3=C2)=NN1.[H]N1N=C(C2=CC3=C(C=C2)OC2(CC3)CCN(C3CCC3)CC2)C=CC1=O.[H]N1N=C(OC2=CC3=C(C=C2)OC2(CC3)CCN(C3CCC3)CC2)C=CC1=O AIBGSDIXVKPEIZ-UHFFFAOYSA-N 0.000 description 1
- USYXRQFFAFOCJO-UHFFFAOYSA-N CN1N=C(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)OC3)C=CC1=O.O=C1C=C(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)OC3)C=NN1.O=C1C=CC=NN1CC(O)COC1=CC2=C(C=C1)OC1(CC2)CCN(C2CCC2)CC1.O=C1C=CC=NN1CCCOC1=CC2=C(C=C1)OC1(CC2)CCN(C2CCC2)CC1.O=C1NN=C(C2=CC3=C(C=C2)OC2(CC3)CCN(C3CCC3)CC2)C2CCC12.O=C1NN=C(C2=CC3=C(C=C2)OC2(CC3)CCN(C3CCC3)CC2)C2CCC12 Chemical compound CN1N=C(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)OC3)C=CC1=O.O=C1C=C(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)OC3)C=NN1.O=C1C=CC=NN1CC(O)COC1=CC2=C(C=C1)OC1(CC2)CCN(C2CCC2)CC1.O=C1C=CC=NN1CCCOC1=CC2=C(C=C1)OC1(CC2)CCN(C2CCC2)CC1.O=C1NN=C(C2=CC3=C(C=C2)OC2(CC3)CCN(C3CCC3)CC2)C2CCC12.O=C1NN=C(C2=CC3=C(C=C2)OC2(CC3)CCN(C3CCC3)CC2)C2CCC12 USYXRQFFAFOCJO-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- PBWHZAGYVLTJJQ-UHFFFAOYSA-N ClC1=NN=C(OC2=CC=C3OC4(CCC3=C2)CCN(C2CCC2)CC4)C=C1 Chemical compound ClC1=NN=C(OC2=CC=C3OC4(CCC3=C2)CCN(C2CCC2)CC4)C=C1 PBWHZAGYVLTJJQ-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 240000002989 Euphorbia neriifolia Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- FSBIGDSBMBYOPN-VKHMYHEASA-N L-canavanine Chemical compound OC(=O)[C@@H](N)CCONC(N)=N FSBIGDSBMBYOPN-VKHMYHEASA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- QKDDJDBFONZGBW-UHFFFAOYSA-N N-Cyclohexy-4-(imidazol-4-yl)-1-piperidinecarbothioamide Chemical compound C1CC(C=2NC=NC=2)CCN1C(=S)NC1CCCCC1 QKDDJDBFONZGBW-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- FSBIGDSBMBYOPN-UHFFFAOYSA-N O-guanidino-DL-homoserine Natural products OC(=O)C(N)CCON=C(N)N FSBIGDSBMBYOPN-UHFFFAOYSA-N 0.000 description 1
- FWKBDNAKVZRFLI-UHFFFAOYSA-N O=C(N1CCC2(CC1)CC1=CC=CC=C1O2)C(F)(F)F Chemical compound O=C(N1CCC2(CC1)CC1=CC=CC=C1O2)C(F)(F)F FWKBDNAKVZRFLI-UHFFFAOYSA-N 0.000 description 1
- UYQYYHLFQRWFPJ-UHFFFAOYSA-N O=C(O)CCC(=O)C1=CC=C2OC3(CCC2=C1)CCN(C(=O)C(F)(F)F)CC3 Chemical compound O=C(O)CCC(=O)C1=CC=C2OC3(CCC2=C1)CCN(C(=O)C(F)(F)F)CC3 UYQYYHLFQRWFPJ-UHFFFAOYSA-N 0.000 description 1
- YDCBXYAESLCOPJ-UHFFFAOYSA-N OC1=CC=C2OC3(CCC2=C1)CCN(C1CCC1)CC3 Chemical compound OC1=CC=C2OC3(CCC2=C1)CCN(C1CCC1)CC3 YDCBXYAESLCOPJ-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- VHQZFMBLXJEDQN-UHFFFAOYSA-N [H]N1CCC2(CC1)CC1=CC(C3=NN([H])C(=O)CC3)=CC=C1O2 Chemical compound [H]N1CCC2(CC1)CC1=CC(C3=NN([H])C(=O)CC3)=CC=C1O2 VHQZFMBLXJEDQN-UHFFFAOYSA-N 0.000 description 1
- HJBHOBRMNJBGNA-UHFFFAOYSA-N [H]N1CCC2(CC1)CC1=CC(C3=NN([H])C(=O)CC3C)=CC=C1O2 Chemical compound [H]N1CCC2(CC1)CC1=CC(C3=NN([H])C(=O)CC3C)=CC=C1O2 HJBHOBRMNJBGNA-UHFFFAOYSA-N 0.000 description 1
- MZJZEDKSTIVGHS-UHFFFAOYSA-N [H]N1N=C(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)OC3)C(C)=C(C)C1=O.[H]N1N=C(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)OC3)C(C)=CC1=O.[H]N1N=C(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)OC3)C(C)CC1=O Chemical compound [H]N1N=C(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)OC3)C(C)=C(C)C1=O.[H]N1N=C(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)OC3)C(C)=CC1=O.[H]N1N=C(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)OC3)C(C)CC1=O MZJZEDKSTIVGHS-UHFFFAOYSA-N 0.000 description 1
- GYMQJVMFRLZUEW-UHFFFAOYSA-N [H]N1N=C(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)OC3)C(C2=CC=CC=C2)=CC1=O.[H]N1N=C(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)OC3)C2CC2C1=O.[H]N1N=C(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)OC3)C2CCC2C1=O.[H]N1N=C(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)OC3)CC(C)(C)C1=O.[H]N1N=C(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)OC3)CCC1=O Chemical compound [H]N1N=C(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)OC3)C(C2=CC=CC=C2)=CC1=O.[H]N1N=C(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)OC3)C2CC2C1=O.[H]N1N=C(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)OC3)C2CCC2C1=O.[H]N1N=C(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)OC3)CC(C)(C)C1=O.[H]N1N=C(C2=CC3=C(C=C2)OC2(CCN(C4CCC4)CC2)OC3)CCC1=O GYMQJVMFRLZUEW-UHFFFAOYSA-N 0.000 description 1
- ZBJLSAJZTPAASU-UHFFFAOYSA-N [N].[Li]C(C)CC Chemical compound [N].[Li]C(C)CC ZBJLSAJZTPAASU-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 125000006278 bromobenzyl group Chemical group 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000011965 cell line development Methods 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000037011 constitutive activity Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- ACQBHJXEAYTHCY-UHFFFAOYSA-N cyclopropyl-[4-[3-(1H-imidazol-5-yl)propoxy]phenyl]methanone Chemical compound C=1C=C(OCCCC=2NC=NC=2)C=CC=1C(=O)C1CC1 ACQBHJXEAYTHCY-UHFFFAOYSA-N 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000005050 dihydrooxazolyl group Chemical group O1C(NC=C1)* 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000010575 fractional recrystallization Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 239000003453 histamine agonist Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- HEBMCVBCEDMUOF-UHFFFAOYSA-N isochromane Chemical compound C1=CC=C2COCCC2=C1 HEBMCVBCEDMUOF-UHFFFAOYSA-N 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- NAYYNDKKHOIIOD-UHFFFAOYSA-N phthalamide Chemical compound NC(=O)C1=CC=CC=C1C(N)=O NAYYNDKKHOIIOD-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- TVPRCLHSULCNLV-UHFFFAOYSA-N pyridazin-3-one Chemical group O=C1C=CC=N[N]1 TVPRCLHSULCNLV-UHFFFAOYSA-N 0.000 description 1
- 150000004892 pyridazines Chemical class 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- LJRGBERXYNQPJI-UHFFFAOYSA-M sodium;3-nitrobenzenesulfonate Chemical compound [Na+].[O-][N+](=O)C1=CC=CC(S([O-])(=O)=O)=C1 LJRGBERXYNQPJI-UHFFFAOYSA-M 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- IDKWKFTXXFZPQK-UHFFFAOYSA-N spiro[3,4-dihydrochromene-2,4'-piperidine] Chemical compound C1CNCCC21OC1=CC=CC=C1CC2 IDKWKFTXXFZPQK-UHFFFAOYSA-N 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- UIUJIQZEACWQSV-UHFFFAOYSA-N succinic semialdehyde Chemical compound OC(=O)CCC=O UIUJIQZEACWQSV-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- RIFXIGDBUBXKEI-UHFFFAOYSA-N tert-butyl 3-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(=O)C1 RIFXIGDBUBXKEI-UHFFFAOYSA-N 0.000 description 1
- JSOMVCDXPUXKIC-UHFFFAOYSA-N tert-butyl 3-oxopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)C1 JSOMVCDXPUXKIC-UHFFFAOYSA-N 0.000 description 1
- PMLBUVZPRKXMOX-UHFFFAOYSA-N tert-butyl 4-oxoazepane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(=O)CC1 PMLBUVZPRKXMOX-UHFFFAOYSA-N 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000005306 thianaphthenyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002306 tributylsilyl group Chemical group C(CCC)[Si](CCCC)(CCCC)* 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Definitions
- the present invention is related to substituted spirocyclic piperidine derivatives, their use as H 3 antagonists/inverse agonists, processes for their preparation, and pharmaceuticals compositions thereof.
- Histamine is a well established modulator of neuronal activity. At least four subtypes of histamine receptors have been reported in the literature—H 1 , H 2 , H 3 , H 4 .
- the histamine H 3 receptors play a key role in neurotransmission in the central nervous system.
- the H 3 receptor was discovered in 1983 originally on histamine-containing neurons where it was shown to function presynaptically, regulating the release and synthesis of the biogenic amine histamine (Arrang et al, 1983) now a well established neurotransmitter.
- H 3 receptors are predominately expressed in the brain, localizing to the cerebral cortex, amygdala, hippocampus, striatum, thalamus and hypothalamus.
- H 3 receptors are also localized presynaptically on histaminergic nerve terminals and act as inhibitory autoreceptors (Alguacil and Perez-Garcia, 2003; Passani et al, 2004; Leurs at al, 2005; Celanire et al, 2005; Witkin and Nelson, 2004). When these receptors are activated by histamine, histamine release is inhibited. H 3 receptors can also be found in the periphery (skin, lung, cardiovascular system, intestine, GI tract, etc).
- H 3 receptors are also involved in presynaptic regulation of the release of acetylcholine, dopamine, GABA, glutamate and serotonin (see Repka-Ramirez, 2003; Chazot and Hann, 2001; Leurs et al, 1998).
- the H 3 receptor demonstrates a high degree of constitutive or spontaneous activity (e.g., receptor is active in the absence of agonist stimulation) in vitro and in vivo, thus, ligands to the receptor can display, agonist, neutral antagonist or inverse agonist effects.
- H 3 receptor may have utility in a number of therapeutic applications including narcolepsy or sleep/wake disorders, feeding behavior, eating disorders, obesity, cognition, arousal, memory, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders and epilepsy (Leurs et al, 2005; Witkin and Nelson, 2004, Hancock and Fox 2004; Esbenshade et al. 2006).
- An H 3 antagonist/inverse agonist could be important for gastrointestinal disorders, respiratory disorders such as asthma, inflammation, and myocardial infarction.
- Ohtake et al. (US 2006/0178375 A1) disclosed compounds that reportedly exhibit histamine receptor H 3 antagonist or inverse agonist activity and may be useful for the treatment or prevention of obesity, diabetes, hormonal secretion abnormality, or sleep disorders.
- Bertrand et al. (WO 2006/117609 A2) disclosed novel histamine H 3 receptor ligands, processes for their preparation, and their therapeutic applications.
- WO 2006/103546 A2 disclosed certain methods of treatment for Parkinson's disease, obstructive sleep apnea, narcolepsy, dementia with Lewy bodies, and/or vascular dementia using non-imidazole alkylamine derivatives that are antagonists of the H 3 receptors of histamine
- Apodaca et al. (EP 1 311 482 B1) disclosed certain non-imidazole aryloxypiperidines as H 3 receptor ligands, their synthesis, and their use for the treatment of disorders and conditions mediated by the histamine receptor.
- Xu et al. disclosed certain 6-substituted phenyl-4,5-dihydro-3(2H)-pyridazinones, their synthesis, and rabbit platelet aggregation inhibitory activity induced by ADP in vitro.
- Barker et al. discloses spiro[benzodioxane] compounds as active antagonists of the orexin-1 receptor and potentially useful in the prophylaxis and treatment of orexin-1 receptor related disorders and orexin-2 receptor related disorders.
- the present invention is directed to compounds of Formula (I):
- the present invention is also directed to methods of making compounds of Formula (I), as well as methods of their pharmaceutical use.
- the present invention provides compounds of Formula (I):
- the present invention provides novel compounds of Formula (I):
- the present invention provides compounds wherein R 1 is C 3 -C 8 cycloalkyl.
- the present invention provides compounds wherein R 1 is cyclobutyl or cyclopentyl.
- the present invention provides compounds wherein W is —CH 2 — or —CH 2 —CH 2 —.
- the present invention provides compounds wherein R 2 is
- the present invention provides compounds wherein R 4 and R 5 , together with the carbon atoms to which they are attached, form a fused cyclopropyl or cyclobutyl ring.
- the present invention provides compounds wherein R 4A and R 5A , together with the carbon atoms to which they are attached, form a fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl ring.
- Preferred embodiments of the present invention include those wherein k is 1. Other embodiments include those wherein m is 1. Still other embodiments include those wherein the sum of m and k is 2.
- Y 2 ⁇ Y 3 is —C(X) ⁇ CH—.
- X is R 2 .
- X is —OR 2 .
- R 8 is H. In other embodiments, R 8 is C 1 -C 6 alkyl optionally substituted by 1-3 R 20 . In other embodiments, R 8 is C 1 -C 6 alkyl.
- R 9 is C 1 -C 4 alkyl.
- n is 0. In other embodiments, it is preferred that n is 1. In other embodiments, z is preferably 0.
- the present invention provides compounds of Formula (II):
- the present invention provides compounds wherein R 1 is cyclobutyl or cyclopentyl.
- the present invention provides compounds wherein R 2 is
- the present invention provides compounds wherein R 4 and R 5 , together with the carbon atoms to which they are attached, form a fused cyclopropyl or cyclobutyl ring.
- the present invention provides compounds wherein R 4A and R 5A , together with the carbon atoms to which they are attached, form a fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl ring.
- the present invention provides compounds wherein R 8 is H.
- the present invention provides compounds of Formula (III):
- the present invention provides compounds of Formula (III):
- the present invention provides compounds wherein R 2 is
- the present invention provides pharmaceutical compositions comprising a compound according to the present invention and one or more pharmaceutically acceptable excipients.
- the present invention provides for a method for treating a disorder selected from the group consisting of narcolepsy or sleep/wake disorders, feeding behavior disorders, eating disorders, obesity, cognition disorders, arousal disorders, memory disorders, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders, epilepsy, gastrointestinal disorders, respiratory disorders, inflammation, and myocardial infarction comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of the present invention.
- the present invention provides for a method of treating narcolepsy or sleep/wake disorders.
- the present invention provides for a method of treating attention deficit hyperactivity disorder.
- the present invention provides for a method of treating cognition disorders.
- the present invention provides for use of the compounds of the present invention for use in therapy.
- the present invention provides for use of the compounds of the present invention in the manufacture of a medicament for treating a disorder selected from the group consisting of narcolepsy or sleep/wake disorders, feeding behavior disorder, eating disorders, obesity, cognition disorders, arousal disorders, memory disorders, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders, epilepsy, gastrointestinal disorders, respiratory disorders, inflammation, and myocardial infarction comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of the present invention.
- a disorder selected from the group consisting of narcolepsy or sleep/wake disorders, feeding behavior disorder, eating disorders, obesity, cognition disorders, arousal disorders, memory disorders, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychia
- the term “about” refers to a range of values from ⁇ 10% of a specified value.
- the phrase “about 50” includes ⁇ 10% of 50, or from 45 to 55.
- the phrase “from about 10 to 100” includes ⁇ 10% of 10 and ⁇ 10% of 100, or from 9 to 110.
- a range of values in the form “x-y” or “x to y”, or “x through y”, include integers x, y, and the integers therebetween.
- the phrases “1-6”, or “1 to 6” or “1 through 6” are intended to include the integers 1, 2, 3, 4, 5, and 6.
- Preferred embodiments include each individual integer in the range, as well as any subcombination of integers.
- preferred integers for “1-6” can include 1, 2, 3, 4, 5, 6, 1-2, 1-3, 1-4, 1-5, 2-3, 2-4, 2-5, 2-6, etc.
- stable compound or “stable structure” refers to a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and preferably capable of formulation into an efficacious therapeutic agent.
- the present invention is directed only to stable compounds.
- substituted refers to any one or more hydrogen atoms on the indicated atom is replaced with a selected group referred to herein as a “substituent,” provided that the substituted atom's valency is not exceeded, and that the substitution results in a stable compound.
- substituents are —OH, alkyl, cycloalkyl, alkoxy, halogen, haloalkyl, aryl, heteroaryl, and heterocyclyl.
- alkyl refers to a straight-chain, or branched alkyl group having 1 to 8 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, neopentyl, 1-ethylpropyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, hexyl, octyl, etc.
- the alkyl moiety of alkyl-containing groups has the same meaning as alkyl defined above.
- C 1 -C 6 alkyl refers to straight-chain, or branched alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, neopentyl, 1-ethylpropyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, hexyl, etc.
- Lower alkyl groups which are preferred, are alkyl groups as defined above which contain 1 to 4 carbons.
- C 1 -C 4 alkyl refers to an alkyl radical containing from 1 to 4 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.
- a designation such as “C 1 -C 3 alkyl” refers to an alkyl radical containing from 1 to 3 carbon atoms, such as methyl, ethyl, propyl, and isopropyl.
- Alkyl groups can be substituted or unsubstituted. Preferred substituents include —OH and alkoxy.
- alkenyl refers to a straight chain, or branched hydrocarbon chains of 2 to 8 carbon atoms having at least one carbon-carbon double bond.
- a designation “C 2 -C 8 alkenyl” refers to an alkenyl radical containing from 2 to 8 carbon atoms. Examples of alkenyl groups include ethenyl, propenyl, isopropenyl, 2,4-pentadienyl, etc. Alkenyl groups can be substituted or unsubstituted
- alkynyl refers to a straight chain, or branched hydrocarbon chains of 2 to 8 carbon atoms having at least one carbon-carbon triple bond.
- a designation “C 2 -C 8 alkynyl” refers to an alkynyl radical containing from 2 to 8 carbon atoms. Examples include ethynyl, propynyl, isopropynyl, 3,5-hexadiynyl, etc.
- Alkynyl groups can be substituted or unsubstituted.
- C 1 -C 4 haloalkyl refers to an “alkyl” group as defined herein substituted by one or more halogen atoms to form a stable compound.
- haloalkyl include but are not limited to, —CF 3 , —CHF 2 , —CH 2 F and CF 2 CF 3 .
- C 1 -C 4 alkoxy refers to an “alkyl” group as defined herein bonded to and oxygen atom. Alkoxy groups can be substituted or unsubstituted.
- halo refers to an F, Cl, Br, and I. Preferred halo substituents are F and Cl.
- arylalkyl refers to an alkyl group that is substituted with an aryl group.
- a designation “C 7 -C 15 arylalkyl” refers to an arylalkyl radical containing from 7 to 15 carbon atoms. Examples of arylalkyl groups include, but are not limited to, benzyl, phenethyl, diphenylmethyl, diphenylethyl, naphthylmethyl, etc. preferably benzyl.
- Arylalkyl groups can be substituted or unsubstituted.
- cycloalkyl refers to a saturated or partially saturated mono- or bicyclic alkyl ring system containing 3 to 10 carbon atoms. Certain embodiments contain 3 to 6 carbon atoms, and other embodiments contain 5 or 6 carbon atoms.
- a designation such as “C 5 -C 7 cycloalkyl” refers to a cycloalkyl radical containing from 5 to 7 ring carbon atoms.
- Examples of cycloalkyl groups include such groups as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, pinenyl, and adamantanyl. Cycloalkyl groups can be substituted or unsubstituted
- aryl refers to a substituted or unsubstituted, mono- or bicyclic hydrocarbon aromatic ring system having 6 to 12 ring carbon atoms. Examples include phenyl and naphthyl. Preferred aryl groups include unsubstituted or substituted phenyl and naphthyl groups. Aryl groups can be substituted or unsubstituted
- heterocycle refers to a substituted or unsubstituted carbocyclic group in which one or more ring carbon atoms are replaced by at least one hetero atom such as —O—, —N—, or —S—. Certain embodiments include 3 to 6 membered rings, and other embodiments include 5 or 6 membered rings. The nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen may be optionally substituted in non-aromatic rings. Heterocycles are intended to include heteroaryl and heterocycloalkyl groups. Heterocyclic groups can be substituted or unsubstituted.
- heteroaryl refers to an aromatic group or ring system containing 5 to 10 ring carbon atoms in which one or more ring carbon atoms are replaced by at least one hetero atom such as O, N, or S. Certain embodiments include 5 or 6 membered rings.
- heteroaryl groups include pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, isoxazolyl, oxazolyl, oxathiolyl, oxadiazolyl, triazolyl, oxatriazolyl, furazanyl, tetrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, picolinyl, imidazopyridinyl, indolyl, isoindolyl, indazolyl, benzofuranyl, isobenzofuranyl, purinyl, quinazolinyl, quinolyl, isoquinolyl, benzoimidazolyl, benzothiazolyl, benzothiophenyl, thianaphthenyl, benzoxazolyl,
- heterocycloalkyl refers to a cycloalkyl group in which one or more ring carbon atoms are replaced by at least one hetero atom such as O, N, S, SO, and SO 2 . Certain embodiments include 3 to 6 membered rings, and other embodiments include 5 or 6 membered rings.
- heterocycloalkyl groups include azetidinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, oxazolidinyl, pirazolidinyl, pirazolinyl, pyrazalinyl, piperidyl, piperazinyl, hexahydropyrimidinyl, morpholinyl, thiomorpholinyl, dihydrobenzofuranyl, tetrahydrofuranyl, tetrahydropyranyl, dihydro-oxazolyl, dithiolyl, oxathiolyl, dioxazolyl, oxathiazolyl, pyranyl, oxazinyl, oxathiazinyl, and oxadiazinyl.
- heterocycloalkyl include fused ring systems, including, for example, ring systems in which an aromatic ring is fused to a heterocycloalkyl ring.
- fused ring systems include, for example, phthalamide, phthalic anhydride, indoline, isoindoline, tetrahydroisoquinoline, chroman, isochroman, chromene, and isochromene.
- Heterocycloalkyl groups can be substituted or unsubstituted.
- pyridazin-3-one moiety refers to a 6 to 10 membered heterocycloalkyl ring system containing a pyridazin-3-one group and optionally a second fused ring.
- the second fused ring is optionally a substituted or unsubstituted phenyl ring, a substituted or unsubstituted C 3 -C 6 cycloalkyl ring, a substituted or unsubstituted 5 to 6 membered fused heteroaryl ring system containing one, two, or three heteroatoms selected from N, O, and S, or a substituted or unsubstituted 5 to 6 membered fused heterocycloalkyl ring system containing one, two, or three heteroatoms selected from N, O, and S.
- Examples of a second fused ring include, but are not limited to, phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- arylalkyl refers to an alkyl group that is substituted with an aryl group.
- arylalkyl groups include, but are not limited to, benzyl, bromobenzyl, phenethyl, benzhydryl, diphenylmethyl, triphenylmethyl, diphenylethyl, naphthylmethyl, etc.
- Arylalkyl groups can be substituted or unsubstituted.
- amino acid refers to a group containing both an amino group and a carboxyl group.
- Embodiments of amino acids include ⁇ -amino, ⁇ -amino, ⁇ -amino acids.
- the ⁇ -amino acids have a general formula HOOC—CH(side chain)-NH 2 .
- the amino acids can be in their D, L or racemic configurations
- Amino acids include naturally-occurring and non-naturally occurring moieties.
- the naturally-occurring amino acids include the standard 20 ⁇ -amino acids found in proteins, such as glycine, serine, tyrosine, proline, histidine, glutamine, etc.
- Naturally-occurring amino acids can also include non- ⁇ -amino acids (such as ⁇ -alanine, ⁇ -aminobutyric acid, homocysteine, etc.), rare amino acids (such as 4-hydroxyproline, 5-hydroxylysine, 3-methylhistidine, etc.) and non-protein amino acids (such as citrulline, ornithine, canavanine, etc.).
- Non-naturally occurring amino acids are well-known in the art, and include analogs of natural amino acids. See Lehninger, A. L. Biochemistry, 2 nd ed.; Worth Publishers: New York, 1975; 71-77, the disclosure of which is incorporated herein by reference.
- Non-naturally occurring amino acids also include ⁇ -amino acids wherein the side chains are replaced with synthetic derivatives.
- substituent groups for the compounds of the present invention include the residue of an amino acid after removal of the hydroxyl moiety of the carboxyl group thereof; i.e., groups of formula —C( ⁇ O)CH(side chain)-NH 2 .
- Representative side chains of naturally occurring and non-naturally occurring ⁇ -amino acids include are shown below in Table A.
- the term “subject” refers to a warm blooded animal such as a mammal, preferably a human, or a human child, which is afflicted with, or has the potential to be afflicted with, one or more diseases and conditions described herein.
- a “therapeutically effective amount” refers to an amount of a compound of the present invention effective to prevent or treat the symptoms of particular disorder.
- disorders include, but are not limited to, those pathological and neurological disorders associated with the aberrant activity of the receptors described herein, wherein the treatment or prevention comprises inhibiting, inducing, or enhancing the activity thereof by contacting the receptor with a compound of the present invention.
- the term “pharmaceutically acceptable” refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem complications commensurate with a reasonable benefit/risk ratio.
- Pharmaceutically acceptable compounds, materials, compositions, and/or dosage forms should be on the Generally Recognized as Safe (GRAS) list.
- unit dose refers to a single dose which is capable of being administered to a patient, and which can be readily handled and packaged, remaining as a physically and chemically stable unit dose comprising either the active compound itself, or as a pharmaceutically acceptable composition, as described hereinafter.
- the present invention is directed to pharmaceutically acceptable salts of the compounds described above.
- pharmaceutically acceptable salts includes salts of compounds of the present invention derived from the combination of such compounds with non-toxic acid or base addition salts.
- Acid addition salts include inorganic acids such as hydrochloric, hydrobromic, hydroiodic, sulfuric, nitric and phosphoric acid, as well as organic acids such as acetic, citric, propionic, tartaric, glutamic, salicylic, oxalic, methanesulfonic, para-toluenesulfonic, succinic, and benzoic acid, and related inorganic and organic acids.
- inorganic acids such as hydrochloric, hydrobromic, hydroiodic, sulfuric, nitric and phosphoric acid
- organic acids such as acetic, citric, propionic, tartaric, glutamic, salicylic, oxalic, methanesulfonic, para-toluenesulfonic, succinic, and benzoic acid, and related inorganic and organic acids.
- Base addition salts include those derived from inorganic bases such as ammonium and alkali and alkaline earth metal hydroxides, carbonates, bicarbonates, and the like, as well as salts derived from basic organic amines such as aliphatic and aromatic amines, aliphatic diamines, hydroxy alkamines, and the like.
- bases useful in preparing the salts of this invention thus include ammonium hydroxide, potassium carbonate, sodium bicarbonate, calcium hydroxide, methylamine, diethylamine, ethylenediamine, cyclohexylamine, ethanolamine and the like.
- salts are included in the invention. They may serve as intermediates in the purification of the compounds, in the preparation of other salts, or in the identification and characterization of the compounds or intermediates.
- the pharmaceutically acceptable salts of compounds of the present invention can also exist as various solvates, such as with water, methanol, ethanol, dimethylformamide, ethyl acetate and the like. Mixtures of such solvates can also be prepared.
- the source of such solvate can be from the solvent of crystallization, inherent in the solvent of preparation or crystallization, or adventitious to such solvent. Such solvates are within the scope of the present invention.
- prodrug is intended to include any compounds which are converted by metabolic processes within the body of a subject to an active agent that has a formula within the scope of the present invention. Since prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (e.g., solubility, bioavailability, manufacturing, etc.) the compounds of the present invention may be delivered in prodrug form. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in Prodrugs , Sloane, K. B., Ed.; Marcel Dekker: New York, 1992, incorporated by reference herein in its entirety
- compounds of the present invention may exist in various stereoisomeric forms.
- the compounds of the present invention include both diastereomers and enantiomers.
- the compounds are normally prepared as racemates and can conveniently be used as such, but individual enantiomers can be isolated or synthesized by conventional techniques if so desired. Such racemates and individual enantiomers and mixtures thereof form part of the present invention.
- Stereoisomers can be prepared by stereospecific synthesis using enantiomerically pure or enantiomerically enriched starting materials.
- the specific stereoisomers of either starting materials or products can be resolved and recovered by techniques known in the art, such as resolution of racemic forms, normal, reverse-phase, and chiral chromatography, recrystallization, enzymatic resolution, or fractional recrystallization of addition salts formed by reagents used for that purpose.
- functional groups present on the compounds of Formula I may contain protecting groups.
- the amino acid side chain substituents of the compounds of Formula I can be substituted with protecting groups such as benzyloxycarbonyl or t-butoxycarbonyl groups.
- protecting groups are known per se as chemical functional groups that can be selectively appended to and removed from functionalities, such as hydroxyl groups and carboxyl groups. These groups are present in a chemical compound to render such functionality inert to chemical reaction conditions to which the compound is exposed. Any of a variety of protecting groups may be employed with the present invention.
- Preferred groups for protecting lactams include silyl groups such as t-butyldimethylsilyl (“TBDMS”), dimethoxybenzhydryl (“DMB”), acyl, benzyl (“Bn”), and methoxybenzyl groups.
- Preferred groups for protecting hydroxy groups include TBS, acyl, benzyl, benzyloxycarbonyl (“CBZ”), t-butyloxycarbonyl (“Boc”), and methoxymethyl.
- the compounds of the present invention may be prepared in a number of methods well known to those skilled in the art, including, but not limited to those described below, or through modifications of these methods by applying standard techniques known to those skilled in the art of organic synthesis. All processes disclosed in association with the present invention are contemplated to be practiced on any scale, including milligram, gram, multigram, kilogram, multikilogram or commercial industrial scale.
- the compounds of the present invention may be prepared in a number of methods well known to those skilled in the art, including, but not limited to those described below, or through modifications of these methods by applying standard techniques known to those skilled in the art of organic synthesis. All processes disclosed in association with the present invention are contemplated to be practiced on any scale, including milligram, gram, multigram, kilogram, multikilogram or commercial industrial scale.
- Standard transformations of NH III by alkylation or reductive amination reactions produce examples of general structure D.
- the 4,5-dihydropyridazinones structure D may be oxidized to an aromatic pyridazinone of general structure E using MnO 2 , CuCl 2 , DDQ, selenium oxide, DMSO/base or sodium 3-nitrobenzenesulfonate in the presence of sodium hydroxide.
- NH(R 8 ⁇ H) pyridazinones may be alkylated with alkyl or substituted alkyl groups using an R 8 -halide, a base, for example K 2 CO 3 , Cs 2 CO 3 or NaH, in an inert solvent such as DMF, THF or CH 3 CN.
- R 8 is H
- R 8 is aryl or heteroaryl by standard palladium or copper coupling reactions using the appropriate aryl or heteroaryl halide.
- Aryl pyridazinone examples of the invention may also be synthesized using standard Suzuki cross-coupling chemistry.
- a spiro boron ether derivatives of general structure F is subjected to a palladium catalyzed cross-coupling reaction (Suzuki reaction) with a pyridazine derivative of general structure G or a pyridazinone of structure H wherein the R 4a , R 5a or R 7 group may be a halogen, preferably Br or Ito produce examples of general structure J and K.
- Spiro-pyrrolidine, -azepine and -3-piperidine examples of the invention may be synthesized using methods outlined in for the spiro-4-piperidine examples starting with N-Boc-3-pyrrolidinone, N-Boc-hexahydro-1H-azepin-4-one or N-Boc-3-piperidone, respectively, in place of N-Boc-4-piperidone.
- Step 2 Synthesis of 1′-Trifluoroacetyl-5-(4-oxo-butyric acid ethyl ester)-spiro[benzofuran-2(3H), 4′-piperidine]
- Step 3 Synthesis of 6-(Spiro[benzofuran-2(3H), 4′-piperidine]-5-yl)-4,5-dihydro-2H-pyridazin-3-one
- Step 4 Synthesis of 6-(1-Cyclobutyl-spiro[benzofuran-2(3H), 4′-piperidine]-5-yl)-4,5-dihydro-2H-pyridazin-3-one
- the aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na 2 SO 4 ), filtered, and concentrated to provide a crude product.
- the crude product was purified by ISCO (40 g column) chromatography using 5 to 10% methanol in methylene chloride to 10% methanol containing 4 mL ammonium hydroxide in methylene chloride.
- the recovered pure product was dissolved in methylene chloride and washed with saturated aqueous sodium bicarbonate solution, brine, dried (Na 2 SO 4 ), filtered, and concentrated.
- Step 1 Synthesis of 1′-Trifluoroacetyl-5-(propanoyl)-spiro[benzofuran-2(3H), 4′-piperidine]
- the aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na 2 SO 4 ), filtered, and concentrated to provide a crude product.
- Step 2 Synthesis of 1′-Trifluoroacetyl-5-(3-methyl-4-oxo-butyric acid ethyl ester)-spiro[benzofuran-2(3H), 4′-piperidine]
- Step 3 Synthesis of 6-(Spiro[benzofuran-2(3H), 4′-piperidine]-5-yl)-5-methyl-4,5-dihydro-2H-pyridazin-3-one
- Step 4 Synthesis of 6-(1-Cyclobutyl-spiro[benzofuran-2(3H), 4′-piperidine]-5-yl)-5-methyl-4,5-dihydro-2H-pyridazin-3-one
- the reaction mixture was concentrated at reduced pressure and partitioned between aqueous 1M sodium carbonate solution and methylene chloride.
- the aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na 2 SO 4 ), filtered, and concentrated to provide a crude product.
- the crude product was purified by ISCO (120 g column) chromatography using 5 to 10% methanol in methylene chloride to obtain a pure product.
- the crude product was purified by ISCO (80 g) chromatography using 5% to 10% methanol in methylene chloride to 10% methanol containing 1% ammonium hydroxide in methylene chloride.
- the recovered product was dissolved in methylene chloride and washed with saturated aqueous sodium bicarbonate solution, brine, dried (Na 2 SO 4 ), filtered, and concentrated to produce a pure product.
- Step 1 Synthesis of 1′-Trifluoroacetyl-spiro[3,4-dihydrobenzopyran-2,4′-piperidine]
- Step 2 Synthesis of 1′-Trifluoroacetyl-6-(4-oxo-butyric acid)-spiro[3,4-dihydrobenzopyran-2,4′-piperidine]
- Step 3 Synthesis of 6-(4,5-Dihydro-2H-pyridazin-3-one-6-yl)-spiro[3,4-dihydrobenzopyran-2,4′-piperidine]
- Step 4 1′-Cyclobutyl-6-(4,5-dihydro-2H-pyridazin-3-one-6-yl)-spiro[3,4-dihydrobenzopyran-2,4′-piperidine]
- the aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na 2 SO 4 ), filtered, and concentrated to provide a crude product.
- the crude product was purified by ISCO (40 g column) chromatography using 4.5 to 10% methanol in methylene chloride to 10% methanol containing 4 mL of ammonium hydroxide in methylene chloride obtain a pure product.
- the recovered product was dissolved in methylene chloride and washed with saturated sodium bicarbonate solution, brine, dried (Na 2 SO 4 ), filtered, and concentrated.
- Step 1 Synthesis of 1′-Trifluoroacetyl-6-(propanoyl)-spiro[3,4-dihydrobenzopyran-2,4′-piperidine]
- the aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na 2 SO 4 ), filtered, and concentrated to provide a crude product.
- the crude product was purified by ISCO (80 g column) chromatography using 17 to 35% EtOAc in hexane to produce 1′-trifluoroacetyl-6-(propanoyl)-spiro[3,4-dihydrobenzopyran-2,4′-piperidine] (1.42 g, 81%),
- Step 2 Synthesis of 1′-Trifluoroacetyl-6-(3-methyl-4-oxo-butyric acid ethyl ester)-spiro[3,4-dihydrobenzopyran-2,4′-piperidine]
- Step 3 Synthesis of 6-(5-methyl-4,5-dihydro-2H-pyridazin-3-one-6-yl)-spiro[3,4-dihydrobenzopyran-2,4′-piperidine]
- Step 4 Synthesis of 1-Cyclobutyl-6-(5-methyl-4,5-dihydro-2H-pyridazin-3-one-6-yl)-spiro[3,4-dihydrobenzopyran-2,4′-piperidine]
- the aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na 2 SO 4 ), filtered, and concentrated to provide a crude product.
- the crude product was purified by ISCO (40 g) chromatography using 2 to 10% methanol in methylene chloride to 10% methanol containing 4 mL of ammonium hydroxide in methylene chloride to obtain a pure product.
- the recovered pure product was dissolved in methylene chloride and washed with saturated sodium bicarbonate solution, brine, dried (Na 2 SO 4 ), filtered, and concentrated.
- the crude product was purified by ISCO (40 g column) chromatography using 5% to 10% methanol in methylene chloride to 10% methanol containing 4% ammonium hydroxide in methylene chloride.
- the recovered product was dissolved in methylene chloride and washed with saturated aqueous sodium bicarbonate solution, brine, dried (Na 2 SO 4 ), filtered, and concentrated to produce a pure product.
- the recovered pure product was dissolved in methylene chloride and washed with saturated aqueous sodium bicarbonate solution, brine, dried (Na 2 SO 4 ), filtered, and concentrated.
- the pure product was crystallized from a mixture of methylene chloride, methanol, ether, and hexane to produce 6-(3,4-dihydro spiro[2H-1-benzopyran-2,4′-piperidine]-6-yloxy)-2H-pyridazin-3-one as an off-white solid (170 mg, 76%), mp 233-235° C.
- reaction mixture was flashed with N 2 for 25 min and was then heated to reflux for 16 h.
- the reaction was cooled to rt and small amount of NaCNBH 3 was added and stirred for 5 min.
- the reaction was diluted with CH 2 Cl 2 /MeOH (100 mL, 3:1) then washed with saturated NaHCO 3 , brine and dried (Na 2 SO 4 ).
- Example 10 Racemic Example 10 was separated into two isomers using chiral chromatography; ChiralCel OJ-H and 0.1% diethylamine in 35% methanol/CO 2 .
- the individual isomers are designated as Example 22 (Peak A, elutes first from chiral column) and Example 23 (Peak B, elutes second from chiral column)
- the water layer was decanted from the white semi-solid material, which was dissolved in DMC and dried (MgSO4).
- the product was purified on ISCO (silica gel, 95/5 increasing to 9/1 DCM/MeOH) to give 1.9 g (33%). mp 266-269° C.
- the reaction was warmed to rt and concentrated to remove the organic solvents.
- the product was purified using silica gel column chromatography (2-3% methanol/dichloromethane). The fractions were concentrated, triturated with dichloromethane ( ⁇ 5 mL)/ether ( ⁇ 10 mL)/hexanes ( ⁇ 15-20 mL), and filtered off white solid to obtain 5.52 g (34%); MS m/z: 434 (M+H).
- step 1 To the product from step 1 (5.52 g, 12.7 mmol) (1′-carboylic acid tert-butyl ester-6-(2,2-dimethyl-4-oxo-butyric acid)-spiro[1,3-benzodioxine-2,4′-piperidine]) in isopropyl alcohol (70 mL) was added hydrazine monohydrate (0.956 mL, 19.1 mmol) and the reaction was heated at 80° C. overnight and concentrated. The residue was partitioned between water/dichloromethane, washed with brine, dried over sodium sulfate, and concentrated to obtain 5.4 g (>95%) of a crude product; MS m/z: 430 (M+H).
- the reaction was partitioned between dichloromethane/1N sodium carbonate, washed with water and brine, dried over sodium sulfate, and concentrated.
- the product was purified using a single step silica gel column (5% methanol/dichloromethane) and concentrated.
- the free base was dissolved in chloroform ( ⁇ 50 mL) and 1N HCl/ether ( ⁇ 17 mL) was added.
- the product was collected after addition of ether to give 3.64 g (67%) of white solid; mp 269-270° C. MS m/z: 384 (M+H).
- the compounds of the present invention are useful, inter alia, as therapeutic agents. Particularly, the compounds are useful for interacting with the H 3 receptor.
- the present invention provides a method for treating or preventing diseases and disorders, such as those disclosed herein, which comprises administering to a subject in need of such treatment or prevention a therapeutically effective amount of a compound of the present invention.
- the present invention provides a method for inhibiting H 3 activity comprising providing a compound of the present invention in an amount sufficient to result in effective inhibition.
- the compounds of the present invention can be administered to treat such diseases and disorders such as narcolepsy or other sleep/wake disorders, such as obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder; feeding behavior disorder, eating disorders, obesity, cognition disorders, arousal disorders, memory disorders, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders, epilepsy, gastrointestinal disorders, respiratory disorders (such as asthma), inflammation, and myocardial infarction.
- diseases and disorders such as narcolepsy or other sleep/wake disorders, such as obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder
- feeding behavior disorder eating disorders, obesity, cognition disorders,
- the compounds can be administered to treat narcolepsy or other sleep/wake disorders, such as obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder; obesity, cognition disorders, attention deficit hyperactivity disorder (ADHD), and dementia.
- the compounds can be administered to treat narcolepsy or other sleep/wake disorders, such as obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder; or they can used to treat obesity, or they can used to treat cognition disorders, or they can used to treat attention deficit hyperactivity disorder (ADHD), or they can used to treat dementia.
- narcolepsy or other sleep/wake disorders such as obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder
- ADHD attention deficit hyperactivity disorder
- the rat H 3 receptor cDNA was PCR amplified from reverse-transcribed RNA pooled from rat thalamus, hypothalamus, striatum and prefrontal cortex with a sequence corresponding to by #338-1672 of Genbank file #NM — 053506, encoding the entire 445-amino-acid rat histamine H 3 receptor. This was engineered into the pIRES-neo3 mammalian expression vector, which was stably transfected into the CHO-A3 cell line (Euroscreen, Belgium), followed by clonal selection by limiting dilution. Cells were harvested and cell pellets were frozen ( ⁇ 80° C.).
- Cell pellets were resuspended in 5 mM Tris-HCl, pH 7.5 with 5 nM EDTA and a cocktail of protease inhibitors (Complete Protease Inhibitor Tablets, Roche Diagnostics). Cells were disrupted using a polytron cell homogenizer and the suspension was centrifuged at 1000 ⁇ g for 10 minutes at 4° C. The pellet was discarded and the supernatant centrifuged at 40,000 ⁇ g for 30 min at 4° C.
- This membrane pellet was washed in membrane buffer containing 50 mM Tris-HCl, pH 7.5 with 0.6 mM EDTA, 5 mM MgCl 2 and protease inhibitors, recentrifuged as above and the final pellet resuspended in membrane buffer plus 250 mM sucrose and frozen at ⁇ 80° C.
- Membranes were resuspended in 50 mM Tris HCl (pH 7.4), 5 mM MgCl 2 , 0.1% BSA. The membrane suspensions (10 ⁇ g protein per well) were incubated in a 96 well microtiter plate with [ 3 H]-N-alpha-methylhistamine (approximately 1 nM final concentration), test compounds at various concentrations (0.01 nM-30 ⁇ M) and scintillation proximity beads (Perkin Elmer, FlashBlueGPCR Scintillating Beads) in a final volume of 80 ⁇ l for 4 hours at room temperature, protected from light. Non-specific binding was determined in the presence of 10 ⁇ M clobenpropit. Radioligand bound to receptor, and therefore in proximity to the scintillation beads, was measured using a MicroBeta scintillation counter.
- Membranes were resuspended in 20 mM HEPES pH 7.4 containing 1 mM EDTA, 0.17 mg/ml dithiothreitol, 100 mM NaCl, 30 ⁇ g/ml saponin and 5 mM MgCl 2 .
- increasing concentrations of test compounds were incubated in a 96 well microtiter plate with 10 ⁇ g/well membrane protein, 5 ⁇ M GDP, scintillation proximity beads (Perkin Elmer, FlashBlueGPCR Scintillating Beads) and [ 35 S]-GTP ⁇ S (0.1 nM final concentration).
- Membranes were resuspended in 20 mM HEPES pH 7.4 containing 1 mM EDTA, 0.17 mg/ml dithiothreitol, 200 mM NaCl, 30 ⁇ g/ml saponin and 20 mM MgCl 2 .
- the membranes were incubated at 10 ⁇ g/well membrane protein in a microtiter plate with increasing concentrations of test compounds, 20 ⁇ M GDP, scintillation proximity beads and [ 35 S]-GTP ⁇ S (0.1 nM final concentration) plus 30 nM R-alpha-methylhistamine.
- the microtiter plates were incubated and processed as described above. A decrease in R-alpha-methylhistamine stimulated [ 35 S]-GTP ⁇ S binding is indicative of H 3 receptor antagonist activity in this assay.
- CHO cells stably expressing the human H 3 receptor (GenBank: NM — 007232) were harvested and cell pellets were frozen ( ⁇ 80° C.). Cell pellets were resuspended in 5 mM Tris-HCl, pH 7.5 with 5 nM EDTA and a cocktail of protease inhibitors (Complete Protease Inhibitior Tablets, Roche Diagnostics). Cells were disrupted using a polytron cell homogenizer and the suspension was centrifuged at 1000 ⁇ g for 10 minutes at 4° C. The pellet was discarded and the supernatant centrifuged at 40,000 ⁇ g for 30 min at 4° C.
- This membrane pellet was washed in membrane buffer containing 50 mM Tris-HCl, pH 7.5 with 0.6 mM EDTA, 5 mM MgCl 2 and protease inhibitors, recentrifuged as above and the final pellet resuspended in membrane buffer plus 250 mM sucrose and frozen at ⁇ 80° C.
- Membranes were resuspended in 50 mM Tris HCl (pH 7.4), 5 mM MgCl 2 , 0.1% BSA. The membrane suspensions (10 ⁇ g protein per well) were incubated in a 96 well microtiter plate with [ 3 H]-N-alpha-methylhistamine (approximately 1 nM final concentration), test compounds at various concentrations (0.01 nM-30 ⁇ M) and scintillation proximity beads (Perkin Elmer, FlashBlueGPCR Scintillating Beads) in a final volume of 80 ⁇ l for 4 hours at room temperature, protected from light. Non-specific binding was determined in the presence of 10 ⁇ M clobenpropit. Radioligand bound to receptor, and therefore in proximity to the scintillation beads, was measured using a MicroBeta scintillation counter.
- GTP ⁇ S Binding Membranes were resuspended in 20 mM HEPES pH 7.4 containing 1 mM EDTA, 0.17 mg/ml dithiothreitol, 100 mM NaCl, 30 ⁇ g/ml saponin and 5 mM MgCl 2 .
- increasing concentrations of test compounds were incubated in a 96 well microtiter plate with 10 ⁇ g/well membrane protein, 5 ⁇ M GDP, scintillation proximity beads (Perkin Elmer, FlashBlueGPCR Scintillating Beads) and [ 35 S]-GTP ⁇ S (0.1 nM final concentration).
- Membranes were resuspended in 20 mM HEPES pH 7.4 containing 1 mM EDTA, 0.17 mg/ml dithiothreitol, 200 mM NaCl, 30 ⁇ g/ml saponin and 20 mM MgCl 2 .
- the membranes were incubated at 10 ⁇ g/well membrane protein in a microtiter plate with increasing concentrations of test compounds, 20 ⁇ M GDP, scintillation proximity beads and [ 35 S]-GTP ⁇ S (0.1 nM final concentration) plus 30 nM R-alpha-methylhistamine.
- the microtiter plates were incubated and processed as described above. A decrease in R-alpha-methylhistamine stimulated [ 35 S]-GTP ⁇ S binding is indicative of H 3 receptor antagonist activity in this assay.
- Histamine, and the H 3 -selective agonist (R)- ⁇ -methylhistamine (RAMH) induce water drinking behavior in the rat when administered either peripherally or centrally (Kraly, F. S., June, K. R. 1982 Physiol. Behav. 28: 841.; Leibowitz, S. F. 1973 Brain Res. 63:440; Ligneau X., Lin, J-S., Vanni-Mercier G., Jouvet M., Muir J. L., Ganellin C. R., Stark H., Elz S., Schunack W., Schwartz, J-C. 1998 J Pharmcol. Exp. Ther.
- Novel object discrimination is an assay for short-term visual recognition memory that was first described by Ennaceur and Delacour (Ennaceur, A. and Delacour, J. (1988) Behav Brain Res 31: 47-59).
- SR Social recognition
- Binding constants (K i ) for Examples 1-41 in the Human H 3 and Rat H 3 methods described herein are expressed by letter descriptor to indicate the following ranges: “+++” is less than 200 nM; “++” is 200-1000 nM; “+” is >1000 nM.
- the compounds of the present invention can be administered by any means that results in the contact of the active agent with the agent's site of action in the body of the subject.
- the compounds may be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in combination with other therapeutic agents, such as, for example, analgesics.
- the compounds of the present invention are preferably administered in therapeutically effective amounts for the treatment of the diseases and disorders described herein to a subject in need thereof.
- a therapeutically effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of conventional techniques.
- the effective dose will vary depending upon a number of factors, including the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, the formulation of the active agent with appropriate excipients, and the route of administration.
- the compounds are administered at lower dosage levels, with a gradual increase until the desired effect is achieved.
- Typical dose ranges are from about 0.01 mg/kg to about 100 mg/kg of body weight per day, with a preferred dose from about 0.01 mg/kg to 10 mg/kg of body weight per day.
- a preferred daily dose for adult humans includes about 25, 50, 100 and 200 mg, and an equivalent dose in a human child.
- the compounds may be administered in one or more unit dose forms.
- the unit dose ranges from about 1 to about 500 mg administered one to four times a day, preferably from about 10 mg to about 300 mg, two times a day.
- an oral unit dose is one that is necessary to achieve a blood serum level of about 0.05 to 20 ⁇ g/ml in a subject, and preferably about 1 to 20 ⁇ g/ml.
- the compounds of the present invention may be formulated into pharmaceutical compositions by admixture with one or more pharmaceutically acceptable excipients.
- the excipients are selected on the basis of the chosen route of administration and standard pharmaceutical practice, as described, for example, in Remington: The Science and Practice of Pharmacy, 20 th ed.; Gennaro, A. R., Ed.; Lippincott Williams & Wilkins: Philadelphia, Pa., 2000.
- the compositions may be formulated to control and/or delay the release of the active agent(s), as in fast-dissolve, modified-release, or sustained-release formulations.
- Such controlled-release, or extended-release compositions may utilize, for example biocompatible, biodegradable lactide polymers, lactide/glycolide copolymers, polyoxyethylene-polyoxypropylene copolymers, or other solid or semisolid polymeric matrices known in the art.
- compositions can be prepared for administration by oral means; parenteral means, including intravenous, intramuscular, and subcutaneous routes; topical or transdermal means; transmucosal means, including rectal, vaginal, sublingual and buccal routes; ophthalmic means; or inhalation means.
- parenteral means including intravenous, intramuscular, and subcutaneous routes
- transmucosal means including rectal, vaginal, sublingual and buccal routes
- ophthalmic means or inhalation means.
- the compositions are prepared for oral administration, particularly in the form of tablets, capsules or syrups; for parenteral administration, particularly in the form of liquid solutions, suspensions or emulsions; for intranasal administration, particularly in the form of powders, nasal drops, or aerosols; or for topical administration, such as creams, ointments, solutions, suspensions aerosols, powders and the like.
- the tablets, pills, powders, capsules, troches and the like can contain one or more of the following: diluents or fillers such as starch, or cellulose; binders such as microcrystalline cellulose, gelatins, or polyvinylpyrrolidones; disintegrants such as starch or cellulose derivatives; lubricants such as talc or magnesium stearate; glidants such as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin; or flavoring agents such as peppermint or cherry flavoring.
- Capsules may contain any of the afore listed excipients, and may additionally contain a semi-solid or liquid carrier, such as a polyethylene glycol.
- the solid oral dosage forms may have coatings of sugar, shellac, or enteric agents.
- Liquid preparations may be in the form of aqueous or oily suspensions, solutions, emulsions, syrups, elixirs, etc., or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
- Such liquid preparations may contain conventional additives such as surfactants, suspending agents, emulsifying agents, diluents, sweetening and flavoring agents, dyes and preservatives.
- compositions may also be administered parenterally.
- the pharmaceutical forms acceptable for injectable use include, for example, sterile aqueous solutions, or suspensions.
- Aqueous carriers include mixtures of alcohols and water, buffered media, and the like.
- Nonaqueous solvents include alcohols and glycols, such as ethanol, and polyethylene glycols; oils, such as vegetable oils; fatty acids and fatty acid esters, and the like.
- compositions can be added including surfactants; such as hydroxypropylcellulose; isotonic agents, such as sodium chloride; fluid and nutrient replenishers; electrolyte replenishers; agents which control the release of the active compounds, such as aluminum monostearate, and various co-polymers; antibacterial agents, such as chlorobutanol, or phenol; buffers, and the like.
- surfactants such as hydroxypropylcellulose; isotonic agents, such as sodium chloride; fluid and nutrient replenishers; electrolyte replenishers; agents which control the release of the active compounds, such as aluminum monostearate, and various co-polymers; antibacterial agents, such as chlorobutanol, or phenol; buffers, and the like.
- the parenteral preparations can be enclosed in ampules, disposable syringes or multiple dose vials.
- Other potentially useful parenteral delivery systems for the active compounds include ethylene-vinyl acetate copolymer particles, osmotic pumps
- formulations for inhalation which include such means as dry powder, aerosol, or drops. They may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally.
- Formulations for topical use are in the form of an ointment, cream, or gel. Typically these forms include a carrier, such as petrolatum, lanolin, stearyl alcohol, polyethylene glycols, or their combinations, and either an emulsifying agent, such as sodium lauryl sulfate, or a gelling agent, such as tragacanth.
- Formulations suitable for transdermal administration can be presented as discrete patches, as in a reservoir or microreservoir system, adhesive diffusion-controlled system or a matrix dispersion-type system.
- Formulations for buccal administration include, for example lozenges or pastilles and may also include a flavored base, such as sucrose or acacia, and other excipients such as glycocholate.
- Formulations suitable for rectal administration are preferably presented as unit-dose suppositories, with a solid based carrier, such as cocoa butter, and may include a salicylate.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
The present invention is directed to methods of treating disorders mediated by Histamine H3 receptors by administering novel substituted spirocyclic piperidine derivatives according to Formula (I).
In particular, the substituted spirocyclic piperidine derivatives may be effective in the treatment of diseases or disease states, including narcolepsy or sleep/wake disorders, feeding behavior disorders, eating disorders, obesity, cognition disorders, arousal disorders, memory disorders, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders, epilepsy, gastrointestinal disorders, respiratory disorders, inflammation, and myocardial infarction.
Description
- This application is a continuation application of U.S. Ser. No. 12/846,108, filed Jul. 29, 2010, which is a continuation of International Application No. PCT/US2009/032195, filed Jan. 28, 2009, which claims priority to U.S. Provisional Application Ser. No. 61/062,909, filed Jan. 30, 2008. The disclosures of the aforementioned applications are incorporated herein by reference in their entireties for all purposes.
- The present invention is related to substituted spirocyclic piperidine derivatives, their use as H3 antagonists/inverse agonists, processes for their preparation, and pharmaceuticals compositions thereof.
- Publications cited throughout this disclosure are incorporated in their entirety herein by reference.
- Histamine is a well established modulator of neuronal activity. At least four subtypes of histamine receptors have been reported in the literature—H1, H2, H3, H4. The histamine H3 receptors play a key role in neurotransmission in the central nervous system. The H3 receptor was discovered in 1983 originally on histamine-containing neurons where it was shown to function presynaptically, regulating the release and synthesis of the biogenic amine histamine (Arrang et al, 1983) now a well established neurotransmitter. H3 receptors are predominately expressed in the brain, localizing to the cerebral cortex, amygdala, hippocampus, striatum, thalamus and hypothalamus. H3 receptors are also localized presynaptically on histaminergic nerve terminals and act as inhibitory autoreceptors (Alguacil and Perez-Garcia, 2003; Passani et al, 2004; Leurs at al, 2005; Celanire et al, 2005; Witkin and Nelson, 2004). When these receptors are activated by histamine, histamine release is inhibited. H3 receptors can also be found in the periphery (skin, lung, cardiovascular system, intestine, GI tract, etc). H3 receptors are also involved in presynaptic regulation of the release of acetylcholine, dopamine, GABA, glutamate and serotonin (see Repka-Ramirez, 2003; Chazot and Hann, 2001; Leurs et al, 1998). The H3 receptor demonstrates a high degree of constitutive or spontaneous activity (e.g., receptor is active in the absence of agonist stimulation) in vitro and in vivo, thus, ligands to the receptor can display, agonist, neutral antagonist or inverse agonist effects.
- The location and function of histaminergic neurons in the CNS suggests that compounds interacting with the H3 receptor may have utility in a number of therapeutic applications including narcolepsy or sleep/wake disorders, feeding behavior, eating disorders, obesity, cognition, arousal, memory, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders and epilepsy (Leurs et al, 2005; Witkin and Nelson, 2004, Hancock and Fox 2004; Esbenshade et al. 2006). An H3 antagonist/inverse agonist could be important for gastrointestinal disorders, respiratory disorders such as asthma, inflammation, and myocardial infarction.
- Ohtake et al. (US 2006/0178375 A1) disclosed compounds that reportedly exhibit histamine receptor H3 antagonist or inverse agonist activity and may be useful for the treatment or prevention of obesity, diabetes, hormonal secretion abnormality, or sleep disorders.
- Celanire et al. (WO 2006/103057 A1 and WO 2006/103045) have disclosed compounds comprising an oxazoline or thiazoline moiety, processes for preparing them, their pharmaceutical compositions and their uses as H3 ligands.
- Bertrand et al. (WO 2006/117609 A2) disclosed novel histamine H3 receptor ligands, processes for their preparation, and their therapeutic applications.
- Schwartz et al. (WO 2006/103546 A2) disclosed certain methods of treatment for Parkinson's disease, obstructive sleep apnea, narcolepsy, dementia with Lewy bodies, and/or vascular dementia using non-imidazole alkylamine derivatives that are antagonists of the H3 receptors of histamine
- Apodaca et al. (EP 1 311 482 B1) disclosed certain non-imidazole aryloxypiperidines as H3 receptor ligands, their synthesis, and their use for the treatment of disorders and conditions mediated by the histamine receptor.
- Xu et al. disclosed certain 6-substituted phenyl-4,5-dihydro-3(2H)-pyridazinones, their synthesis, and rabbit platelet aggregation inhibitory activity induced by ADP in vitro.
- Barker et al. (US 2006/0217375) discloses spiro[benzodioxane] compounds as active antagonists of the orexin-1 receptor and potentially useful in the prophylaxis and treatment of orexin-1 receptor related disorders and orexin-2 receptor related disorders.
- Thus, there is a need for novel classes of compounds that interact with the H3 receptor.
- The present invention is directed to compounds of Formula (I):
- and the stereoisomeric forms, mixtures of stereoisomeric forms, and pharmaceutically acceptable salt forms thereof,
wherein: - R1 is H, C1-C4 alkyl, or C3-C8 cycloalkyl;
- W is —CH2—, —CH2CH2—, or —CH2—O—;
- k is 0, 1, or 2; m is 0, 1, or 2; and the sum of m and k is 1, 2, or 3;
- Y2═Y3 is —C(X)═CH— or —CH═C(X)—;
- X is R2, —OR2, —(C1-C3 alkyl)-R2, —O—(C1-C3 alkyl)-R2, —NHR2, —NHC(═O)R2, or —NHC(═O)NHR2; wherein said C1-C3 alkyl is optionally substituted with —OH or C1-C4 alkoxy;
- R2 is
- A is F, Cl, or Br;
- R3 is H, F, or C1-C4 alkyl;
- R4 is H, F, or C1-C4 alkyl;
- R4A is H, F, Cl, Br, or C1-C4 alkyl;
- R5 is H, F, or C1-C4 alkyl;
- R5A is H, F, Cl, Br, C1-C4 alkyl or phenyl;
- alternatively, R4 and R5, together with the carbon atoms to which they are attached, may form a fused C3-C6 cycloalkyl ring optionally substituted with 1, 2, or 3 R14;
- alternatively, R4A and R5A, together with the carbon atoms to which they are attached, may form a fused phenyl ring optionally substituted with 1, 2, or 3 R14;
- a C3-C6 cycloalkyl ring optionally substituted with 1, 2 or 3 R14;
- a 5 to 6 membered fused heteroaryl ring system containing one, two, or three heteroatoms selected from N, O, and S, wherein said heteroaryl ring system is optionally substituted with 1, 2, or 3 R14; or
- a 5 to 6 membered fused heterocycloalkyl ring system containing one, two, or three heteroatoms selected from N, O, S, SO, and SO2, wherein said heterocycloalkyl ring system is optionally substituted with 1, 2, or 3 R14;
- R6 is H, F, or C1-C4 alkyl;
- R7 is H, F, Cl, Br, or C1-C4 alkyl;
- R8 is H, —C(═O)R27, —CO2R27, C1-C6 alkyl optionally substituted by 1-3 R20;
- C3-C8 cycloalkyl optionally substituted by 1-3 R20A;
- C6-C10 aryl optionally substituted by 1-3 R20A;
- C7-C15 arylalkyl optionally substituted by 1-3 R20A; or
- a 5 to 10 membered heteroaryl ring system containing one, two, or three heteroatoms selected from N, O, and S, wherein said heteroaryl ring system is optionally substituted with 1-3 R20A;
- R9, at each occurrence, is independently F, Cl, Br, C1-C4 alkyl, or C1-C4 alkoxy;
- R10 is F, Cl, Br, C1-C3 alkyl, or C1-C3 alkoxy;
- R14 at each occurrence is independently F, Cl, Br, I, —OR21, —OR22, —NR23R24, —NHOH, —NO2, —CN, —CF3, (═O), —C(═O)R21, —CO2R21, —OC(═O)R21, —C(═O)NR23R24, —NR27C(═O)R21, —NR27C(═O)OR21, —OC(═O)NR23R24, —NR27C(═S)R21, —SR21, —S(O)R21, or —S(O)2R21; C1-C6 alkyl optionally substituted with OR26; C2-C6 alkenyl, or C2-C6 alkynyl;
- R20 at each occurrence is independently F, Cl, Br, I, —OR21, —OR22, —NR23R24, —NHOH, —NO2, —CN, —CF3, (═O), —C(═O)R21, —CO2R21, —OC(═O)R21, —C(═)NR23R24, —NR27C(═O)R21, —NR27C(O)OR21, —OC(═O)NR23R24, —NR27C(═S)R21, —SR21, —S(O)R21, or —S(O)2R21; C1-C6 alkyl optionally substituted with OR26; C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, phenyl, 3- to 7-membered heterocycloalkyl group, or 5- or 6-membered heteroaryl group;
- R20A at each occurrence is independently F, Cl, Br, I, —OR21, —OR22, —NR23R24, —NHOH, —NO2, —CN, —CF3, (═O), —C(═O)R21, —CO2R21, —OC(═O)R21, —C(═O)NR23R24, —NR27C(═O)R21, —NR27C(═O)OR21, —OC(═O)NR23R24, —NR27C(═S)R21, —SR21, —S(O)R21, or —S(O)2R21; C1-C6 alkyl optionally substituted with OR26; C2-C6 alkenyl, or C2-C6 alkynyl;
- R21 at each occurrence is independently H, C1-C6 alkyl, C6-C10 aryl, or C7-C15 arylalkyl;
- R22 at each occurrence is independently the residue of an amino acid after the hydroxyl group of the carboxyl group is removed;
- R23 and R24 at each occurrence is independently selected from H, C1-C6 alkyl, and C6-C10 aryl;
- alternatively, R23 and R24, together with the nitrogen atom to which they are attached, form a 3 to 7 membered heterocycloalkyl ring system containing one, two, or three heteroatoms selected from N, O, and S, wherein said heterocycloalkyl ring system is optionally substituted with ═O;
- R26 is H or C1-C6 alkyl;
- R27 is H or C1-C6 alkyl;
- n is 0, 1, 2, or 3; and
- z is 0, 1, 2, 3, 4, 5, or 6.
- The present invention is also directed to methods of making compounds of Formula (I), as well as methods of their pharmaceutical use.
- In preferred embodiments, the present invention provides compounds of Formula (I):
- or a stereoisomeric form, mixtures of stereoisomeric forms, or pharmaceutically acceptable salt forms thereof,
wherein: - R1 is H, C1-C4 alkyl, or C3-C8 cycloalkyl;
- W is —CH2—, —CH2CH2—, or —CH2—O—;
- k is 0, 1, or 2; m is 0, 1, or 2; and the sum of m and k is 1, 2, or 3;
- Y2═Y3 is —C(X)═CH— or —CH═C(X)—;
- X is R2, —OR2, —(C1-C3 alkyl)-R2, —O—(C1-C3 alkyl)-R2, —NHR2, —NHC(═O)R2, or —NHC(═O)NHR2; wherein said C1-C3 alkyl is optionally substituted with —OH or C1-C4 alkoxy;
- R2 is
- A is F, Cl, or Br;
- R3 is H, F, or C1-C4 alkyl;
- R4 is H, F, or C1-C4 alkyl;
- R4A is H, F, Cl, Br, or C1-C4 alkyl;
- R5 is H, F, or C1-C4 alkyl;
- R5A is H, F, Cl, Br, C1-C4 alkyl or phenyl;
- alternatively, R4 and R5, together with the carbon atoms to which they are attached, may form a fused C3-C6 cycloalkyl ring optionally substituted with 1, 2, or 3 R14;
- alternatively, R4A and R5A, together with the carbon atoms to which they are attached, may form a fused phenyl ring optionally substituted with 1, 2, or 3 R14;
- a C3-C6 cycloalkyl ring optionally substituted with 1, 2 or 3 R14;
- a 5 to 6 membered fused heteroaryl ring system containing one, two, or three heteroatoms selected from N, O, and S, wherein said heteroaryl ring system is optionally substituted with 1, 2, or 3 R14; or
- a 5 to 6 membered fused heterocycloalkyl ring system containing one, two, or three heteroatoms selected from N, O, S, SO, and SO2, wherein said heterocycloalkyl ring system is optionally substituted with 1, 2, or 3 R14;
- R6 is H, F, or C1-C4 alkyl;
- R7 is H, F, Cl, Br, or C1-C4 alkyl;
- R8 is H, —C(═O)R27, —CO2R27, C1-C6 alkyl optionally substituted by 1-3 R20;
- C3-C8 cycloalkyl optionally substituted by 1-3 R20A;
- C6-C10 aryl optionally substituted by 1-3 R20A;
- C7-C15 arylalkyl optionally substituted by 1-3 R20A; or
- a 5 to 10 membered heteroaryl ring system containing one, two, or three heteroatoms selected from N, O, and S, wherein said heteroaryl ring system is optionally substituted with 1-3 R20A;
- R9, at each occurrence, is independently F, Cl, Br, C1-C4 alkyl, or C1-C4 alkoxy;
- R10 is F, Cl, Br, C1-C3 alkyl, or C1-C3 alkoxy;
- R14 at each occurrence is independently F, Cl, Br, I, —OR21, —OR22, —NR23R24, —NHOH, —NO2, —CN, —CF3, (═O), —C(═O)R21, —CO2R21, —OC(═O)R21, —C(═O)NR23R24, —NR27C(═O)R21, —NR27C(═O)OR21, —OC(═O)NR23R24, —NR27C(═S)R21, —SR21, —S(O)R21, or —S(O)2R21; C1-C6 alkyl optionally substituted with OR26; C2-C6 alkenyl, or C2-C6 alkynyl;
- R20 at each occurrence is independently F, Cl, Br, I, —OR21, —OR22, —NR23R24, —NHOH, —NO2, —CN, —CF3, (═O), —C(═O)R21, —CO2R21, —OC(═O)R21, —C(═O)NR23R24, —NR27C(═O)R21, NR27C(O)OR21, —OC(═O)NR23R24, —NR27C(═S)R21, —SR21, —S(O)R21, or —S(O)2R21; C1-C6 alkyl optionally substituted with OR26; C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, phenyl, 3- to 7-membered heterocycloalkyl group, or 5- or 6-membered heteroaryl group;
- R20A at each occurrence is independently F, Cl, Br, I, —OR21, —OR22, —NR23R24, —NHOH, —NO2, —CN, —CF3, (═O), —C(═O)R21, —CO2R21, —OC(═O)R21, —C(═O)NR23R24, —NR27C(═O)R21, —NR27C(═O)OR21, —OC(═O)NR23R24, —NR27C(═S)R21, —SR21, —S(O)R21, or —S(O)2R21; C1-C6 alkyl optionally substituted with OR26; C2-C6 alkenyl, or C2-C6 alkynyl;
- R21 at each occurrence is independently H, C1-C6 alkyl, C6-C10 aryl, or C7-C15 arylalkyl;
- R22 at each occurrence is independently the residue of an amino acid after the hydroxyl group of the carboxyl group is removed;
- R23 and R24 at each occurrence is independently selected from H, C1-C6 alkyl, and C6-C10 aryl;
- alternatively, R23 and R24, together with the nitrogen atom to which they are attached, form a 3 to 7 membered heterocycloalkyl ring system containing one, two, or three heteroatoms selected from N, O, and S, wherein said heterocycloalkyl ring system is optionally substituted with ═O;
- R26 is H or C1-C6 alkyl;
- R27 is H or C1-C6 alkyl;
- n is 0, 1, 2, or 3; and
- z is 0, 1, 2, 3, 4, 5, or 6.
- In preferred embodiments, the present invention provides novel compounds of Formula (I):
- and stereoisomeric forms, mixtures of stereoisomeric forms or pharmaceutically acceptable salt forms thereof, wherein:
- R1 is H, C1-C4 alkyl, or C3-C8 cycloalkyl;
- W is —CH2—, —CH2CH2—, or —CH2—O—;
- k is 0, 1, or 2; m is 0, 1, or 2; and the sum of m and k is 1, 2, or 3;
- Y2═Y3 is —C(X)═CH— or —CH═C(X)—;
- X is R2, —OR2, —(C1-C3 alkyl)-R2, —O—(C1-C3 alkyl)-R2, —NHR2, —NHC(═O)R2, or —NHC(═O)NHR2;
- R2 is
- R3 is H, F, or C1-C4 alkyl;
- R4 is H, F, or C1-C4 alkyl;
- R4A is H, F, Cl, Br, or C1-C4 alkyl;
- R5 is H, F, or C1-C4 alkyl;
- R5A is H, F, Cl, Br, or C1-C4 alkyl;
- alternatively, R4 and R5, together with the carbon atoms to which they are attached, may form a fused C3-C6 cycloalkyl ring optionally substituted with 1-3 R14;
- alternatively, R4A and R5A, together with the carbon atoms to which they are attached, may form a fused phenyl ring optionally substituted with 1-3 R14;
- C3-C6cycloalkyl ring optionally substituted with 1-3 R14;
- a 5 to 6 membered fused heteroaryl ring system containing one, two, or three heteroatoms selected from N, O, and S, wherein said heteroaryl ring system is optionally substituted with 1-3 R14; or
- 5 to 6 membered fused heterocycloalkyl ring system containing one, two, or three heteroatoms selected from N, O, S, SO, and SO2, wherein said heterocycloalkyl ring system is optionally substituted with 1-3 R14;
- R6 is H, F, or C1-C4 alkyl;
- R7 is H, F, Cl, Br, or C1-C4 alkyl;
- R8 is H, —C(═O)R27, —CO2R27, C1-C6 alkyl optionally substituted by 1-3 R20;
- C3-C8 cycloalkyl optionally substituted by 1-3 R20A;
- C6-C10 aryl optionally substituted by 1-3 R20A;
- C7-C15 arylalkyl optionally substituted by 1-3 R20A; and
- a 5 to 10 membered heteroaryl ring system containing one, two, or three heteroatoms selected from N, O, and S, wherein said heteroaryl ring system is optionally substituted with 1-3 R20A;
- R9, at each occurrence, is independently, F, Cl, Br, C1-C4 alkyl, or C1-C4 alkoxy;
- R10 is F, Cl, C1-C3 alkyl, or C1-C3 alkoxy;
- R14 at each occurrence is independently, H, F, Cl, Br, I, —OR21, —OR22, —NR23R24, —NHOH, —NO2, —CN, —CF3, (═O), —C(═O)R21, —CO2R21, —OC(═O)R21, —C(═O)NR23R24, —NR27C(═O)R21, —NR27C(═O)OR21, —OC(═O)NR23R24, —NR27C(═S)R21, —SR21, —S(O)R21, or —S(O)2R21; C1-C6 alkyl optionally substituted with OR26; C2-C6 alkenyl, or C2-C6 alkynyl;
- R20 at each occurrence is independently, H, F, Cl, Br, I, —OR21, —0R22, —NR23R24, —NHOH, —NO2, —CN, —CF3, (═O), —C(═O)R21, —CO2R21, —OC(═O)R21, —C(═O)NR23R24, —NR27C(═O)R21, —NR27C(═O)OR21, —OC(═O)NR23R24, —NR27C(═S)R21, —SR21, —S(O)R21, or —S(O)2R21; C1-C6 alkyl optionally substituted with OR26; C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, phenyl, 3- to 7-membered heterocycloalkyl group, or 5- or 6-membered heteroaryl group;
- R20A at each occurrence is independently, H, F, Cl, Br, I, —OR21, —OR22, —NR23R24, —NHOH, —NO2, —CN, —CF3, (═O), —C(═O)R21, —CO2R21, —OC(═O)R21, —C(═O)NR23R24, —NR27C(═O)R21, —NR27C(═O)OR21, —OC(═O)NR23R24, —NR27C(═S)R21, —SR21, —S(O)R21, or —S(O)2R21; C1-C6 alkyl optionally substituted with OR26; C2-C6 alkenyl, or C2-C6 alkynyl;
- R21 at each occurrence is independently H, C1-C6 alkyl, C6-C10 aryl, or C7-C15 arylalkyl;
- R22 at each occurrence is independently the residue of an amino acid after the hydroxyl group of the carboxyl group is removed;
- R23 and R24 at each occurrence is independently selected from H, C1-C6 alkyl, and C6-C10 aryl;
- alternatively, R23 and R24, together with the nitrogen atom to which they are attached, form a 3 to 7 membered heterocycloalkyl ring system containing one, two, or three heteroatoms selected from N, O, and S, wherein said heterocycloalkyl ring system is optionally substituted with ═O;
- R26 is H or C1-C6 alkyl;
- R27 is H or C1-C6 alkyl; and
- n is 0, 1, 2, or 3.
- In preferred embodiments, the present invention provides compounds wherein R1 is C3-C8 cycloalkyl.
- In preferred embodiments, the present invention provides compounds wherein R1 is cyclobutyl or cyclopentyl.
- In preferred embodiments, the present invention provides compounds wherein W is —CH2— or —CH2—CH2—.
- In preferred embodiments, the present invention provides compounds wherein R2 is
- In preferred embodiments, the present invention provides compounds wherein R4 and R5, together with the carbon atoms to which they are attached, form a fused cyclopropyl or cyclobutyl ring.
- In preferred embodiments, the present invention provides compounds wherein R4A and R5A, together with the carbon atoms to which they are attached, form a fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl ring.
- Preferred embodiments of the present invention include those wherein k is 1. Other embodiments include those wherein m is 1. Still other embodiments include those wherein the sum of m and k is 2.
- Also preferred within the present invention are those compounds wherein Y2═Y3 is —C(X)═CH—. Also preferred are those compounds wherein X is R2. In other preferred compounds of the invention, X is —OR2.
- In some embodiments of the present invention, R8 is H. In other embodiments, R8 is C1-C6 alkyl optionally substituted by 1-3 R20. In other embodiments, R8 is C1-C6 alkyl.
- In certain preferred embodiments, R9 is C1-C4 alkyl.
- In some embodiments of the invention, n is 0. In other embodiments, it is preferred that n is 1. In other embodiments, z is preferably 0.
- In a preferred embodiment, the present invention provides compounds of Formula (II):
- and stereoisomeric forms, mixtures of stereoisomeric forms or pharmaceutically acceptable salt forms thereof, wherein:
- R1 is C3-C8 cycloalkyl;
- W is —CH2— or —CH2—CH2—;
- X is R2, —OR2, or —NHR2;
- R2 is
- R3 is H or C1-C4 alkyl;
- R4 is H or C1-C4 alkyl;
- R4A is H or C1-C4 alkyl;
- R5 is H or C1-C4 alkyl;
- R5A is H or C1-C4 alkyl;
- alternatively, R4 and R5, together with the carbon atoms to which they are attached, may form a fused C3-C6 cycloalkyl ring optionally substituted with 1-3 R14;
- alternatively, R4A and R5A, together with the carbon atoms to which they are attached, may form a fused phenyl ring optionally substituted with 1-3 R14;
- C3-C6 cycloalkyl ring optionally substituted with 1-3 R14;
- a 5 to 6 membered fused heteroaryl ring system containing one, two, or three heteroatoms selected from N, O, and S, wherein said heteroaryl ring system is optionally substituted with 1-3 R14; or
- 5 to 6 membered fused heterocycloalkyl ring system containing one, two, or three heteroatoms selected from N, O, S, SO, and SO2, wherein said heterocycloalkyl ring system is optionally substituted with 1-3 R14;
- R6 is H or C1-C4 alkyl;
- R7 is H or C1-C4 alkyl;
- R8 is H, —C(═O)R27, —CO2R27, C1-C6 alkyl optionally substituted by 1-3 R20;
- C3-C8 cycloalkyl optionally substituted by 1-3 R20A;
- C6-C10 aryl optionally substituted by 1-3 R20A;
- C7-C15 arylalkyl optionally substituted by 1-3 R20A; and
- a 5 to 10 membered heteroaryl ring system containing one, two, or three heteroatoms selected from N, O, and S, wherein said heteroaryl ring system is optionally substituted with 1-3 R20A;
- R9, at each occurrence, is independently, F, Cl, Br, C1-C4 alkyl, or C1-C4 alkoxy;
- R10 is F, Cl, C1-C3 alkyl, or C1-C3 alkoxy;
- R14 at each occurrence is independently, H, F, Cl, Br, I, —OR21, —OR22, —NR23R24, —NHOH, —NO2, —CN, —CF3, (═O), —C(═O)R21, —CO2R21, —OC(═O)R21, —C(═O)NR23R24, —NR27C(═O)R21, —NR27C(═O)OR21, —OC(═O)NR23R24, —NR27C(═S)R21, —SR21, —S(O)R21, or —S(O)2R21; C1-C6 alkyl optionally substituted with OR26; C2-C6 alkenyl, or C2-C6 alkynyl;
- R20 at each occurrence is independently, H, F, Cl, Br, I, —OR21, —OR22, —NR23R24, —NHOH, —NO2, —CN, —CF3, (═O), —C(═O)R21, —CO2R21, —OC(═O)R21, —C(═O)NR23R24, —NR27C(═O)R21, —NR27C(═O)OR21, —OC(═O)NR23R24, —NR27C(═O)R21, —SR21, —S(O)R21, or —S(O)2R21; C1-C6 alkyl optionally substituted with OR26; C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, phenyl, 3- to 7-membered heterocycloalkyl group, or 5- or 6-membered heteroaryl group;
- R20A at each occurrence is independently, H, F, Cl, Br, I, —OR21, —OR22, —NR23R24, —NHOH, —NO2, —CN, —CF3, (═O), —C(═O)R21, —CO2R21, —OC(═O)R21, —C(═O)NR23R24, —NR27C(═O)R21, —NR27C(═O)OR21, —OC(═O)NR23R24, —NR27C(═S)R21, —SR21, —S(O)R21, or —S(O)2R21; C1-C6 alkyl optionally substituted with OR26; C2-C6 alkenyl, or C2-C6 alkynyl;
- R21 at each occurrence is independently H, C1-C6 alkyl, C6-C10 aryl, or C7-C15 arylalkyl;
- R22 at each occurrence is independently the residue of an amino acid after the hydroxyl group of the carboxyl group is removed;
- R23 and R24 at each occurrence is independently selected from H, C1-C6 alkyl, and C6-C10 aryl;
- alternatively, R23 and R24, together with the nitrogen atom to which they are attached, form a 3 to 7 membered heterocycloalkyl ring system containing one, two, or three heteroatoms selected from N, O, and S, wherein said heterocycloalkyl ring system is optionally substituted with ═O;
- R26 is H or C1-C6 alkyl;
- R27 is H or C1-C6 alkyl; and
- n is 0, 1, 2, or 3.
- In preferred embodiments, the present invention provides compounds wherein R1 is cyclobutyl or cyclopentyl.
- In preferred embodiments, the present invention provides compounds wherein R2 is
- In preferred embodiments, the present invention provides compounds wherein R4 and R5, together with the carbon atoms to which they are attached, form a fused cyclopropyl or cyclobutyl ring.
- In preferred embodiments, the present invention provides compounds wherein R4A and R5A, together with the carbon atoms to which they are attached, form a fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl ring.
- In preferred embodiments, the present invention provides compounds wherein R8 is H.
- In preferred embodiments, the present invention provides compounds of Formula (III):
- and stereoisomeric forms, mixtures of stereoisomeric forms or pharmaceutically acceptable salt forms thereof, wherein:
- R1 is C3-C6 cycloalkyl;
- W is —CH2— or —CH2—CH2—;
- R2 is
- R3 is H, methyl, or ethyl;
- R4 is H, methyl, or ethyl;
- R4A is H, methyl, or ethyl;
- R5 is H, methyl, or ethyl;
- R5A is H, methyl, or ethyl;
- alternatively, R4 and R5, together with the carbon atoms to which they are attached, may form a fused C3-C6 cycloalkyl ring;
- alternatively, R4A and R5A, together with the carbon atoms to which they are attached, may form a fused phenyl ring;
- C3-C6 cycloalkyl ring;
- a 5 to 6 membered fused heteroaryl ring system containing one, two, or three heteroatoms selected from N, O, and S; or
- 5 to 6 membered fused heterocycloalkyl ring system containing one, two, or three heteroatoms selected from N, O, S, SO, and SO2;
- R6 is H, methyl, or ethyl;
- R7 is H, methyl, or ethyl;
- R9, at each occurrence, is independently, F, Cl, methyl, ethyl, methoxy, or ethoxy;
- R10 is F, Cl, methyl, ethyl, methoxy, or ethoxy; and
- n is 0, 1, or 2.
- In a preferred embodiment, the present invention provides compounds of Formula (III):
- and stereoisomeric forms, mixtures of stereoisomeric forms or pharmaceutically acceptable salt forms thereof, wherein:
- R1 is cyclobutyl or cyclopentyl;
- W is —CH2— or —CH2—CH2—;
- R2 is
- R3 is H, methyl, or ethyl;
- R4 is H, methyl, or ethyl;
- R4A is H, methyl, or ethyl;
- R5 is H, methyl, or ethyl;
- R5A is H, methyl, or ethyl;
- alternatively, R4 and R5, together with the carbon atoms to which they are attached, may form a fused cyclopropyl, cyclobutyl, or cyclopentyl ring;
- alternatively, R4A and R5A, together with the carbon atoms to which they are attached, may form a fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl ring;
- R6 is H, methyl, or ethyl;
- R7 is H, methyl, or ethyl;
- R9, at each occurrence, is independently, F, Cl, methyl, ethyl, methoxy, or ethoxy;
- R10 is F, Cl, methyl, ethyl, methoxy, or ethoxy; and
- n is 0, 1, or 2.
- In a preferred embodiment, the present invention provides compounds wherein R2 is
- In another embodiment, the present invention provides pharmaceutical compositions comprising a compound according to the present invention and one or more pharmaceutically acceptable excipients.
- In a further embodiment the present invention provides for a method for treating a disorder selected from the group consisting of narcolepsy or sleep/wake disorders, feeding behavior disorders, eating disorders, obesity, cognition disorders, arousal disorders, memory disorders, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders, epilepsy, gastrointestinal disorders, respiratory disorders, inflammation, and myocardial infarction comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of the present invention. In a preferred embodiment the present invention provides for a method of treating narcolepsy or sleep/wake disorders. In a preferred embodiment the present invention provides for a method of treating attention deficit hyperactivity disorder. In a preferred embodiment the present invention provides for a method of treating cognition disorders.
- In another embodiment the present invention provides for use of the compounds of the present invention for use in therapy.
- In a further embodiment the present invention provides for use of the compounds of the present invention in the manufacture of a medicament for treating a disorder selected from the group consisting of narcolepsy or sleep/wake disorders, feeding behavior disorder, eating disorders, obesity, cognition disorders, arousal disorders, memory disorders, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders, epilepsy, gastrointestinal disorders, respiratory disorders, inflammation, and myocardial infarction comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of the present invention.
- In the formulas described and claimed herein, it is intended that when any symbol appears more than once in a particular formula or substituent, its meaning in each instance is independent of the other.
- The following terms and expressions have the indicated meanings.
- As used herein, the term “about” refers to a range of values from ±10% of a specified value. For example, the phrase “about 50” includes ±10% of 50, or from 45 to 55. The phrase “from about 10 to 100” includes ±10% of 10 and ±10% of 100, or from 9 to 110.
- As used herein, a range of values in the form “x-y” or “x to y”, or “x through y”, include integers x, y, and the integers therebetween. For example, the phrases “1-6”, or “1 to 6” or “1 through 6” are intended to include the integers 1, 2, 3, 4, 5, and 6. Preferred embodiments include each individual integer in the range, as well as any subcombination of integers. For example, preferred integers for “1-6” can include 1, 2, 3, 4, 5, 6, 1-2, 1-3, 1-4, 1-5, 2-3, 2-4, 2-5, 2-6, etc.
- As used herein “stable compound” or “stable structure” refers to a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and preferably capable of formulation into an efficacious therapeutic agent. The present invention is directed only to stable compounds.
- As used herein, “substituted” refers to any one or more hydrogen atoms on the indicated atom is replaced with a selected group referred to herein as a “substituent,” provided that the substituted atom's valency is not exceeded, and that the substitution results in a stable compound. Examples of preferred substituents are —OH, alkyl, cycloalkyl, alkoxy, halogen, haloalkyl, aryl, heteroaryl, and heterocyclyl.
- As used herein, the term “alkyl” refers to a straight-chain, or branched alkyl group having 1 to 8 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, neopentyl, 1-ethylpropyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, hexyl, octyl, etc. The alkyl moiety of alkyl-containing groups has the same meaning as alkyl defined above. A designation such as “C1-C6 alkyl” refers to straight-chain, or branched alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, neopentyl, 1-ethylpropyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, hexyl, etc. Lower alkyl groups, which are preferred, are alkyl groups as defined above which contain 1 to 4 carbons. A designation such as “C1-C4 alkyl” refers to an alkyl radical containing from 1 to 4 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl. A designation such as “C1-C3 alkyl” refers to an alkyl radical containing from 1 to 3 carbon atoms, such as methyl, ethyl, propyl, and isopropyl. Alkyl groups can be substituted or unsubstituted. Preferred substituents include —OH and alkoxy.
- As used herein, the term “alkenyl” refers to a straight chain, or branched hydrocarbon chains of 2 to 8 carbon atoms having at least one carbon-carbon double bond. A designation “C2-C8 alkenyl” refers to an alkenyl radical containing from 2 to 8 carbon atoms. Examples of alkenyl groups include ethenyl, propenyl, isopropenyl, 2,4-pentadienyl, etc. Alkenyl groups can be substituted or unsubstituted
- As used herein, the term “alkynyl” refers to a straight chain, or branched hydrocarbon chains of 2 to 8 carbon atoms having at least one carbon-carbon triple bond. A designation “C2-C8 alkynyl” refers to an alkynyl radical containing from 2 to 8 carbon atoms. Examples include ethynyl, propynyl, isopropynyl, 3,5-hexadiynyl, etc. Alkynyl groups can be substituted or unsubstituted.
- As used herein, the term “C1-C4 haloalkyl” refers to an “alkyl” group as defined herein substituted by one or more halogen atoms to form a stable compound. Examples of haloalkyl, include but are not limited to, —CF3, —CHF2, —CH2F and CF2CF3.
- As used herein, the term “C1-C4 alkoxy” refers to an “alkyl” group as defined herein bonded to and oxygen atom. Alkoxy groups can be substituted or unsubstituted.
- As used herein, the term “halo” refers to an F, Cl, Br, and I. Preferred halo substituents are F and Cl.
- As used herein, the term “arylalkyl” or “aralkyl” refers to an alkyl group that is substituted with an aryl group. A designation “C7-C15 arylalkyl” refers to an arylalkyl radical containing from 7 to 15 carbon atoms. Examples of arylalkyl groups include, but are not limited to, benzyl, phenethyl, diphenylmethyl, diphenylethyl, naphthylmethyl, etc. preferably benzyl. Arylalkyl groups can be substituted or unsubstituted.
- As used herein, the term “cycloalkyl” refers to a saturated or partially saturated mono- or bicyclic alkyl ring system containing 3 to 10 carbon atoms. Certain embodiments contain 3 to 6 carbon atoms, and other embodiments contain 5 or 6 carbon atoms. A designation such as “C5-C7 cycloalkyl” refers to a cycloalkyl radical containing from 5 to 7 ring carbon atoms. Examples of cycloalkyl groups include such groups as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, pinenyl, and adamantanyl. Cycloalkyl groups can be substituted or unsubstituted
- As used herein, the term “aryl” refers to a substituted or unsubstituted, mono- or bicyclic hydrocarbon aromatic ring system having 6 to 12 ring carbon atoms. Examples include phenyl and naphthyl. Preferred aryl groups include unsubstituted or substituted phenyl and naphthyl groups. Aryl groups can be substituted or unsubstituted
- As used herein, the terms “heterocycle”, “heterocyclic” or “heterocyclyl” refer to a substituted or unsubstituted carbocyclic group in which one or more ring carbon atoms are replaced by at least one hetero atom such as —O—, —N—, or —S—. Certain embodiments include 3 to 6 membered rings, and other embodiments include 5 or 6 membered rings. The nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen may be optionally substituted in non-aromatic rings. Heterocycles are intended to include heteroaryl and heterocycloalkyl groups. Heterocyclic groups can be substituted or unsubstituted.
- As used herein, the term “heteroaryl” refers to an aromatic group or ring system containing 5 to 10 ring carbon atoms in which one or more ring carbon atoms are replaced by at least one hetero atom such as O, N, or S. Certain embodiments include 5 or 6 membered rings. Examples of heteroaryl groups include pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, isoxazolyl, oxazolyl, oxathiolyl, oxadiazolyl, triazolyl, oxatriazolyl, furazanyl, tetrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, picolinyl, imidazopyridinyl, indolyl, isoindolyl, indazolyl, benzofuranyl, isobenzofuranyl, purinyl, quinazolinyl, quinolyl, isoquinolyl, benzoimidazolyl, benzothiazolyl, benzothiophenyl, thianaphthenyl, benzoxazolyl, benzooxadiazolyl, benzisoxazolyl, cinnolinyl, phthalazinyl, naphthyridinyl, and quinoxalinyl. Heteroaryl groups can be substituted or unsubstituted.
- As used herein, the term “heterocycloalkyl” refers to a cycloalkyl group in which one or more ring carbon atoms are replaced by at least one hetero atom such as O, N, S, SO, and SO2. Certain embodiments include 3 to 6 membered rings, and other embodiments include 5 or 6 membered rings. Examples of heterocycloalkyl groups include azetidinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, oxazolidinyl, pirazolidinyl, pirazolinyl, pyrazalinyl, piperidyl, piperazinyl, hexahydropyrimidinyl, morpholinyl, thiomorpholinyl, dihydrobenzofuranyl, tetrahydrofuranyl, tetrahydropyranyl, dihydro-oxazolyl, dithiolyl, oxathiolyl, dioxazolyl, oxathiazolyl, pyranyl, oxazinyl, oxathiazinyl, and oxadiazinyl. Included within the definition of “heterocycloalkyl” are fused ring systems, including, for example, ring systems in which an aromatic ring is fused to a heterocycloalkyl ring. Examples of such fused ring systems include, for example, phthalamide, phthalic anhydride, indoline, isoindoline, tetrahydroisoquinoline, chroman, isochroman, chromene, and isochromene. Heterocycloalkyl groups can be substituted or unsubstituted.
- As used herein, the term “pyridazin-3-one moiety” refers to a 6 to 10 membered heterocycloalkyl ring system containing a pyridazin-3-one group and optionally a second fused ring. The second fused ring, if present, is optionally a substituted or unsubstituted phenyl ring, a substituted or unsubstituted C3-C6 cycloalkyl ring, a substituted or unsubstituted 5 to 6 membered fused heteroaryl ring system containing one, two, or three heteroatoms selected from N, O, and S, or a substituted or unsubstituted 5 to 6 membered fused heterocycloalkyl ring system containing one, two, or three heteroatoms selected from N, O, and S. Examples of a second fused ring include, but are not limited to, phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- As used herein, the term “arylalkyl” refers to an alkyl group that is substituted with an aryl group. Examples of arylalkyl groups include, but are not limited to, benzyl, bromobenzyl, phenethyl, benzhydryl, diphenylmethyl, triphenylmethyl, diphenylethyl, naphthylmethyl, etc. Arylalkyl groups can be substituted or unsubstituted.
- As used herein, the term “amino acid” refers to a group containing both an amino group and a carboxyl group. Embodiments of amino acids include α-amino, β-amino, γ-amino acids. The α-amino acids have a general formula HOOC—CH(side chain)-NH2. The amino acids can be in their D, L or racemic configurations Amino acids include naturally-occurring and non-naturally occurring moieties. The naturally-occurring amino acids include the standard 20 α-amino acids found in proteins, such as glycine, serine, tyrosine, proline, histidine, glutamine, etc. Naturally-occurring amino acids can also include non-α-amino acids (such as β-alanine, γ-aminobutyric acid, homocysteine, etc.), rare amino acids (such as 4-hydroxyproline, 5-hydroxylysine, 3-methylhistidine, etc.) and non-protein amino acids (such as citrulline, ornithine, canavanine, etc.). Non-naturally occurring amino acids are well-known in the art, and include analogs of natural amino acids. See Lehninger, A. L. Biochemistry, 2nd ed.; Worth Publishers: New York, 1975; 71-77, the disclosure of which is incorporated herein by reference. Non-naturally occurring amino acids also include α-amino acids wherein the side chains are replaced with synthetic derivatives. In certain embodiments, substituent groups for the compounds of the present invention include the residue of an amino acid after removal of the hydroxyl moiety of the carboxyl group thereof; i.e., groups of formula —C(═O)CH(side chain)-NH2. Representative side chains of naturally occurring and non-naturally occurring α-amino acids include are shown below in Table A.
-
TABLE A H HS—CH2— CH3— HO2C—CH(NH2)—CH2— S— S— CH2— HO—CH2— CH3—CH2— C6H5—CH2— CH3— S—CH2—CH2— HO—C6H4—CH2— CH3—CH2— S—CH2—CH2— HO—CH2—CH2— C5H9— C6H11— C6H11—CH2— CH3—CH(OH)— HO2C—CH2— NHC(═O)—CH2— HO2C—CH2— HO2C—CH2—CH2— NH2C(═O)—CH2— NH2C(═O)—CH2—CH2— (CH3)2—CH— (CH3)2—CH—CH2— CH3—CH2—CH2— H2N—CH2—CH2—CH2— H2N—C(═NH)— NH—CH2—CH2—CH2— H2N—C(═O)— NH—CH2—CH2—CH2— CH3—CH2—CH(CH3)— CH3—CH2—CH2—CH2— H2N—CH2—CH2—CH2—CH2— - As used herein, the term “subject” refers to a warm blooded animal such as a mammal, preferably a human, or a human child, which is afflicted with, or has the potential to be afflicted with, one or more diseases and conditions described herein.
- As used herein, a “therapeutically effective amount” refers to an amount of a compound of the present invention effective to prevent or treat the symptoms of particular disorder. Such disorders include, but are not limited to, those pathological and neurological disorders associated with the aberrant activity of the receptors described herein, wherein the treatment or prevention comprises inhibiting, inducing, or enhancing the activity thereof by contacting the receptor with a compound of the present invention.
- As used herein, the term “pharmaceutically acceptable” refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem complications commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable compounds, materials, compositions, and/or dosage forms should be on the Generally Recognized as Safe (GRAS) list.
- As used herein, the term “unit dose” refers to a single dose which is capable of being administered to a patient, and which can be readily handled and packaged, remaining as a physically and chemically stable unit dose comprising either the active compound itself, or as a pharmaceutically acceptable composition, as described hereinafter.
- All other terms used in the description of the present invention have their meanings as is well known in the art.
- In another aspect, the present invention is directed to pharmaceutically acceptable salts of the compounds described above. As used herein, “pharmaceutically acceptable salts” includes salts of compounds of the present invention derived from the combination of such compounds with non-toxic acid or base addition salts.
- Acid addition salts include inorganic acids such as hydrochloric, hydrobromic, hydroiodic, sulfuric, nitric and phosphoric acid, as well as organic acids such as acetic, citric, propionic, tartaric, glutamic, salicylic, oxalic, methanesulfonic, para-toluenesulfonic, succinic, and benzoic acid, and related inorganic and organic acids.
- Base addition salts include those derived from inorganic bases such as ammonium and alkali and alkaline earth metal hydroxides, carbonates, bicarbonates, and the like, as well as salts derived from basic organic amines such as aliphatic and aromatic amines, aliphatic diamines, hydroxy alkamines, and the like. Such bases useful in preparing the salts of this invention thus include ammonium hydroxide, potassium carbonate, sodium bicarbonate, calcium hydroxide, methylamine, diethylamine, ethylenediamine, cyclohexylamine, ethanolamine and the like.
- In addition to pharmaceutically-acceptable salts, other salts are included in the invention. They may serve as intermediates in the purification of the compounds, in the preparation of other salts, or in the identification and characterization of the compounds or intermediates.
- The pharmaceutically acceptable salts of compounds of the present invention can also exist as various solvates, such as with water, methanol, ethanol, dimethylformamide, ethyl acetate and the like. Mixtures of such solvates can also be prepared. The source of such solvate can be from the solvent of crystallization, inherent in the solvent of preparation or crystallization, or adventitious to such solvent. Such solvates are within the scope of the present invention.
- The present invention also encompasses the pharmaceutically acceptable prodrugs of the compounds disclosed herein. As used herein, “prodrug” is intended to include any compounds which are converted by metabolic processes within the body of a subject to an active agent that has a formula within the scope of the present invention. Since prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (e.g., solubility, bioavailability, manufacturing, etc.) the compounds of the present invention may be delivered in prodrug form. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in Prodrugs, Sloane, K. B., Ed.; Marcel Dekker: New York, 1992, incorporated by reference herein in its entirety
- It is recognized that compounds of the present invention may exist in various stereoisomeric forms. As such, the compounds of the present invention include both diastereomers and enantiomers. The compounds are normally prepared as racemates and can conveniently be used as such, but individual enantiomers can be isolated or synthesized by conventional techniques if so desired. Such racemates and individual enantiomers and mixtures thereof form part of the present invention.
- It is well known in the art how to prepare and isolate such optically active forms. Specific stereoisomers can be prepared by stereospecific synthesis using enantiomerically pure or enantiomerically enriched starting materials. The specific stereoisomers of either starting materials or products can be resolved and recovered by techniques known in the art, such as resolution of racemic forms, normal, reverse-phase, and chiral chromatography, recrystallization, enzymatic resolution, or fractional recrystallization of addition salts formed by reagents used for that purpose. Useful methods of resolving and recovering specific stereoisomers described in Eliel, E. L.; Wilen, S. H. Stereochemistry of Organic Compounds; Wiley: New York, 1994, and Jacques, J, et al. Enantiomers, Racemates, and Resolutions; Wiley: New York, 1981, each incorporated by reference herein in their entireties.
- It is further recognized that functional groups present on the compounds of Formula I may contain protecting groups. For example, the amino acid side chain substituents of the compounds of Formula I can be substituted with protecting groups such as benzyloxycarbonyl or t-butoxycarbonyl groups. Protecting groups are known per se as chemical functional groups that can be selectively appended to and removed from functionalities, such as hydroxyl groups and carboxyl groups. These groups are present in a chemical compound to render such functionality inert to chemical reaction conditions to which the compound is exposed. Any of a variety of protecting groups may be employed with the present invention. Preferred groups for protecting lactams include silyl groups such as t-butyldimethylsilyl (“TBDMS”), dimethoxybenzhydryl (“DMB”), acyl, benzyl (“Bn”), and methoxybenzyl groups. Preferred groups for protecting hydroxy groups include TBS, acyl, benzyl, benzyloxycarbonyl (“CBZ”), t-butyloxycarbonyl (“Boc”), and methoxymethyl. Many other standard protecting groups employed by one skilled in the art can be found in Greene, T. W. and Wuts, P. G. M., “Protective Groups in Organic Synthesis” 2d. Ed., Wiley & Sons, 1991.
- The compounds of the present invention may be prepared in a number of methods well known to those skilled in the art, including, but not limited to those described below, or through modifications of these methods by applying standard techniques known to those skilled in the art of organic synthesis. All processes disclosed in association with the present invention are contemplated to be practiced on any scale, including milligram, gram, multigram, kilogram, multikilogram or commercial industrial scale.
- The compounds of the present invention may be prepared in a number of methods well known to those skilled in the art, including, but not limited to those described below, or through modifications of these methods by applying standard techniques known to those skilled in the art of organic synthesis. All processes disclosed in association with the present invention are contemplated to be practiced on any scale, including milligram, gram, multigram, kilogram, multikilogram or commercial industrial scale.
- Condensation of an 4-oxobutyric acid or ester intermediate of general structure A, or a derivative there of, with hydrazine or an R8 N-substituted hydrazine derivative in a solvent such as ethanol or 2-propanol provided a route to 4,5-dihydropyridazinone of general structure B. Keto-acid intermediates with substitution at the 4- and 5-position are known and may be readily prepared. Pyridazinones with R3/4a and R5/5a fused with heteroaryl or cycloalkyl groups are synthesized from the corresponding anhydrides or acid-esters. In cases where R1 is a protecting group, deprotection gives R1═H compounds of general structure C. Standard transformations of NH III by alkylation or reductive amination reactions produce examples of general structure D. The 4,5-dihydropyridazinones structure D may be oxidized to an aromatic pyridazinone of general structure E using MnO2, CuCl2, DDQ, selenium oxide, DMSO/base or sodium 3-nitrobenzenesulfonate in the presence of sodium hydroxide. NH(R8═H) pyridazinones may be alkylated with alkyl or substituted alkyl groups using an R8-halide, a base, for example K2CO3, Cs2CO3 or NaH, in an inert solvent such as DMF, THF or CH3CN. Examples wherein R8 is H may be converted to analogs wherein R8 is aryl or heteroaryl by standard palladium or copper coupling reactions using the appropriate aryl or heteroaryl halide.
- Aryl pyridazinone examples of the invention may also be synthesized using standard Suzuki cross-coupling chemistry. A spiro boron ether derivatives of general structure F, is subjected to a palladium catalyzed cross-coupling reaction (Suzuki reaction) with a pyridazine derivative of general structure G or a pyridazinone of structure H wherein the R4a, R5a or R7 group may be a halogen, preferably Br or Ito produce examples of general structure J and K.
- Spiro-pyrrolidine, -azepine and -3-piperidine examples of the invention may be synthesized using methods outlined in for the spiro-4-piperidine examples starting with N-Boc-3-pyrrolidinone, N-Boc-hexahydro-1H-azepin-4-one or N-Boc-3-piperidone, respectively, in place of N-Boc-4-piperidone.
- Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments as shown below. These examples are given for illustration of the invention and are not intended to be limiting thereof.
-
-
- A solution of spiro[benzofuran-2(3H)-4′-piperidine] (8 g, 40 mmol) in methylene chloride (70 mL) was treated with pyridine (8 mL, 100 mmol) and trifluoroacetic anhydride (7 mL, 50 mmol) at 10° C. The mixture was stirred at 10° C. for 2 h, then quenched with 1N HCl and extracted twice with methylene chloride. The combined organic layer was dried (Na2SO4), filtered, and concentrated to produce 1′-trifluoroacetyl-spiro[benzofuran-2(3H)-4′-piperidine] (10.86 g, 91%),
- MS m/z=286 (M+H).
-
- A mixture of the product from step 1 (0.51 g, 1.8 mmol) and ethyl succinyl chloride (0.25 mL, 1.8 mmol) in methylene chloride (2 mL) was cooled to 0° C. Tin tetrachloride (1M solution in methylene chloride) (2.32 mL, 2.32 mmol) was added at 10° C., stirred for 30 min then quenched with aqueous 2N HCl at 0° C. The aqueous layer was extracted twice with methylene chloride and the combined organic layer was washed with brine, dried (Na2SO4), filtered, and concentrated. The product was purified by ISCO silica gel chromatography (40 g column) using 20% EtOAc in hexane to furnish 1′-trifluoroacetyl-5-(4-oxo-butyric acid ethyl ester)-spiro[benzofuran-2(3H), 4′-piperidine] (0.61 g, 83%), MS m/z=414 (M+H).
-
- A mixture of the product from step 2 (0.61 g, 1.5 mmol) and hydrazine monohydrate (0.57 mL, 11 mmol) in isopropanol (7 mL) was heated at 110° C. for 15 h. Isopropanol was evaporated at reduced pressure and partitioned between saturated aqueous sodium bicarbonate solution and methylene chloride. The aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na2SO4), filtered, and concentrated to provide 6-(spiro[benzofuran-2(3H), 4′-piperidine]-5-yl)-4,5-dihydro-2H-pyridazin-3-one (0.4 g, 95%), MS m/z=286 (M+H). The crude material was used for the next reaction without further purification.
-
- A solution of the product from step 3 (0.4 g, 1.4 mmol) in a mixture of DMF (2 mL) and MeOH (10 mL) was stirred under argon. Cyclobutanone (0.42 mL, 6.4 mmol), sodium cyanoborohydride (0.35 g, 5.6 mmol) and acetic acid (0.2 mL, 3.17 mmol) were added sequentially and stirred at 60° C. for 15 h. The reaction mixture was concentrated at reduced pressure and partitioned between aqueous 1M sodium carbonate solution and methylene chloride. The aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na2SO4), filtered, and concentrated to provide a crude product. The crude product was purified by ISCO (40 g column) chromatography using 5 to 10% methanol in methylene chloride to 10% methanol containing 4 mL ammonium hydroxide in methylene chloride. The recovered pure product was dissolved in methylene chloride and washed with saturated aqueous sodium bicarbonate solution, brine, dried (Na2SO4), filtered, and concentrated. The product was crystallized from a mixture of methylene chloride, ethanol, ether, and hexane to give example 1 (6-(1-cyclobutyl-spiro[benzofuran-2(3H), 4′-piperidine]-5-yl)-4,5-dihydro-2H-pyridazin-3-one) (94 mg, 20%, 96% purity), mp 207-209° C. (methylene chloride, ethanol, ether, and hexane), MS m/z=340 (M+H); 1H NMR (400 MHz, CDCl3): δ 1.57-2.15 (m, 12H), 2.37-2.56 (m, 2H), 2.60 (t, J=16.16 Hz, 2H), 2.76-2.87 (m, 1H), 2.96 (t, J=16.32 Hz, 2H), 3.01 (S, 2H), 6.78 (d, J=8.33 Hz, 1H), 7.46 (d, J=8.36 Hz, 1H), 7.59 (S, 1H), 8.44 (S, 1H).
-
- This compound was prepared using the method described for Example 1 using cyclopropane dicarboxylic acid anhydride to give 1′-cyclobutyl-5-(3,4-diaza-bicyclo[4.1.0]hepten-2-one-5-yl)-spiro[benzofuran-2(3H), 4′-piperidine]: mp 189-191° C., MS m/z=352 (M+H); 1H NMR (400 MHz, CDCl3): δ 0.97 (dt, J1=10.14 Hz, J2=5.31 Hz, 1H), 1.54-2.13 (m, 12H), 2.17-2.24 (m, 1H), 2.40-2.58 (m, 4H), 2.77-2.89 (m, 1H), 3.03 (s, 2H), 6.81 (d, J=8.42 Hz, 1H), 7.57 (d, J=8.50 Hz, 1H), 7.63 (s, 1H), 8.23 (s, 1H).
-
-
- A mixture of 1′-trifluoroacetyl-spiro[benzofuran-2(3H)-4′-piperidine] (3.1 g, 11 mmol) and propanoyl chloride (1 mL, 10 mmol) in methylene chloride (25 mL) was cooled at 10° C. Tin tetrachloride (1M solution in methylene chloride) (14.14 mL, 14.11 mmol) was added at 10° C. and stirred at 10° C. for 30 min then quenched with aqueous 2N HCl at 0° C. The aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na2SO4), filtered, and concentrated to provide a crude product. The crude product was purified by ISCO (120 g) chromatography using 22% EtOAc in hexane to produce 1′-trifluoroacetyl-5-(propanoyl)-spiro[benzofuran-2(3H)-4′-piperidine] (2.2 g, 59%), MS m/z=342 (M+H).
-
- A solution of 1′-trifluoroacetyl-5-(propanoyl)-spiro[benzofuran-2(3H), 4′-piperidine] (2.2 g, 6.45 mmol) in tetrahydrofuran (22 mL) was cooled at 0° C. Lithium diisopropylamide, (2M solution in THF) (3.56 mL, 7.09 mmol) was added dropwise and warmed to rt for 30 min. The reaction was cooled to 0° C. and ethyl bromoacetate (0.79 mL, 7.1 mmol) was added dropwise and warmed to rt for 30 min then quenched with aqueous 1M HCl acid at 0° C. The aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na2SO4), filtered, and concentrated to give a crude 1′-trifluoroacetyl-5-(3-methyl-4-oxo-butyric acid ethyl ester)-spiro[benzofuran-2(3H), 4′-piperidine] (3.34 g), MS m/z=428 (M−55).
-
- A mixture of 1′-trifluoroacetyl-5-(3-methyl-4-oxo-butyric acid ethyl ester)-spiro[benzofuran-2(3H), 4′-piperidine] (3.34 g, 7.8 mmol) and hydrazine monohydrate (3 mL, 60 mmol) in isopropanol (25 mL) was heated at 110° C. for 15 h. Isopropanol was evaporated at reduced pressure and partitioned between saturated aqueous sodium bicarbonate solution and methylene chloride. The aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na2SO4), filtered, and concentrated to produce a crude 6-(spiro[benzofuran-2(3H), 4′-piperidine]-5-yl)-5-methyl-4,5-dihydro-2H-pyridazin-3-one (1.4 g, 60%), MS m/z=300 (M+H). The crude material was used for the next reaction without further purification.
-
- A solution of the product from step 3 (6-(spiro[benzofuran-2(3H), 4′-piperidine]-5-yl)-5-methyl-4,5-dihydro-2H-pyridazin-3-one) (1.4 g, 4.7 mmol) in a mixture of DMF (2 mL) and MeOH (10 mL) was stirred under argon. Cyclobutanone (1.4 mL, 19 mmol), sodium cyanoborohydride (1.2 g, 19 mmol) and acetic acid (0.65 mL, 11.36 mmol) were added sequentially and stirred at 60° C. for 13 h. The reaction mixture was concentrated at reduced pressure and partitioned between aqueous 1M sodium carbonate solution and methylene chloride. The aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na2SO4), filtered, and concentrated to provide a crude product. The crude product was purified by ISCO (120 g column) chromatography using 5 to 10% methanol in methylene chloride to obtain a pure product. The pure product was crystallized from a mixture of methylene chloride, ethanol, ether, and hexane to produce 6-(1-cyclobutyl-spiro[benzofuran-2(3H), 4′-piperidine]-5-yl)-5-methyl-4,5-dihydro-2H-pyridazin-3-one (512 mg, 31%, 98% purity), mp 213-215° C. (methylene chloride, ethanol, ether, and hexane), MS m/z=354 (M+H); 1H NMR (400 MHz, CDCl3): δ 1.25 (d, J=7.35 Hz, 3H), 1.63-2.14 (m, 10H), 2.36-2.57 (m, 4H), 2.70 (dd, J1=16.90 Hz, J2=6.78 Hz, 1H), 2.76-2.86 (m, 1H), 3.01 (s, 2H), 3.27-3.37 (m, 1H), 6.785 (d, J=8.43 Hz, 1H), 7.50 (d, J=8.47 Hz, 1H), 7.63 (s, 1H), 8.61 (s, 1H).
-
- A mixture of 6-(1-cyclobutyl-spiro[benzofuran-2(3H), 4′-piperidine]-5-yl)-5-methyl-4,5-dihydro-2H-pyridazin-3-one (202 mg, 0.57 mmol) and cesium carbonate (372 mg, 1.14 mmol) in dimethyl sulfoxide (8.5 mL) was heated at 130° C. 4 h. The mixture was cooled to RT and partitioned between water and methylene chloride. Sodium chloride was added to the mixture and the aqueous layer was extracted twice with methylene chloride. The combined organics was washed with brine, dried (Na2SO4), filtered, and concentrated to provide a crude product. The crude product was purified by ISCO (80 g) chromatography using 5% to 10% methanol in methylene chloride to 10% methanol containing 1% ammonium hydroxide in methylene chloride. The recovered product was dissolved in methylene chloride and washed with saturated aqueous sodium bicarbonate solution, brine, dried (Na2SO4), filtered, and concentrated to produce a pure product. The pure product was crystallized from a mixture of methylene chloride, methanol, ether and hexane to give example 4 (6-(cyclobutyl-spiro[benzofuran-2(3H), 4′-piperidine]-5-yl)-5-methyl-2H-pyridazin-3-one) (42 mg, 21%, 96% purity), mp 243-245° C., MS m/z=352 (M+H); 1H NMR (400 MHz, CDCl3): δ 1.55-2.97 (m, 18H), 3.05 (s, 2H), 6.80-6.86 (m, 2H), 7.14-7.19 (m, 1H), 7.21 (s, 1H), 10.55 (s, 1H).
-
-
- A solution of 3,4-dihydrospiro[benzopyran-2,4′-piperidine].HCl (7 g, 30 mmol) in methylene chloride (60 mL) was treated with pyridine (10 mL, 100 mmol) and trifluoroacetic anhydride (4.5 mL, 32 mmol) at 10° C. The mixture was stirred at 10° C. for 3 h then quenched with 1N HCl and extracted twice with methylene chloride. The combined organics was dried (Na2SO4), filtered, and concentrated to produce a crude product. The crude product was purified by ISCO (330 g column) chromatography using 12 to 18% ethyl acetate in hexane to obtain a pure 1′-trifluoroacetyl-3,4-dihydrospiro[benzopyran-2,4′-piperidine] (7.48 g, 72%), MS m/z=300 (M+H).
-
- A mixture of 1′-trifluoroacetyl-spiro[3,4-dihydrobenzopyran-2,4′-piperidine] (0.66 g, 2.20 mmol) and succinic anhydride (0.24 g, 2.43 mmol) in 1,2-dichloroethane (8 mL) was cooled to 0° C. Aluminium chloride (0.90 g, 7 mmol) was added at 0° C. and the mixture was heated at 80° C. for 16 h then quenched with aqueous 1N HCl at 0° C. The aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na2SO4), filtered, and concentrated to provide a crude 1′-trifluoroacetyl-6-(4-oxo-butyric acid)-spiro[3,4-dihydrobenzopyran-2,4′-piperidine] (0.97 g), MS m/z=400 (M+H) and 399 (M−H).
-
- A mixture of 1′-trifluoroacetyl-6-(4-oxo-butyric acid)-spiro[3,4-dihydrobenzopyran-2,4′-piperidine] (0.97 g, 2.4 mmol) and hydrazine monohydrate (2.5 mL, 80 mmol) in isopropanol (12 mL) was heated at 110° C. for 19 h. Isopropanol was evaporated at reduced pressure and azeotrophed three times with benzene to produce a crude 6-(4,5-dihydro-2H-pyridazin-3-one-6-yl)-spiro[3,4-dihydrobenzopyran-2,4′-piperidine] (0.92 g), MS m/z=300 (M+H). The crude product was used for the next reaction without further purification.
-
- A solution of the product from step 3 (0.92 g, 3.10 mmol) in a mixture of DMF (2 mL) and MeOH (6 mL) was stirred under argon. Cyclobutanone (0.9 mL, 10 mmol), sodium cyanoborohydride (0.8 g, 10 mmol) and acetic acid (0.42 mL, 7.4 mmol) were added sequentially and stirred at 60° C. for 20 h. The reaction mixture was concentrated at reduced pressure and partitioned between aqueous 1M sodium carbonate solution and methylene chloride. The aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na2SO4), filtered, and concentrated to provide a crude product. The crude product was purified by ISCO (40 g column) chromatography using 4.5 to 10% methanol in methylene chloride to 10% methanol containing 4 mL of ammonium hydroxide in methylene chloride obtain a pure product. The recovered product was dissolved in methylene chloride and washed with saturated sodium bicarbonate solution, brine, dried (Na2SO4), filtered, and concentrated. The pure product was crystallized from a mixture of methylene chloride, ethanol, ether, and hexane to produce 1′-cyclobutyl-6-(4,5-dihydro-2H-pyridazin-3-one-6-yl)-spiro[3,4-dihydrobenzopyran-2,4′-piperidine] (39 mg, 95% purity), mp 242-243.5° C. (methylene chloride, ethanol, ether, and hexane), MS m/z=354 (M+H); 1H NMR (400 MHz, CDCl3): δ 1.52-2.02 (m, 12H), 2.03-2.14 (m, 2H), 2.19-2.36 (m, 2H), 2.59 (t, J=8.49 Hz, 2H), 2.64-2.75 (m, 1H), 2.79-2.91 (m, 2H), 2.96 (t, J=7.82 Hz, 2H), 6.85-6.90 (m, 1H), 7.45-7.50 (m, 2H), 8.43 (s, 1H).
- The following examples were prepared using the methods disclosed herein.
-
- Example 6: mp 284-287° C.; MS m/z=312 (M+H); 1H NMR (400 MHz, DMSO): δ 0.71 (dt, J1=9.28 Hz, J2=4.71 Hz, 1H), 1.63-1.90 (m, 6H), 1.90-2.09 (m, 1H), 2.56-2.64 (m, 1H), 2.75-2.84 (m, 2H), 2.92-3.02 (m, 4H), 6.82-6.90 (m, 2H), 7.52-7.59 (m, 2H), 10.69 (s, 1H).
-
- Example 7: mp 228-230° C.; MS m/z=366 (M+H); 1H NMR (400 MHz, CDCl3): δ 0.96 (dt, J1=9.75 Hz, J2=4.76 Hz, 1H), 1.57-2.15 (m, 14H), 2.17-2.35 (m, 3H), 2.50-2.58 (m, 1H), 2.79-2.91 (m, 2H), 6.87-6.92 (m, 2H), 7.51-7.58 (m, 2H), 8.29 (s, 1H).
-
- Example 8: mp 229-231° C.; MS m/z=380 (M+H); 1H NMR (400 MHz, CDCl3): δ 0.96 (dt, J1=9.74 Hz, J2=4.83 Hz, 1H), 1.41-1.99 (m, 16H), 2.18-2.25 (m, 1H), 2.41-2.70 (m, 4H), 2.77-2.91 (m, 3H), 6.88-6.93 (m, 1H), 7.51-7.58 (m, 2H), 8.32 (s, 1H).
-
- Example 9: mp 160.6-164° C. (methylene chloride, ethanol, ether, and hexane); MS m/z=354 (M+H); 1H NMR (400 MHz, CDCl3): δ 0.96 (dt, J1=10.14 Hz, J2=5.21 Hz, 1H), 1.10-1.22 (m, 6H), 1.74-1.95 (m, 7H), 2.17-2.26 (m, 1H), 2.50-2.92 (m, 8H), 6.88-6.93 (m, 1H), 7.51-7.59 (m, 2H), 8.31 (s, 1H).
-
- Example 10: mp 202-204° C. (methylene chloride, ethanol, ether, and hexane); MS m/z=380 (M+H); 1H NMR (400 MHz, CDCl3): δ 1.54-2.93 (m, 23H), 3.32-3.42 (m, 1H), 3.83-3.93 (m, 1H), 6.81-6.87 (m, 1H), 7.32-7.40 (m, 2H), 8.34 (s, 2H).
-
- Example 11: mp 246-248° C. (methylene chloride, ethanol, ether, and hexane); MS m/z=382 (M+H); 1H NMR (400 MHz, CDCl3): δ 1.25 (s, 6H), 1.62-1.93 (m, 8H), 1.95-2.16 (m, 4H), 2.24-2.39 (m, 1H), 2.65-2.95 (m, 7H), 6.83-6.90 (m, 2H), 7.43-7.52 (m, 2H), 8.44 (s, 1H).
-
-
- A mixture of 1′-trifluoroacetyl-spiro[3,4-dihydrobenzopyran-2,4′-piperidine] (1.49 g, 4.98 mmol) and propanoyl chloride (0.4 mL, 5 mmol) in methylene chloride (13 mL) was cooled at 10° C. Tin tetrachloride (1M solution in methylene chloride) (0.76 mL, 6.5 mmol) was added at 10° C. and stirred at 10° C. for 20 min then quenched with aqueous 2N HCl at 0° C. The aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na2SO4), filtered, and concentrated to provide a crude product. The crude product was purified by ISCO (80 g column) chromatography using 17 to 35% EtOAc in hexane to produce 1′-trifluoroacetyl-6-(propanoyl)-spiro[3,4-dihydrobenzopyran-2,4′-piperidine] (1.42 g, 81%),
- MS m/z=356 (M+H).
-
- A solution of the product from step 1 (1′-trifluoroacetyl-6-(propanoyl)-spiro[3,4-dihydrobenzopyran-2,4′-piperidine]) (1.4 g, 3.9 mmol) in tetrahydrofuran (13 mL) was cooled at 0° C. Lithium diisopropylamide, (2M solution in THF) (2.16 mL, 4.33 mmol) was added dropwise and warmed to rt for 30 min. The reaction was cooled again to 0° C. and ethyl bromoacetate (0.48 mL, 4.30 mmol) was added dropwise and warmed to RT for 30 min then quenched with aqueous 1M HCl acid at 0° C. The aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na2SO4), filtered, and concentrated to give a crude 1′-trifluoroacetyl-6-(3-methyl-4-oxo-butyric acid ethyl ester)-spiro[3,4-dihydrobenzopyran-2,4′-piperidine] (2.21 g), MS m/z=442 (M+H).
-
- A mixture of the product from step 2 (2.21 g, 5.01 mmol) and hydrazine monohydrate (1.5 mL, 30 mmol) in isopropanol (15 mL) was heated at 110° C. for 36 h. Isopropanol was evaporated at reduced pressure and azeotrophed twice with benzene to produce a crude product (2.45 g), MS m/z=314 (M+H). The material was used for the next reaction without further purification.
-
- A solution of the product from step 3 (2.45 g, 7.82 mmol) in a mixture of DMF (5 mL) and MeOH (15 mL) was stirred under argon. Cyclobutanone (1.8 mL, 24 mmol), sodium cyanoborohydride (1.2 g, 19 mmol) and acetic acid (0.90 mL, 20 mmol) were added sequentially and stirred at 60° C. for 24 h. The reaction mixture was concentrated at reduced pressure and partitioned between aqueous 1M sodium carbonate solution and methylene chloride. The aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na2SO4), filtered, and concentrated to provide a crude product. The crude product was purified by ISCO (40 g) chromatography using 2 to 10% methanol in methylene chloride to 10% methanol containing 4 mL of ammonium hydroxide in methylene chloride to obtain a pure product. The recovered pure product was dissolved in methylene chloride and washed with saturated sodium bicarbonate solution, brine, dried (Na2SO4), filtered, and concentrated. The pure product was crystallized from a mixture of methylene chloride, ethanol, ether, and hexane to produce 1-cyclobutyl-6-(5-methyl-4,5-dihydro-2H-pyridazin-3-one-6-yl)-spiro[3,4-dihydrobenzopyran-2,4′-piperidine]: (550 mg, 19%, 95% purity), mp 207-209° C. (methylene chloride, ethanol, ether, and hexane), MS m/z=368 (M+H); 1H NMR (400 MHz, CDCl3): δ 1.26 (d, J=7.33 Hz, 3H), 1.61-2.01 (m, 12H), 2.02-2.14 (m, 2H), 2.19-2.32 (m, 2H), 2.42-2.50 (m, 1H), 2.60-2.74 (m, 2H), 2.77-2.90 (m, 2H), 3.28-3.39 (m, 1H), 6.84-6.92 (m, 1H), 7.47-7.54 (m, 2H), 8.50 (s, 1H).
-
- A mixture of example 12 (103 mg, 0.28 mmol) and cesium carbonate (536 mg, 1.60 mmol) in dimethyl sulfoxide (6 mL) was heated at 100-110° C. for 27 h. The mixture was cooled to rt and partitioned between water and methylene chloride. Sodium chloride was added to the mixture and the aqueous layer was extracted three times with methylene chloride. The combined organics was washed with brine, dried (Na2SO4), filtered, and concentrated to provide a crude product. The crude product was purified by ISCO (40 g column) chromatography using 5% to 10% methanol in methylene chloride to 10% methanol containing 4% ammonium hydroxide in methylene chloride. The recovered product was dissolved in methylene chloride and washed with saturated aqueous sodium bicarbonate solution, brine, dried (Na2SO4), filtered, and concentrated to produce a pure product. The pure product was crystallized from a mixture of methylene chloride, ethanol, ether and hexane to give 1′-cyclobutyl-6-(5-methyl-2H-pyridazin-3-one-6-yl)-spiro[3,4-dihydrobenzopyran-2,4′-piperidine] (32 mg, 21%, 93% purity), mp 270-272° C. (methylene chloride, ethanol, ether and hexane), MS m/z=366 (M+H); 1H NMR (400 MHz, DMSO-d6): δ 1.56-1.85 (m, 11H), 1.92-2.03 (m, 2H), 2.12 (s, 3H), 2.14-2.26 (m, 1H), 2.45-2.55 (m, 2H), 2.72-2.80 (m, 3H), 6.76-6.82 (m, 2H), 7.15-7.19 (m, 2H), 12.92 (s, 1H).
-
- 1′-Isopropyl-[6-(4,4-dimethyl-4,5-dihydro-2H-pyridazin-3-one-6-yl)-spiro[3,4-dihydro[benzopyran-2,4′-piperidine]: mp 210-213° C. (methylene chloride, ethanol, ether, and hexane); MS m/z=370 (M+H); 1H NMR (400 MHz, CDCl3): δ 1.15 (d, 6H, J=6.5 Hz), 1.25 (s, 6H), 1.8-1.91 (m, 6H), 2.66-2.84 (m, 9H), 6.88 (d, 2H, J=8.1 Hz), 7.47-7.49 (m, 2H), 8.45 (s, 1H).
-
- To a solution of 5-bromo-spiro[benzofuran-2-(3H)-4′-piperidine] (260.0 mg, 0.97 mmol) in methanol (5.0 mL, 120 mmol) was added 100 μl (1.75 mmol) of AcOH followed by cyclobutanone (679.6 mg, 9.7 mmol;) at rt. To this mixture was added sodium cyanoborohydride (200 mg, 3.18 mmol) in small portions over 5 min. After 5 min. HPLC indicated about 10% of starting material. Added another 100 μl of AcOH followed by another 200 mg of NaCNBH3. After stirring for 15 min, LCMS indicated total disappearance of the starting material. The mixture was concentrated and extracted with CH2Cl2/sat. NaHCO3. After evaporation and drying (Na2SO4), a pale yellow oil was obtained which was purified by ISCO chromatography using CH2Cl2 and 0-10% MeOH containing 1% aq. NH4OH to afford the title compound as a waxy white solid (250 mg, 74%). Mp 79-80° C., MS: m/z 322/324 (M+1, Br isotopic peaks). 1HNMR (400 MHz, CDCl3): δ 7.28 (d, J=0.75 Hz, 1H), 7.20 (d, J=8.4 Hz, 1H), 6.64 (d, J=8.4 Hz, 1H), 2.98 (s, 2H), 2.80 (m, 1H), 2.1-2.6 (br.s, 4H) & 1.6-2.1 (m, 10H).
-
- Into a dry, round bottom flask was added tris(dibenzylideneacetone)dipalladium(0) (22 mg, 0.024 mmol;) and tricyclohexylphosphine (28.0 mg, 0.1 mmol) under N2 atmosphere. Dioxane (6 mL) was added and the dark solution was stirred for 30 min at rt. To this dark brownish solution was added 4,4,5,5,4′,4′,5′,5′-octamethyl-[2,2′]bi[[1,3,2]dioxaborolanyl] (0.20 g, 0.79 mmol), potassium acetate (0.10 g, 1.02 mmol) and a solution of 1′-cyclobutyl-5-bromo-spiro[benzofuran-2(3H)-4′-piperidine] (245.00 mg, 0.76 mmol) in dioxane (5 mL) in that order. The mixture was purged with N2 for 10 min. and heated at 80° C. After refluxing for 14 h, the LCMS indicated the absence of the bromide with the expected m/z 370 mass for the borolane. The crude borolane intermediate was subjected to the Suzuki coupling reaction by adding 3,6-dichloropyridazine (0.55 g, 3.69 mmole), (Ph3P)4Pd (85 mg, 0.073 mmole), THF (15 mL), EtOH (5 mL) and saturated aqueous NaHCO3 (8 mL). After 10 h, HPLC indicated the expected product as the major peak. The reaction was concentrated and purified by ISCO chromatography (DCM/MeOH/NH4OH) to obtain the product a beige solid (80 mg, 28%). mp 193-194° C., MS: m/z 356 (M+1). 1HNMR (CDCl3): δ 7.97 (s, 1H), 7.73-7.77 (m, 2H), 7.52 (dd, J=8.8, 1.5 Hz, 1H), 6.9 (d, J=8.4 Hz, 1H), 3.1 (s, 2H), (2.8, m, 1H), 2.4-2.6 (br.s, 4H) & 1.65-2.15 (m, 10H).
-
- To example 15 (F-cyclobutyl-5-(6-chloropyridazin-3-yl)spiro[benzofuran-2(3H)-4′-piperidine]) (75.00 mg, 0.2108 mmol) in acetic acid (5.0 mL, 88 mmol) was added sodium acetate (100.00 mg, 1.219 mmol) and refluxed for 3 h. The mixture was evaporated, the residue co-evaporated with toluene (2×10 mL) and then chromatographed by ISCO chromatography (DCM/MeOH/NH4OH) to afford the title compound 50 mg (68%). mp 227-228° C., MS: m/z 338 (M+1). 1HNMR (CDCl3): δ 12 (s, 1H), 7.7 (d, J=9.85 Hz, 1H), 7.6 (s, 1H), 7.55 (d, J=8.4 Hz, 1H), 7.05 (d, J=9.85 Hz, 1H), 6.80 (d, J=8.4 Hz, 1H), 3.05 (s, 2H), (2.85, m, 1H), 2.4-2.6 (br.s, 4H) & 1.65-2.15 (m, 10H).
-
-
- A solution of 2,5-dihydroxyacetophenone (15 g, 98 mmol), 4-oxo-piperidine-1-carboxylic acid tert-butyl ester (20 g, 100 mmol) and pyrrolidine (21 mL, 260 mmol) in methanol (146 mL) was stirred at reflux for 23 h and concentrated under vacuum to produce a red oily crude material. The oily crude material was purified by ISCO (330 g column) chromatography using 27 to 80% ethyl acetate in hexane to afford the product of step 1 (27 g, 82%), mp 72-74° C. (ethyl acetate, ether and hexane), MS m/z=332 (M−H).
-
- A solution of the product from step 1 (4.51 g, 13.5 mmol) in methanol (50 mL) was cooled to 15° C. and sodium borohydride was added slowly and the mixture was further stirred for 30 min and then concentrated. The crude residue was partitioned between methylene chloride and water and the aqueous layer was extracted twice with methylene chloride. The combined organics was washed with brine, dried (Na2SO4), filtered and concentrated to produce the product of step 2 (4.1 g, 90%), mp 171-173° C. (ethyl acetate, ether and hexane), MS m/z=334 (M−H).
-
- A solution of the product from step 2 (23.5 g, 70.1 mmol) and triethylsilane (49 mL, 310 mmol) in methylene chloride (150 mL) was cooled to 10° C. Trifluoroacetic acid (78 mL, 1000 mmol) was added dropwise and further stirred at room temperature for 15 h. The mixture was concentrated under vacuum and then azeotroped thrice with toluene to produce amber color oily material, which upon standing under vacuum gave a solid product. The crude product was triturated with a mixture of hexane:ether (1:1 ratio, 175 mL) to produce a pure product, which was dried at 80° C. to give a tan solid as the TFA salt (21 g, 90%), mp 208-210° C. (ether and hexane), MS m/z=220 (M+H).
-
- A solution of the product from step 3 (0.76 g, 3.5 mmol) in a mixture of DMF (2 mL) and MeOH (10 mL) was stirred under argon. Cyclobutanone (1.00 mL, 10 mmol), acetic acid (0.4 mL, 7 mmol) sodium cyanoborohydride (0.9 g, 10 mmol) were added sequentially and stirred at 60° C. for 15 h. The reaction mixture was concentrated at reduced pressure and partitioned between aqueous 1M sodium carbonate solution and methylene chloride. The aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na2SO4), filtered, and concentrated to provide a crude product. The recovered pure product was dissolved in methylene chloride and washed with saturated aqueous sodium bicarbonate solution, brine, dried (Na2SO4), filtered, and concentrated. The product was crystallized from a mixture of methylene chloride, ethanol, ether, and hexane to produce the product of step 4 (0.5 g, 53%), mp 211-213° C. (methylene chloride, ethanol, ether and hexane), MS m/z=274 (M+H).
- A solution of the product from step 4 (200 mg, 0.73 mmol) in dimethyl sulfoxide (10 mL) was added sodium hydride (35 mg, 1.4 mmol) at room temperature. After stirring for 30 min at room temperature 3,6-dichloro pyridazine (218 mg, 1.46 mmol) was added and the reaction mixture was heated to 60° C. for 1 h and poured into brine solution at room temperature. The aqueous layer was extracted four times with methylene chloride and the combined organics was washed with brine, dried (Na2SO4), filtered and concentrated to produce a crude material. The crude material was purified by ISCO (40 g) chromatography using a mixture of methanol in methylene chloride to afford Example 17 (250 mg, 87%), mp 128-130° C. (methylene chloride, methanol, ether and hexane), MS m/z=386 (M+H).
-
- A mixture of example 17 (209 mg, 0.54 mmol) and sodium acetate (32 mg, 0.39 mmol) in acetic acid (5 mL) was heated to 110-115° C. for 7 h. The reaction mixture was concentrated and azeotroped twice with toluene then partitioned between methylene chloride and the aqueous saturated sodium bicarbonate solution. The aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na2SO4), filtered, and concentrated to afford relatively pure product. The pure product was crystallized from a mixture of methylene chloride, methanol, ether, and hexane to produce 6-(3,4-dihydro spiro[2H-1-benzopyran-2,4′-piperidine]-6-yloxy)-2H-pyridazin-3-one as an off-white solid (170 mg, 76%), mp 233-235° C. (methylene chloride, methanol, ether and hexane), MS m/z=368 (M+H); 1H NMR (400 MHz, CDCl3): δ 1.54-2.01 (m, 10H), 2.03-2.13 (m, 2H), 2.18-2.32 (m, 2H), 2.60-2.71 (m, 2H), 2.74-2.89 (m, 3H), 6.82-6.91 (m, 3H), 7.00 (d, J=9.92 Hz, 1H) 7.185 (d, J=9.91 Hz, 1H), 9.84 (br s, 1H).
-
- To a 100 mL flask was added 2-hydroxymethyl-5-iodo-2H-pyridazin-3-one (0.19 g, 0.76 mmol), 1′-cyclobutyl-6-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolane)-spiro[3,4-dihydro-benzopyran-2,4′-piperidine] (0.34 g, 0.89 mmol), tetrakis(triphenylphosphine)palladium(0) (0.088 g 0.076 mmol), K2CO3 (0.53 g, 3.8 (mmol), in 1,2-dimethoxyethane (8 mL) and water (8 mL). The reaction mixture was flashed with N2 for 25 min and was then heated to reflux for 16 h. The reaction was cooled to rt and small amount of NaCNBH3 was added and stirred for 5 min. The reaction was diluted with CH2Cl2/MeOH (100 mL, 3:1) then washed with saturated NaHCO3, brine and dried (Na2SO4). The product was purified by prep TLC (6% MeOH/CH2Cl2) and the product collected and triturated with CH3CN to give 115 mg; mp 216-219° C.; 1HNMR (DMSO): 12.95 (s, 1H), 8.25 (s, 1H), 7.6 (s, 1H), 7.45 (d, 1H), 6.95 (s, 1H), 6.8 (d, 1H), 2.8 (m, 3H), 2.2-2.3 (br, 2H), 1.95-2.0 (br, 2H), 1.6-1.9 (m, 11H). MS m/z 352 (M+1)
- The following examples were synthesized using the methods for example 19 with 6-chloro-2-methyl-2H-pyridazin-3-one (Ex. 20) and 3-chloro-6-methoxypyridazine (Ex. 21).
- Racemic Example 10 was separated into two isomers using chiral chromatography; ChiralCel OJ-H and 0.1% diethylamine in 35% methanol/CO2. The individual isomers are designated as Example 22 (Peak A, elutes first from chiral column) and Example 23 (Peak B, elutes second from chiral column)
-
- 1′-Cyclobutyl-4-hydroxy-spiro[3,4-dihydro-benzopyran-2,4′-piperidine] (0.3 g, 1.1 mmol) in DMF (7 mL) was added NaH (88 mg, 3.7 mmol). After 0.5 h, 2-(3-chloropropyl)-2-H-pyridazin-3-one (0.2 g, 1.15 mmol) was added and the reaction heated to 60° C. for 1 h, concentrated and partitioned between DCM and aqueous NaHCO3, NaCl solution and dried (Na2SO4). The product was purified by silica gel chromatography (5-12% MeOH/DCM) to give 360 mg (80%). mp 207-209° C. (HCl salt), MS m/z=410 (M+H).
-
- This compound was synthesized using the method for example 24 and 2-oxiranylmethyl-2H-pyridazin-3one. mp 201-203° C. (HCl salt), MS m/z=426 (M+H).
- The following examples were synthesized from 6-bromo-1′-cyclobutyl-spiro[1,3-benzodioxine-2,4′-piperidine] using methods for example 19-21.
-
Example Structure Mp (° C. ) MS m/z 26 258-262 (HCl) 354 (M + 1) 1′-Cyclobutyl-6-(2H-pyridazin-2- one-5-yl)-spiro[1,3benzodioxine- 2,4′-piperidine] 27 185-187 368 (M + H) 1′-Cyclobutyl-6-(2-methyl- pyridazin-2-one-6-yl)- spiro[1,3benzodioxine-2,4′- piperidine] 28 273-275 354 (M + H) 1′-Cyclobutyl-6-(2H-pyridazin-2- one-6-yl)-spiro[1,3benzodioxine- 2,4′-piperidine] 29 230-232 368 (M + H) 1′-Cyclobutyl-7-methyl-6-(2H- pyridazin-2-one-6-yl)- spiro[1,3benzodioxine-2,4′- piperidine] 30 269-270 (HCl) 382 (M + H) 1′-Cyclobutyl-7-methyl-6-(2- methyl-pyridazin-2-one-6-yl)- spiro[1,3benzodioxine-2,4′- piperidine] 31 255-257 (HCl) 368 (M + H) 1′-Cyclobutyl-5-methyl-6-(2H- pyridazin-2-one-6-yl)- spiro[1,3benzodioxine-2,4′- piperidine] 32 258-259 404 (M + H) 1′-Cyclobutyl-6-(2H-phthalazin-l- one-4-yl)-spiro[1,3benzodioxine- 2,4′-piperidine] 33 260-262 430 (M + H) 1′-Cyclobutyl-6-(2H-5-phenyl- pyridazin-2-one-6-yl)- spiro[1,3benzodioxine-2,4′- piperidine] -
- To a solution of 6-bromo-1′H-spiro[1,3-benzodioxine-2,4′-piperidine] (238 g, 0.84 mol) and cyclobutanone (117 g, 1.676 mol) in THF (2 L) on an ice bath was added NaBH(OAc)3 (266 g, 1.255 mol) portion wise over 25 min under nitrogen. The resulting mixture was allowed to warm to rt and stirred overnight. The reaction mixture was poured into a mixture of ice (1.7 L), saturated NaHCO3 (1.7 L) and ethyl acetate (1.7 L) with vigorous stirring. After separation, the aqueous phase was adjusted to pH 11 by addition of 2M NaOH and extracted with ethyl acetate (2 L×2). The extracts were combined, washed with saturated NaHCO3 (1.5 L), brine (1.5 L), dried over Na2SO4 and concentrated. The obtained solid was purified by column chromatography (hexanes/ethyl acetate 3/1 to 1/1) to give 208 g (73%). MS m/z=339 (M+1).
-
- Into a 3-neck round bottom flask 6-bromo-1′-cyclobutyl-spiro[1,3-benzodioxine-2,4′-piperidine] (5.0 g, 15 mmol) in 80 mL THF/ether (4:1) was cooled at −76° C. under an atmosphere of nitrogen sec-Butyl lithium (1.4 M in cyclohexane, 13 mL, 18 mmol) was added dropwise and the mixture stirred at that temperature for 4 h. Then, 3,3-dimethyl-dihydrofuran-2,5-dione (2.8 g, 22 mmol) in THF (10 mL) was added dropwise, the cooling bath was removed and the reaction was allowed to warm to 0° C. for 1 h. LCMS showed the acid product (MS m/z=386 (M−1). Water (5 mL) was added, and the mixture concentrated and the resulting oil dissolved in iPrOH (40 mL). Hydrazine hydrate (2 mL, 50 mmol) was added and the reaction heated at 110° C. for 24 h, cooled to rt and concentrated to remove iPrOH. The water layer was decanted from the white semi-solid material, which was dissolved in DMC and dried (MgSO4). The product was purified on ISCO (silica gel, 95/5 increasing to 9/1 DCM/MeOH) to give 1.9 g (33%). mp 266-269° C. (HCl salt; MeOH-ether), 1H NMR (DMSO) δ 11.4 (s, 1H), 10.8 (s, 1H), 7.6-7.65 (m, 1H), 7.54 (s, 1H), 6.9-6.95 (m, 1H), 4.92-4.94 (d, 2H, J=10 Hz), 3.68-3.76 (p, 1H, J=7.6 Hz), 3.2-3.3 (b, 3H), 2.88 (m, 2H), 2.78 (m, 2H), 2.37-2.4 (m, 1H), 2.16-2.25 (m, 6H), 1.67-1.77 (m, 2H), 1.06 (s, 6H). LCMS m/z=384 (M+1).
-
- To 1′-carboxylic acid tert-butyl ester-6-bromo-spiro[1,3-benzodioxine-2,4′-piperidine] (14.58 g, 37.94 mmol) in ether (300 mL) under argon at −78° C. was added sec-butyllithium (1.4 M; 32.5 mL, 45.5 mmol) dropwise and the reaction was stirred at −78° C. for 30 min. 3,3-Dimethyldihydrofuran-2,5-dione in ether (10 mL) was added and the reaction was stirred for 30 min at −78° C. and quenched with water (˜40 mL). The reaction was warmed to rt and concentrated to remove the organic solvents. The aqueous layer was acidified with 5N HCl to pH=3-4, extracted with dichloromethane (150 mL), and the organic layer was washed with water and brine, dried over sodium sulfate, and concentrated. The product was purified using silica gel column chromatography (2-3% methanol/dichloromethane). The fractions were concentrated, triturated with dichloromethane (˜5 mL)/ether (˜10 mL)/hexanes (˜15-20 mL), and filtered off white solid to obtain 5.52 g (34%); MS m/z: 434 (M+H).
- To the product from step 1 (5.52 g, 12.7 mmol) (1′-carboylic acid tert-butyl ester-6-(2,2-dimethyl-4-oxo-butyric acid)-spiro[1,3-benzodioxine-2,4′-piperidine]) in isopropyl alcohol (70 mL) was added hydrazine monohydrate (0.956 mL, 19.1 mmol) and the reaction was heated at 80° C. overnight and concentrated. The residue was partitioned between water/dichloromethane, washed with brine, dried over sodium sulfate, and concentrated to obtain 5.4 g (>95%) of a crude product; MS m/z: 430 (M+H).
- To the product from step 2 (1′-carboxylic acid tert-butyl ester-6-(4,4-dimethyl-4,5-dihydro-2H-pyridazin-2-one)-spiro[1,3-benzodioxine-2,4′-piperidine] (5.46 g, 12.7 mmol) in dichloromethane (100 mL) was added trifluoroacetic acid (10 mL, 129.8 mmol) and the reaction was stirred for 4 h at rt and concentrated. The product was azeotroped with benzene and dried under vacuum to give 5.6 g of crude product as an oil; MS m/z: 330 (M+H).
- To the product from step 3 (1′-H-6-(4,4-dimethyl-pyridazinone)-spiro[1,3-benzodioxine-2,4′-piperidine]trifluoroacetic acid salt) (5.6 g, 12.6 mmol) and cyclobutanone (2.83 mL, 37.9 mmol) in DMF (10 mL)/methanol (50 mL)/acetic acid (3 mL) under argon cooled at 0° C. was added sodium cyanoborohydride (3.97 g, 63.2 mmol) slowly in portions. The reaction was heated at 60° C. overnight and concentrated. The reaction was partitioned between dichloromethane/1N sodium carbonate, washed with water and brine, dried over sodium sulfate, and concentrated. The product was purified using a single step silica gel column (5% methanol/dichloromethane) and concentrated. The free base was dissolved in chloroform (˜50 mL) and 1N HCl/ether (˜17 mL) was added. The product was collected after addition of ether to give 3.64 g (67%) of white solid; mp 269-270° C. MS m/z: 384 (M+H).
- The following examples were synthesized using modifications to the procedure for example 34 or methods described herein.
-
Example Structure Mp (° C.) MS m/z 36 192-194 356 (M + H) 1′-Cyclobutyl-6-(4,5- dihydropyridazin-3-one)-spiro[1,3- benzodioxine-2,4′-piperidine] 37 >300 (HCl) 368 (M + H) 1′-Cyclobutyl-6-(4,5-dihydro-4,5- cyclopropylpyridazin-3-one)- spiro[1,3-benzodioxine-2,4′- piperidine] 38 271-274 (HCl) 382 (M + H) 1′-Cyclobutyl-6-(4,5-dihydro-4,5- cyclobutylpyridazin-3-one)-spiro[1,3- benzodioxine-2,4′-piperidine] 39 209-214 (HCl) 370 (M + H) 1′-Cyclobutyl-6-(4,5-dihydro-5- methylpyridazin-3-one)-spiro[1,3- benzodioxine-2,4′-piperidine] 40 265-267 (HCl) 368 (M + H) 1′-Cyclobutyl-6-(5-methylpyridazin- 3-one)-spiro[1,3-benzodioxine-2,4′- piperidine] 41 >300 (HCl) 382 (M + H) 1′-Cyclobutyl-6-(4,5- dimethylpyridazin-3-one)-spiro[1,3- benzodioxine-2,4′-piperidine] - The compounds of the present invention are useful, inter alia, as therapeutic agents. Particularly, the compounds are useful for interacting with the H3 receptor. In one embodiment, the present invention provides a method for treating or preventing diseases and disorders, such as those disclosed herein, which comprises administering to a subject in need of such treatment or prevention a therapeutically effective amount of a compound of the present invention.
- In an additional embodiment, the present invention provides a method for inhibiting H3 activity comprising providing a compound of the present invention in an amount sufficient to result in effective inhibition. Particularly, the compounds of the present invention can be administered to treat such diseases and disorders such as narcolepsy or other sleep/wake disorders, such as obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder; feeding behavior disorder, eating disorders, obesity, cognition disorders, arousal disorders, memory disorders, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders, epilepsy, gastrointestinal disorders, respiratory disorders (such as asthma), inflammation, and myocardial infarction. In certain embodiments, the compounds can be administered to treat narcolepsy or other sleep/wake disorders, such as obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder; obesity, cognition disorders, attention deficit hyperactivity disorder (ADHD), and dementia. In other embodiments, the compounds can be administered to treat narcolepsy or other sleep/wake disorders, such as obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder; or they can used to treat obesity, or they can used to treat cognition disorders, or they can used to treat attention deficit hyperactivity disorder (ADHD), or they can used to treat dementia.
- Compounds of the invention either have demonstrated or are expected to demonstrate inhibition of H3 and thereby for utility for treatment of the indications described herein. Such utilities can be determined using, for example, the following assays as set forth below. They are not intended, nor are they to be construed, as limiting the scope of the disclosure.
- Cell Line Development and Membrane Preparation.
- The rat H3 receptor cDNA was PCR amplified from reverse-transcribed RNA pooled from rat thalamus, hypothalamus, striatum and prefrontal cortex with a sequence corresponding to by #338-1672 of Genbank file #NM—053506, encoding the entire 445-amino-acid rat histamine H3 receptor. This was engineered into the pIRES-neo3 mammalian expression vector, which was stably transfected into the CHO-A3 cell line (Euroscreen, Belgium), followed by clonal selection by limiting dilution. Cells were harvested and cell pellets were frozen (−80° C.). Cell pellets were resuspended in 5 mM Tris-HCl, pH 7.5 with 5 nM EDTA and a cocktail of protease inhibitors (Complete Protease Inhibitor Tablets, Roche Diagnostics). Cells were disrupted using a polytron cell homogenizer and the suspension was centrifuged at 1000×g for 10 minutes at 4° C. The pellet was discarded and the supernatant centrifuged at 40,000×g for 30 min at 4° C. This membrane pellet was washed in membrane buffer containing 50 mM Tris-HCl, pH 7.5 with 0.6 mM EDTA, 5 mM MgCl2 and protease inhibitors, recentrifuged as above and the final pellet resuspended in membrane buffer plus 250 mM sucrose and frozen at −80° C.
- Radioligand Binding.
- Membranes were resuspended in 50 mM Tris HCl (pH 7.4), 5 mM MgCl2, 0.1% BSA. The membrane suspensions (10 μg protein per well) were incubated in a 96 well microtiter plate with [3H]-N-alpha-methylhistamine (approximately 1 nM final concentration), test compounds at various concentrations (0.01 nM-30 μM) and scintillation proximity beads (Perkin Elmer, FlashBlueGPCR Scintillating Beads) in a final volume of 80 μl for 4 hours at room temperature, protected from light. Non-specific binding was determined in the presence of 10 μM clobenpropit. Radioligand bound to receptor, and therefore in proximity to the scintillation beads, was measured using a MicroBeta scintillation counter.
- GTPγS Binding.
- Membranes were resuspended in 20 mM HEPES pH 7.4 containing 1 mM EDTA, 0.17 mg/ml dithiothreitol, 100 mM NaCl, 30 μg/ml saponin and 5 mM MgCl2. For measurement of inverse agonist activity, increasing concentrations of test compounds were incubated in a 96 well microtiter plate with 10 μg/well membrane protein, 5 μM GDP, scintillation proximity beads (Perkin Elmer, FlashBlueGPCR Scintillating Beads) and [35S]-GTPγS (0.1 nM final concentration). Following incubation for 45 minutes in the dark at room temperature, the microtiter plate was centrifuged at 1000×g for 5 minutes and radioactivity bound to the membranes was counted using a MicroBeta scintillation counter. Non-specific binding was measured in the presence of 10 μM GTP. A decrease in bound [35S]-GTPγS is indicative of H3 receptor inverse agonist activity in this assay. Antagonist activity of test compounds was determined in a similar experiment under the following conditions. Membranes were resuspended in 20 mM HEPES pH 7.4 containing 1 mM EDTA, 0.17 mg/ml dithiothreitol, 200 mM NaCl, 30 μg/ml saponin and 20 mM MgCl2. The membranes were incubated at 10 μg/well membrane protein in a microtiter plate with increasing concentrations of test compounds, 20 μM GDP, scintillation proximity beads and [35S]-GTPγS (0.1 nM final concentration) plus 30 nM R-alpha-methylhistamine. The microtiter plates were incubated and processed as described above. A decrease in R-alpha-methylhistamine stimulated [35S]-GTPγS binding is indicative of H3 receptor antagonist activity in this assay.
- Methods:
- CHO cells stably expressing the human H3 receptor (GenBank: NM—007232) were harvested and cell pellets were frozen (−80° C.). Cell pellets were resuspended in 5 mM Tris-HCl, pH 7.5 with 5 nM EDTA and a cocktail of protease inhibitors (Complete Protease Inhibitior Tablets, Roche Diagnostics). Cells were disrupted using a polytron cell homogenizer and the suspension was centrifuged at 1000×g for 10 minutes at 4° C. The pellet was discarded and the supernatant centrifuged at 40,000×g for 30 min at 4° C. This membrane pellet was washed in membrane buffer containing 50 mM Tris-HCl, pH 7.5 with 0.6 mM EDTA, 5 mM MgCl2 and protease inhibitors, recentrifuged as above and the final pellet resuspended in membrane buffer plus 250 mM sucrose and frozen at −80° C.
- Radioligand Binding.
- Membranes were resuspended in 50 mM Tris HCl (pH 7.4), 5 mM MgCl2, 0.1% BSA. The membrane suspensions (10 μg protein per well) were incubated in a 96 well microtiter plate with [3H]-N-alpha-methylhistamine (approximately 1 nM final concentration), test compounds at various concentrations (0.01 nM-30 μM) and scintillation proximity beads (Perkin Elmer, FlashBlueGPCR Scintillating Beads) in a final volume of 80 μl for 4 hours at room temperature, protected from light. Non-specific binding was determined in the presence of 10 μM clobenpropit. Radioligand bound to receptor, and therefore in proximity to the scintillation beads, was measured using a MicroBeta scintillation counter.
- GTPγS Binding. Membranes were resuspended in 20 mM HEPES pH 7.4 containing 1 mM EDTA, 0.17 mg/ml dithiothreitol, 100 mM NaCl, 30 μg/ml saponin and 5 mM MgCl2. For measurement of inverse agonist activity, increasing concentrations of test compounds were incubated in a 96 well microtiter plate with 10 μg/well membrane protein, 5 μM GDP, scintillation proximity beads (Perkin Elmer, FlashBlueGPCR Scintillating Beads) and [35S]-GTPγS (0.1 nM final concentration). Following incubation for 45 minutes in the dark at room temperature, the microtiter plate was centrifuged at 1000×g for 5 minutes and radioactivity bound to the membranes was counted using a MicroBeta scintillation counter. Non-specific binding was measured in the presence of 10 μM GTP. A decrease in bound [35S]-GTPγS is indicative of H3 receptor inverse agonist activity in this assay. Antagonist activity of test compounds was determined in a similar experiment under the following conditions. Membranes were resuspended in 20 mM HEPES pH 7.4 containing 1 mM EDTA, 0.17 mg/ml dithiothreitol, 200 mM NaCl, 30 μg/ml saponin and 20 mM MgCl2. The membranes were incubated at 10 μg/well membrane protein in a microtiter plate with increasing concentrations of test compounds, 20 μM GDP, scintillation proximity beads and [35S]-GTPγS (0.1 nM final concentration) plus 30 nM R-alpha-methylhistamine. The microtiter plates were incubated and processed as described above. A decrease in R-alpha-methylhistamine stimulated [35S]-GTPγS binding is indicative of H3 receptor antagonist activity in this assay.
- Other assays that may be used in connection with the present invention are set forth below. Examples of the present invention can be tested in the following in vivo models:
- The methodology utilized for evaluating wake promoting activity of test compounds is based on that described by Edgar and Seidel, Journal of Pharmacology and Experimental Therapeutics, 283:757-769, 1997, and incorporated herein in its entirety by reference.
- Compounds of the invention either have demonstrated or are expected to demonstrate utility for wake promoting activity.
- Inhibition of histamine agonist-induced water drinking in the rat. Histamine, and the H3-selective agonist (R)-α-methylhistamine (RAMH) induce water drinking behavior in the rat when administered either peripherally or centrally (Kraly, F. S., June, K. R. 1982 Physiol. Behav. 28: 841.; Leibowitz, S. F. 1973 Brain Res. 63:440; Ligneau X., Lin, J-S., Vanni-Mercier G., Jouvet M., Muir J. L., Ganellin C. R., Stark H., Elz S., Schunack W., Schwartz, J-C. 1998 J Pharmcol. Exp. Ther. 287:658-66.; Clapham, J. and Kilpatrick G. J. 1993 Eur. J. Pharmacol. 232:99-103) an effect which is blocked by H3 receptor antagonists thioperamide and ciproxifan. Compounds of the invention either have demonstrated or are expected to block RAMH induce water drinking behavior.
- Novel object discrimination (NOD; also referred to as novel object recognition) is an assay for short-term visual recognition memory that was first described by Ennaceur and Delacour (Ennaceur, A. and Delacour, J. (1988) Behav Brain Res 31: 47-59).
- Social recognition (SR) is an assay for short-term social (olfactory) memory that was first described by Thor and Holloway (1982). Thor, D. and Holloway, W. (1982) J Comp Physiolog Psychcol 96: 1000-1006.
- Compounds of the invention either have demonstrated or are expected to demonstrate inhibition of H3 and thereby utility for treatment of the indications described herein.
- Table B lists the Human and Rat H3 binding data for Examples 1-18 of the present invention. Binding constants (Ki) for Examples 1-41 in the Human H3 and Rat H3 methods described herein are expressed by letter descriptor to indicate the following ranges: “+++” is less than 200 nM; “++” is 200-1000 nM; “+” is >1000 nM.
-
TABLE B Human H3 Rat H3 Example Structure Ki nM Ki nM 1 +++ +++ 2 +++ +++ 3 +++ ++ 4 +++ +++ 5 +++ +++ 6 + + 7 +++ +++ 8 +++ +++ 9 +++ +++ 10 +++ +++ 11 +++ +++ 12 +++ +++ 13 +++ +++ 14 +++ +++ 15 +++ +++ 16 +++ +++ 18 +++ +++ 19 +++ +++ 20 +++ +++ 21 +++ +++ 22 +++ +++ 23 +++ +++ 24 +++ +++ 25 +++ +++ 26 +++ +++ 27 +++ +++ 28 +++ +++ 29 ++ ++ 30 +++ +++ 31 +++ +++ 32 +++ +++ 33 +++ +++ 34 +++ +++ 36 +++ +++ 37 +++ +++ 38 +++ +++ 39 +++ +++ 40 +++ +++ 41 +++ +++ - For therapeutic purposes, the compounds of the present invention can be administered by any means that results in the contact of the active agent with the agent's site of action in the body of the subject. The compounds may be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in combination with other therapeutic agents, such as, for example, analgesics. The compounds of the present invention are preferably administered in therapeutically effective amounts for the treatment of the diseases and disorders described herein to a subject in need thereof.
- A therapeutically effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of conventional techniques. The effective dose will vary depending upon a number of factors, including the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, the formulation of the active agent with appropriate excipients, and the route of administration. Typically, the compounds are administered at lower dosage levels, with a gradual increase until the desired effect is achieved.
- Typical dose ranges are from about 0.01 mg/kg to about 100 mg/kg of body weight per day, with a preferred dose from about 0.01 mg/kg to 10 mg/kg of body weight per day. A preferred daily dose for adult humans includes about 25, 50, 100 and 200 mg, and an equivalent dose in a human child. The compounds may be administered in one or more unit dose forms. The unit dose ranges from about 1 to about 500 mg administered one to four times a day, preferably from about 10 mg to about 300 mg, two times a day. In an alternate method of describing an effective dose, an oral unit dose is one that is necessary to achieve a blood serum level of about 0.05 to 20 μg/ml in a subject, and preferably about 1 to 20 μg/ml.
- The compounds of the present invention may be formulated into pharmaceutical compositions by admixture with one or more pharmaceutically acceptable excipients. The excipients are selected on the basis of the chosen route of administration and standard pharmaceutical practice, as described, for example, in Remington: The Science and Practice of Pharmacy, 20th ed.; Gennaro, A. R., Ed.; Lippincott Williams & Wilkins: Philadelphia, Pa., 2000. The compositions may be formulated to control and/or delay the release of the active agent(s), as in fast-dissolve, modified-release, or sustained-release formulations. Such controlled-release, or extended-release compositions may utilize, for example biocompatible, biodegradable lactide polymers, lactide/glycolide copolymers, polyoxyethylene-polyoxypropylene copolymers, or other solid or semisolid polymeric matrices known in the art.
- The compositions can be prepared for administration by oral means; parenteral means, including intravenous, intramuscular, and subcutaneous routes; topical or transdermal means; transmucosal means, including rectal, vaginal, sublingual and buccal routes; ophthalmic means; or inhalation means. Preferably the compositions are prepared for oral administration, particularly in the form of tablets, capsules or syrups; for parenteral administration, particularly in the form of liquid solutions, suspensions or emulsions; for intranasal administration, particularly in the form of powders, nasal drops, or aerosols; or for topical administration, such as creams, ointments, solutions, suspensions aerosols, powders and the like.
- For oral administration, the tablets, pills, powders, capsules, troches and the like can contain one or more of the following: diluents or fillers such as starch, or cellulose; binders such as microcrystalline cellulose, gelatins, or polyvinylpyrrolidones; disintegrants such as starch or cellulose derivatives; lubricants such as talc or magnesium stearate; glidants such as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin; or flavoring agents such as peppermint or cherry flavoring. Capsules may contain any of the afore listed excipients, and may additionally contain a semi-solid or liquid carrier, such as a polyethylene glycol. The solid oral dosage forms may have coatings of sugar, shellac, or enteric agents. Liquid preparations may be in the form of aqueous or oily suspensions, solutions, emulsions, syrups, elixirs, etc., or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as surfactants, suspending agents, emulsifying agents, diluents, sweetening and flavoring agents, dyes and preservatives.
- The compositions may also be administered parenterally. The pharmaceutical forms acceptable for injectable use include, for example, sterile aqueous solutions, or suspensions. Aqueous carriers include mixtures of alcohols and water, buffered media, and the like. Nonaqueous solvents include alcohols and glycols, such as ethanol, and polyethylene glycols; oils, such as vegetable oils; fatty acids and fatty acid esters, and the like. Other components can be added including surfactants; such as hydroxypropylcellulose; isotonic agents, such as sodium chloride; fluid and nutrient replenishers; electrolyte replenishers; agents which control the release of the active compounds, such as aluminum monostearate, and various co-polymers; antibacterial agents, such as chlorobutanol, or phenol; buffers, and the like. The parenteral preparations can be enclosed in ampules, disposable syringes or multiple dose vials. Other potentially useful parenteral delivery systems for the active compounds include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.
- Other possible modes of administration include formulations for inhalation, which include such means as dry powder, aerosol, or drops. They may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally. Formulations for topical use are in the form of an ointment, cream, or gel. Typically these forms include a carrier, such as petrolatum, lanolin, stearyl alcohol, polyethylene glycols, or their combinations, and either an emulsifying agent, such as sodium lauryl sulfate, or a gelling agent, such as tragacanth. Formulations suitable for transdermal administration can be presented as discrete patches, as in a reservoir or microreservoir system, adhesive diffusion-controlled system or a matrix dispersion-type system. Formulations for buccal administration include, for example lozenges or pastilles and may also include a flavored base, such as sucrose or acacia, and other excipients such as glycocholate. Formulations suitable for rectal administration are preferably presented as unit-dose suppositories, with a solid based carrier, such as cocoa butter, and may include a salicylate.
- As those skilled in the art will appreciate, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein, and the scope of the invention is intended to encompass all such variations.
-
- Alguacil L. F.; Perez-Garcia C. Histamine H3 Receptor: A potential drug target for the treatment of central nervous systems disorders. Current Drug Targets-CNS & Neurological Disorders 2003, 2, 303-131.
- Arrang, J. M.; Garbarg, M.; Schwartz, J. C., Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983, 302, (5911), 832-7.
- Celanire, S.; Wijtmans, M.; Talaga, P.; Leurs, R.; de Esch, I. J., Keynote review: histamine H3 receptor antagonists reach out for the clinic. Drug Discov Today 2005, 10, (23-24), 1613-27.
- Chazot P. L.;, Hann V. H3 histamine receptor isoforms: New therapeutic targets in the CNS? Current Opinions in Investigational Drugs 2001, 2, 1428-1431.
- Chen Z. Effect of histamine H3-receptor antagonist clobenprobit on spatial memory of radial maze performance in rats. Acta Pharmacol Sin 2000, 21, 905-910.
- Esbenshade, T. A.; ox, G. B.; Cowart, M. D. Histamine H3 receptor antagonists: Preclinical promise for treating obesity and cognitive disorders. Molecular interventions 2006, 6, 77-88.
- Fox G. B.; Pan J. B.; Esbenshade T. A.; Bennani Y. L.; Black L. A.; Faghih R.; Hancock A. A.; Decker M. W. Effects of histamine H3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition response in the spontaneously hypertensive rat pup. Behav. Brain Res. 2002, 131, 151-161.
- Fox G. B.; Pan J. B.; Radek R. J.; Lewis A. M.; Bitner R. S.; Esbenshade T. A.; Faghih R.; Bennani Y. L.; Williams W.; Yao B. B. Decker M. W.; Hancock A. A. Two novel and selective nonimidazole H3 receptor Antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization. J. Pharmacol. Exper. Ther. 2003, 305, 897-908.
- Hancock, A. A.; Esbenshade, T. A.; Krueger, K. M.; Yao, B. B., Genetic and pharmacological aspects of histamine H3 receptor heterogeneity. Life Sci 2003, 73, (24), 3043-72.
- Hancock, A. A.; Fox, G. B. Perspectives on cognitive domains, H3 receptor ligands and neurological disease. Expert Opin. Investig. Drugs, 2004, 13, 1237-1248.
- Komater V. A.; Browman K. E.; Curzon P.; Hancock A. A., Decker M. W.; Fox B. H3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization. Psychopharmacology 2003, 167, 363-372.
- Leurs R.; Blandina P.; Tedford C.; Timmerman H. Therapeutic potential of histamine H3 receptor agonists and antagonists. Trends in Pharmacology 1998, 19, 177-183.
- Leurs, R.; Bakker, R. A.; Timmerman, H.; de Esch, I. J., The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov 2005, 4, (2), 107-20.
- Lin, J. S.; Sakai, K.; Vanni-Mercier, G.; Arrang, J. M.; Garbarg, M.; Schwartz, J. C.; Jouvet, M., Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat. Brain Res 1990, 523, (2), 325-30.
- Lloyd G. K.; Williams M. Neuronal nicotinic acetylcholine receptors as novel drug targets. J Pharmacol Exp Ther. 2000, 292, 461-467.
- Monti, J. M.; Jantos, H.; Ponzoni, A.; Monti, D., Sleep and waking during acute histamine H3 agonist BP 2.94 or H3 antagonist carboperamide (MR 16155) administration in rats. Neuropsychopharmacology 1996, 15, 31-5.
- Orsetti M.; Ferretti C.; Gamalero S. R.; Ghi P. Histamine H3-receptor blockade in the rat nucleus basalis magnocellularis improves place recognition memory. Psychopharmacology 2002, 159, 133-137.
- Parmentier R.; Ohtsu H.; Djebbara-Hannas Z.; Valatx J-L.; Watanabe T.; Lin J-S. Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock-out mice: evidence for the role of brain histamine in behavioral and sleep-wake control. J. Neurosci. 2002, 22, 7695-7711.
- Passani, M. B.; Lin, J. S.; Hancock, A.; Crochet, S.; Blandina, P., The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 2004, 25, 618-25.
- Repka-Ramirez M. S. New concepts of histamine receptors and actions. Current Allergy and Asthma Reports 2003, 3, 227-231.
- Ritz A.; Curley J.; Robertson J.; Raber J. Anxiety and cognition in histamine H3 receptor −/− mice. Eur J Neurosci 2004, 19, 1992-1996.
- Rouleau, A.; Heron, A.; Cochois, V.; Pillot, C.; Schwartz, J. C.; Arrang, J. M., Cloning and expression of the mouse histamine H3 receptor: evidence for multiple isoforms. J Neurochem 2004, 90, 1331-8.
- Vanni-Merci G.; Gigout S.; Debilly G.; Lin J. S. Waking selective neurons in the posterior hypothalamus and their response to histamine H3-receptor ligands: an electrophysiological study in freely moving cats. Behav Brain Res 2003, 144, 227-241.
- Witkin, J. M.; Nelson, D. L., Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. Pharmacol Ther 2004, 103, 1-20.
- Yao, B. B.; Sharma, R.; Cassar, S.; Esbenshade, T. A.; Hancock, A. A., Cloning and pharmacological characterization of the monkey histamine H3 receptor. Eur J Pharmacol 2003, 482, (1-3), 49-60.
Claims (22)
1. A method for treating a disorder selected from the group consisting of narcolepsy or sleep/wake disorders, feeding behavior disorders, eating disorders, obesity, cognition disorders, arousal disorders, memory disorders, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders, epilepsy, gastrointestinal disorders, respiratory disorders, inflammation, and myocardial infarction, said method comprising administering to a subject in need of treatment a therapeutically effective amount of a compound according to Formula (I):
or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof,
wherein:
R1 is C3-C8 cycloalkyl;
W is —CH2—, —CH2CH2—, or —CH2—O—;
k is 0, 1, or 2; m is 0, 1, or 2; and the sum of m and k is 1, 2, or 3;
Y2═Y3 is —C(X)═CH— or —CH═C(X)—;
X is R2, —OR2, —(C1-C3 alkyl)-R2, —O—(C1-C3 alkyl)-R2, —NHR2, —NHC(═O)R2, or —NHC(═O)NHR2; wherein said C1-C3 alkyl is optionally substituted with —OH or C1-C4 alkoxy;
R2 is:
A is F, Cl, or Br;
R3 is H, F, or C1-C4 alkyl;
R4 is H, F, or C1-C4 alkyl;
R4A is H, F, Cl, Br, or C1-C4 alkyl;
R5 is H, F, or C1-C4 alkyl;
R5A is H, F, Cl, Br, C1-C4 alkyl or phenyl;
or, R4 and R5, together with the carbon atoms to which they are attached, form a fused C3-C6 cycloalkyl ring optionally substituted with 1, 2, or 3 R14;
or, R4A and R5A, together with the carbon atoms to which they are attached, form a fused phenyl ring optionally substituted with 1, 2, or 3 R14;
a C3-C6 cycloalkyl ring optionally substituted with 1, 2 or 3 R14;
a 5 to 6 membered fused heteroaryl ring system containing one, two, or three heteroatoms selected from N, O, and S, wherein said heteroaryl ring system is optionally substituted with 1, 2, or 3 R14; or
a 5 to 6 membered fused heterocycloalkyl ring system containing one, two, or three heteroatoms selected from N, O, S, SO, and SO2, wherein said heterocycloalkyl ring system is optionally substituted with 1, 2, or 3 R14;
R6 is H, F, or C1-C4 alkyl;
R7 is H, F, Cl, Br, or C1-C4 alkyl;
R8 is H, —C(═O)R27, —CO2R27, C1-C6 alkyl optionally substituted by 1-3 R20;
C3-C8 cycloalkyl optionally substituted by 1-3 R20A;
C6-C10 aryl optionally substituted by 1-3 R20A;
C7-C15 arylalkyl optionally substituted by 1-3 R20A; or
a 5 to 10 membered heteroaryl ring system containing one, two, or three heteroatoms selected from N, O, and S, wherein said heteroaryl ring system is optionally substituted with 1-3 R20A;
R9, at each occurrence, is independently F, Cl, Br, C1-C4 alkyl, or C1-C4 alkoxy;
R10 is F, Cl, Br, C1-C3 alkyl, or C1-C3 alkoxy;
R14 at each occurrence is independently F, Cl, Br, I, —OR21, —OR22, —NR23R24, —NHOH, —NO2, —CN, —CF3, (═O), —C(═O)R21, —CO2R21, —OC(═O)R21, —C(═O)NR23R24, —NR27C(═O)R21, —NR27C(═O)OR21, —OC(═O)NR23R24, —NR27C(═S)R21, —SR21, —S(O)R21, or —S(O)2R21; C1-C6 alkyl optionally substituted with OR26; C2-C6 alkenyl, or C2-C6 alkynyl;
R20 at each occurrence is independently F, Cl, Br, I, —OR21, —OR22, —NR23R24, —NHOH, —NO2, —CN, —CF3, (═O), —C(═O)R21, —CO2R21, —OC(═O)R21, —C(═O)NR23R24, —NR27C(═O)R21, —NR27C(═O)OR21, —OC(═O)NR23R24, —NR27C(═S)R21, —SR21, —S(O)R21, or —S(O)2R21; C1-C6 alkyl optionally substituted with OR26; C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, phenyl, 3- to 7-membered heterocycloalkyl group, or 5- or 6-membered heteroaryl group;
R20A at each occurrence is independently F, Cl, Br, I, —OR21, —OR22, —NR23R24, —NHOH, —NO2, —CN, —CF3, (═O), —C(═O)R21, —CO2R21, —OC(═O)R21, —C(═O)NR23R24, —NR27C(═O)R21, —NR27C(═O)OR21, —OC(═O)NR23R24, —NR27C(═S)R21, —SR21, —S(O)R21, or —S(O)2R21; C1-C6 alkyl optionally substituted with OR26; C2-C6 alkenyl, or C2-C6 alkynyl;
R21 at each occurrence is independently H, C1-C6 alkyl, C6-C10 aryl, or C7-C15 arylalkyl;
R22 at each occurrence is independently the residue of an amino acid after the hydroxyl group of the carboxyl group is removed;
R23 and R24 at each occurrence are independently selected from H, C1-C6 alkyl, and C6-C10 aryl;
or, R23 and R24, together with the nitrogen atom to which they are attached, form a 3 to 7 membered heterocycloalkyl ring system containing one, two, or three heteroatoms selected from N, O, and S, wherein said heterocycloalkyl ring system is optionally substituted with ═O;
R26 is H or C1-C6 alkyl;
R27 is H or C1-C6 alkyl;
n is 0, 1, 2, or 3; and
z is 0, 1, 2, 3, 4, 5, or 6.
2. A method according to claim 1 wherein the disorder is narcolepsy or sleep/wake disorders.
3. A method according to claim 1 wherein the disorder is attention deficit hyperactivity disorder.
4. A method according to claim 1 wherein the disorder is cognition disorder.
5. A method according to claim 1 wherein R1 is C3-C8 cycloalkyl.
6. A method according to claim 1 wherein W is —CH2— or —CH2—CH2—.
8. A method according to claim 1 wherein R4 and R5, together with the carbon atoms to which they are attached, form a fused cyclopropyl or cyclobutyl ring.
9. A method according to claim 1 wherein R4A and R5A, together with the carbon atoms to which they are attached, form a fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl ring.
10. A method according to claim 1 wherein k is 1.
11. A method according to claim 1 wherein m is 1.
12. A method according to claim 1 wherein the sum of m and k is 2.
13. A method according to claim 1 wherein Y2═Y3 is —C(X)═CH—.
14. A method according to claim 1 wherein X is R2.
15. A method according to claim 1 wherein X is —OR2.
16. A method according to claim 1 wherein R8 is H.
17. A method according to claim 1 wherein R8 is C1-C6 alkyl optionally substituted by 1-3 R20.
18. A method according to claim 1 wherein R9 is C1-C4 alkyl.
19. A method according to claim 1 wherein n is 0.
20. A method according to claim 1 wherein n is 1.
21. A method according to claim 1 wherein z is 0.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/949,323 US20130310389A1 (en) | 2008-01-30 | 2013-07-24 | Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6290908P | 2008-01-30 | 2008-01-30 | |
PCT/US2009/032195 WO2009097309A1 (en) | 2008-01-30 | 2009-01-28 | Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands |
US12/846,108 US8524713B2 (en) | 2008-01-30 | 2010-07-29 | Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands |
US13/949,323 US20130310389A1 (en) | 2008-01-30 | 2013-07-24 | Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/846,108 Continuation US8524713B2 (en) | 2008-01-30 | 2010-07-29 | Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130310389A1 true US20130310389A1 (en) | 2013-11-21 |
Family
ID=40445314
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/846,108 Active 2029-12-07 US8524713B2 (en) | 2008-01-30 | 2010-07-29 | Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands |
US13/949,323 Abandoned US20130310389A1 (en) | 2008-01-30 | 2013-07-24 | Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/846,108 Active 2029-12-07 US8524713B2 (en) | 2008-01-30 | 2010-07-29 | Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands |
Country Status (19)
Country | Link |
---|---|
US (2) | US8524713B2 (en) |
EP (1) | EP2257553B1 (en) |
JP (1) | JP5524082B2 (en) |
KR (1) | KR20100105789A (en) |
CN (1) | CN101932585B (en) |
AT (1) | ATE522538T1 (en) |
AU (1) | AU2009209235B2 (en) |
BR (1) | BRPI0905849A2 (en) |
CA (1) | CA2712888A1 (en) |
EA (1) | EA018537B1 (en) |
ES (1) | ES2370378T3 (en) |
HK (1) | HK1151526A1 (en) |
IL (1) | IL206914A (en) |
MX (1) | MX2010008382A (en) |
MY (1) | MY150062A (en) |
NZ (1) | NZ587034A (en) |
UA (1) | UA100877C2 (en) |
WO (1) | WO2009097309A1 (en) |
ZA (1) | ZA201005136B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110098269A1 (en) * | 2008-05-20 | 2011-04-28 | Cephalon, Inc. | Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands |
US8912183B2 (en) | 2008-01-30 | 2014-12-16 | Cephalon, Inc. | Substituted pyridazine derivatives |
JP2017137270A (en) * | 2016-02-05 | 2017-08-10 | 国立大学法人岐阜大学 | Anticancer agent |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2858816A1 (en) * | 2006-07-25 | 2008-01-31 | Cephalon, Inc. | Pyridizinone derivatives and uses thereof to treat diseases, disorders and/or conditions that may be mediated or modulated by inhibition of h3 receptors |
JP5627574B2 (en) | 2008-06-03 | 2014-11-19 | インターミューン, インコーポレイテッド | Compounds and methods for treating inflammatory and fibrotic diseases |
TWI543984B (en) | 2010-07-09 | 2016-08-01 | 艾伯維公司 | Spiro-piperidine derivatives as s1p modulators |
TWI522361B (en) | 2010-07-09 | 2016-02-21 | 艾伯維公司 | Fused heterocyclic derivatives as s1p modulators |
TW201206893A (en) | 2010-07-09 | 2012-02-16 | Abbott Healthcare Products Bv | Bisaryl (thio) morpholine derivatives as S1P modulators |
WO2012077655A1 (en) * | 2010-12-07 | 2012-06-14 | 塩野義製薬株式会社 | Spiro derivative having gpr119 agonist activity |
ES2547916T3 (en) * | 2011-02-18 | 2015-10-09 | Novartis Pharma Ag | MTOR / JAK inhibitor combination therapy |
AR092742A1 (en) | 2012-10-02 | 2015-04-29 | Intermune Inc | ANTIFIBROTIC PYRIDINONES |
JP6525437B2 (en) | 2014-04-02 | 2019-06-05 | インターミューン, インコーポレイテッド | Antifibrotic pyridinone |
US11535632B2 (en) | 2019-10-31 | 2022-12-27 | ESCAPE Bio, Inc. | Solid forms of an S1P-receptor modulator |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0313762D0 (en) * | 2003-06-13 | 2003-07-23 | Biofocus Plc | Compound libraries |
AU2004278414B2 (en) * | 2003-10-01 | 2012-05-24 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
SE0403160D0 (en) * | 2004-12-23 | 2004-12-23 | Biovitrum Ab | New compounds |
US8158791B2 (en) * | 2005-11-10 | 2012-04-17 | Msd K.K. | Aza-substituted spiro derivatives |
WO2007063385A2 (en) * | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
WO2007088462A1 (en) * | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
-
2009
- 2009-01-28 JP JP2010545098A patent/JP5524082B2/en not_active Expired - Fee Related
- 2009-01-28 EA EA201070903A patent/EA018537B1/en not_active IP Right Cessation
- 2009-01-28 KR KR1020107019040A patent/KR20100105789A/en not_active Application Discontinuation
- 2009-01-28 UA UAA201010456A patent/UA100877C2/en unknown
- 2009-01-28 WO PCT/US2009/032195 patent/WO2009097309A1/en active Application Filing
- 2009-01-28 MX MX2010008382A patent/MX2010008382A/en active IP Right Grant
- 2009-01-28 NZ NZ587034A patent/NZ587034A/en not_active IP Right Cessation
- 2009-01-28 AT AT09706445T patent/ATE522538T1/en not_active IP Right Cessation
- 2009-01-28 CA CA2712888A patent/CA2712888A1/en not_active Abandoned
- 2009-01-28 AU AU2009209235A patent/AU2009209235B2/en not_active Ceased
- 2009-01-28 ES ES09706445T patent/ES2370378T3/en active Active
- 2009-01-28 CN CN2009801037142A patent/CN101932585B/en not_active Expired - Fee Related
- 2009-01-28 BR BRPI0905849-4A patent/BRPI0905849A2/en not_active IP Right Cessation
- 2009-01-28 EP EP09706445A patent/EP2257553B1/en not_active Not-in-force
- 2009-01-28 MY MYPI2010003298A patent/MY150062A/en unknown
-
2010
- 2010-07-08 IL IL206914A patent/IL206914A/en not_active IP Right Cessation
- 2010-07-19 ZA ZA2010/05136A patent/ZA201005136B/en unknown
- 2010-07-29 US US12/846,108 patent/US8524713B2/en active Active
-
2011
- 2011-06-01 HK HK11105523.2A patent/HK1151526A1/en not_active IP Right Cessation
-
2013
- 2013-07-24 US US13/949,323 patent/US20130310389A1/en not_active Abandoned
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8912183B2 (en) | 2008-01-30 | 2014-12-16 | Cephalon, Inc. | Substituted pyridazine derivatives |
US20110098269A1 (en) * | 2008-05-20 | 2011-04-28 | Cephalon, Inc. | Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands |
JP2017137270A (en) * | 2016-02-05 | 2017-08-10 | 国立大学法人岐阜大学 | Anticancer agent |
Also Published As
Publication number | Publication date |
---|---|
NZ587034A (en) | 2011-12-22 |
AU2009209235B2 (en) | 2013-07-18 |
US8524713B2 (en) | 2013-09-03 |
ZA201005136B (en) | 2013-12-23 |
JP2011510992A (en) | 2011-04-07 |
WO2009097309A1 (en) | 2009-08-06 |
IL206914A (en) | 2013-03-24 |
HK1151526A1 (en) | 2012-02-03 |
ES2370378T3 (en) | 2011-12-14 |
MX2010008382A (en) | 2010-11-25 |
EP2257553B1 (en) | 2011-08-31 |
CA2712888A1 (en) | 2009-08-06 |
EA201070903A1 (en) | 2011-02-28 |
UA100877C2 (en) | 2013-02-11 |
CN101932585A (en) | 2010-12-29 |
JP5524082B2 (en) | 2014-06-18 |
IL206914A0 (en) | 2010-12-30 |
KR20100105789A (en) | 2010-09-29 |
EA018537B1 (en) | 2013-08-30 |
CN101932585B (en) | 2013-07-10 |
US20100298332A1 (en) | 2010-11-25 |
MY150062A (en) | 2013-11-29 |
BRPI0905849A2 (en) | 2015-06-30 |
AU2009209235A1 (en) | 2009-08-06 |
ATE522538T1 (en) | 2011-09-15 |
EP2257553A1 (en) | 2010-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8524713B2 (en) | Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands | |
US20110098269A1 (en) | Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands | |
US8513232B2 (en) | Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands | |
KR101429311B1 (en) | Pyridazinone derivatives | |
US8912183B2 (en) | Substituted pyridazine derivatives | |
EP2459529A1 (en) | Substituted phenoxypropylcycloamine derivatives as histamine-3 (h3) receptor ligands |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |